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SUMMARY
This study describes the development and application of 
sensitive and specific, reverse-phase high performance liquid 
chromatography procedures for the measurement of caffeine and 
its metabolites in biological fluids. Satisfactory resolution 
of these compounds was achieved using Hypersil octadecylsilane 
columns with elution solvents consisting of buffered aceto- 
nitrile solutions containing tetrahydro'furan as an ion-pairing 
reagent. Eluted compounds were detected by monitoring their UV 
absorption at a wavelength of 280 nm. Conditions for 
processing body fluids for analysis were optimised using 
organic extraction techniques with proxyphy11ine incorporated 
as an internal standard. Maximum recovery of urine metabolites 
required the formation of ion-pair complex with tetrabutyl- 
ammonium. hydrogen sulphate. Serum caffeine levels determined 
by KPLC and a radioimmunoassay procedure showed good 
agreement. Furthermore, caffeine concentrations in saliva, 
following oral ingestion of caffeine, correlated well with 
corresponding values found in serum.
An assessment of the consumption of caffeinated beverages 
in a local population indicated that the dietary intake of 
caffeine in the U.K. is significantly higher than that 
previously reported for American and Canadian populations. 
Measurement of serum caffeine levels in non-pregnant subjects 
showed a mean value of 2.42 m g /1; 6% of the values were in
excess of 5 m g /1 which is comparable to the average peak level 
found following a 250 mg oral dose of caffeine.
Reference ranges are established for serum and salivary 
pharmacokinetic data and recoveries of metabolites from urine
of normal volunteers who received oral doses of caffeine. In 
addition the electrophysiological and psychopharmaco1ogica1 
responses to oral doses of caffeine are reported following a 
collaborative study with the Institute of Psychiatry, London.
Evidence for alterations in the biotransformation of 
caffeine during pregnancy was obtained by comparing urine 
metabolite concentrations in pregnant women, receiving a known 
dietary intake of caffeine, with values obtained for a 
non-pregnant control group. It is suggested that hormonal 
influences on the hepatic drug metabolising enzymes may be 
implicated. Whilst pharmacologically significant concentrat­
ions of caffeine and its metabolites were detected in samples 
of maternal serum, cord blood and breast milk, no evidence was 
found to relate caffeine levels in the newborn infant with the 
onset of attacks of jitteriness or neonatal apnoea.
In a study of caffeine elimination in chronic liver 
disease, the clearance of caffeine in compensated cirrhotic 
patients was similar to that of normal controls. However for 
patients with decompensated liver disease, significant levels 
of impairement were found in both serum and salivary caffeine 
clearance. This change in the disposition of caffeine was also 
reflected in the profiles of it metabolites excreted in the 
urine. Since the biotransformation pattern of caffeine in 
these patients was shown to be normal, this impairement of 
caffeine clearance could be attributed to a reduction in 
intrinsic clearance resulting from a reduced mass of viable 
hepatocytes. Preliminary findings indicated that salivary 
caffeine clearance measurements might provide an accurate 
means of assessing the extent of hepato-cellular dysfunction.
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ABBREVIATIONS USED IN TEXT
Meihvlxanihine metabolites
1MX 1-methylxanthine
1MU 1-methyluric acid
3MX 3-methylxanthine
3MU 3-methyluric acid
7MX 7-methylxanthine
7MU 7-methyluric acid
13MX 1,3-dimethylxanthine (Theophylline)
13MU 1,3-dimethyluric acid
17MX 1,7-dimethylxanthine (Paraxanthine)
17MU 1,7-dimethyluric acid
37MX 3,7-dimethylxanthine (Theobromine)
137MX 1,3,7-trimethylxanthine (Caffeine)
137MU 1,3,7-trimethyluric acid
PP 7 (2-hydroxypropy 1 -theophy 11 ine (Proxyphy 11 ine )
THF Tetrahydrofuran
TBAS Tetrabutylammonium hydrogen sulphate
Tl/2 Half-life
k.el Elimination constant
AUC Area under elimination curve
Vd Apparent volume of distribution
- 4 -
i^ „. Introduction
Caffeine,theophy11ine and theobromine are three 
closely related alkaloids occuring in plants from which 
beverages, obtained from aqueous extracts, have been consumed 
for many years. Coffee, obtained from the seeds of Coffea 
arabica and related species contains caffeine. Tea, the leaves 
of Thea sinensis, contains caffeine and a small amount of 
theophylline, whilst cocoa, obtained from the seeds of
Theobroma cacao, contains theobromine and caffeine. In recent\
years, additional dietary sources of caffeine have been 
introduced in the form of cola flavoured drinks made from nuts 
of the tree, Cola acuminata, and from many drugs including 
analgesics, antacids, and common cold remedies. Caffeine can 
be synthesised artificially from dimethyl urea and malonic 
acid.
i^i^_STRUCTURE_1.„ABSORPIION_AND_DISTRIBUIION
The isolation of caffeine from green coffee beans was first 
reported in Germany by Runge (1820) and confirmed the same 
year by von Giese. In 1861 Strecker, using methy1-iodide, 
converted theobromine to caffeine and demonstrated that 
theobromine was a dimethylxanthine in structure and caffeine a 
trimethylxanthine. However, whilst the definitive stuctures of 
xanthine and caffeine were first described by Medicus in 1875, 
synthesis of caffeine was not achieved until a later study by 
Fischer and Ach in 1895.
Caffeine (1,3,7-trimethylxanthine), theophylline (1,3- 
dimethylxanthine) and theobromine (3,7-dimethylxanthine) are
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methylated derivatives of the dioxypurine, xanthine, which is 
structurally related to uric acid and the nucleotide 
constituents of the nucleic acids, adenine and guanine (Fig 
1.). The methylxanthines are readily absorbed after oral, 
rectal or parenteral administration and rapidly distributed 
throughout all tissues and organs. Oral administration of 
caffeine in man produces peak blood levels within 1-2 hours 
after ingestion, although this has been shown to vary 
according to the form in which it is administered (Marks and 
Kelly, 1973). Caffeine in coca-cola is absorbed much more 
slowly than that in tea or coffee, possibly as a result of a 
reduction in the rate of gastrointestinal blood flow caused by
the lower temperature of coca-cola, or by the presence of
sucrose.
The earliest reported study on the pharmacokinetics of
caffeine was in 1953 when Axelrod and Reichenthal reported
elimination half life values ranging from 2.5-4.5 hours in
normal subjects following an oral dose of 7 mg/kg. However the
present understanding of the pharmacokinetics of caffeine is
mainly attributable to studies performed in the last decade.
The combined data from several studies (Neims, 1979; Newton et
a l ., 1981; Blanchard et a l ., 1983) have shown that the
disappearance of caffeine from plasma or saliva follows first
order kinetics after single oral doses of up to 10 mg/kg.
Whilst investigating the effects of increasing doses (50-750
mg) on the plasma/ salivary pharmacokinetics of caffeine,
Newton et al. (1981) showed that the apparent first-order
r
elimination rate constant decreased linearly with dose whilst
- 7 -
total body clearance was unaffected (mean value 0.98 ± 0.38 
ml.kg."’^ min^) . There was also a trend towards increasing 
apparent volume of distribution with increasing dose. A linear 
relationship was observed between the area under plasma 
elimination curves and dose. In addition, dose and dose 
normalised plasma elimination curves were superimposab1e 
suggesting that caffeine obeys linear pharmacokinetics over 
the dose range investigated. The overall sa1iva/piasma 
concentration ratio was 0.74 ± 0.08.
The half life of caffeine for non-smoking, healthy adults 
is approximately 3-6 hours (Cook et a l ., 1976; Patwardhan et
al., 1 9 8 0 ; Newton et al., 1981; Zylber-Katz et al., 1984) 
although it has been reported that in habitual 1ly heavy coffee 
drinkers, a period of up to 7 days may be required to 
completely decaffeinate their blood (Warren, 1969). In 1978 
Parsons and Neims demonstrated that the mean value for 
elimination half-life in smokers (3.5 hr, n =13), was 
significantly less than than that for non-smokers (6.0 hr, n = 
13) with corresponding clearance values of 155 ± 16 ml .k g “ -^hr."! 
and 94 * 18 ml.kgr^hr. Since no significant variations were 
found for the apparent volumes of distribution in smokers (720 
± 67 ml.kg.""'*) and non-smokers (610 ±_ 80 ml.kg.” -^) the 
differences were attributed to an induction of hepatic aryl 
hydrocarbon hydroxylase activity in smokers.
The plasma clearance of caffeine is significantly decreased 
in the third trimester of pregnancy (37 ml/kg/hr) producing an 
extended half-life of about 10 hours (Aldridge et a 1. ,1981; 
Knutti et al., 1982). This,is probably due to changes in the
- 8 -
hormonal milieu since oral contraceptives produce a similar 
decrease in the rate of elimination of caffeine (Callahan et 
al, 1983). A delayed clearance is also observed in patients 
with severe liver disease (Statland et al., 1980; Desmond et 
al., 1980) and in newborns (Aranda et al., 1981), where 
elimination is slow due to immaturity of the enzymes involved 
in the biotransformation of caffeine. The low molecular weight 
of caffeine facilitates transport across the placenta 
(Goldstein and Warren, 1962) and accumulation may occur in 
foetal brain tissue (Galli et a l ., 1975). It is also secreted
into maternal milk and has the ability to enter gonadal tissue 
(Goldstein and Warren, 1962).
1.2. METABOLISM
The metabolic fate of caffeine in man occurs primarily in 
the liver and, as in all other species (Bonati and Garratini, 
1984), involves demethyl ation, oxidation and hydration 
reactions. The observed species differences in metabolite 
output are related to which particular pathways and reactions 
are dominant for a particular species, thereby favouring the 
formation of either demethylated xanthines, uric acids, or 
uracil derivatives of caffeine.
The earliest recorded study on caffeine metabolism in man 
was carried out in 1850 by Lehmann, who failed to detect 
traces of caffeine in urine samples collected following an 
oral dose. Evidence for the demethyl ation of ingested methyl- 
xanthines was first reported by Albanese (1895) who showed 
that dogs and rabbits fed large doses of caffeine or
- 9 -
theobromine excreted a monomethylxanthine. In 1901, Kruger and 
Schmidt concluded that the order of increasing stability of 
the methyl groups was 3,1 and 7 and that the methylated 
purines found in human urine were attributable to the 3-methyl 
demethyl ation of methylated purines present in food.
A significant contribution to the elucidation of the 
metabolism of methlxanthines was the introduction of paper 
chromatographic techniques capable of separating and detecting 
purines, pyrimidines and methylxanthines using only a few 
micrograms of material (Markham and Smith, 1949). In 1951, 
Weinfeld demonstrated that 1-methyluric acid and 1,3-dimethyl- 
uric acid were excreted in rabbit urine after feeding with 
theophylline or caffeine. A year later, Brodie et al. (1952) 
established that the major urinary metabolite of theophylline 
was 1,3-dimethyluric acid which accounted for 45% of the 
administered dose. Axelrod and Reichenthal (1953) showed, in 
three male subjects, that only 0.5%-1.5% of a 500 mg intra­
venous dose of caffeine was excreted unchanged in the urine. 
However, whilst they reported plasma half-lives for both man 
and dog, caffeine metabolites were not analsyed in either 
plasma or urine. Although a report by Weinfeld and Christman 
(1953) confirmed that 1-methyl uric acid was an important 
metabolite of caffeinet and that 1,3-dimethyluric acid and 
1-methyluric acid were the principal metabolites excreted 
following theophylline ingestion, the first metabolic pathways 
for each methylxanthine were proposed by Cornish and Christman 
in 1957.
By semi-quantitative analysis of the methylxanthines and
- 10 -
methyluric acids excreted by two volunteers following the 
ingestion of 1 g of theophylline, Cornish and Christman <1957) 
established that the main metabolites in urine after 
theophylline ingestion were 1,3-dimethyluric acid, 1-methyl 
uric acid, 3-methylxanthine and unchanged theophylline (10%). 
In a similar manner they also investigated the metabolism of 
caffeine and theobromine and found that for caffeine, the 
major urinary metabolites were 1-methylxanthine and 1-methyl 
uric acid. To a lesser degree 1,7-dimethylxanthine, 7-methyl- 
xanthine, 1,3-dimethyluric acid and unchanged caffeine were 
also excreted. Following the ingestion of theobromine, the 
major urinary metabolites were reported to be 7-methyl- 
xanthine, 3-methylxanthine, 7-methyluric acid and unchanged 
theobromine. However, the techniques used in these early 
studies were based on anion exchange and paper chromatography 
and the results were therefore mainly qualitative.
In recent years high performance liquid chromatography 
(HPLC), in combination with liquid scintillation counting and 
ultra-violet monitoring has been used to further elucidate the 
metabolic fate of labelled methylxanthines (Callahan et al. 
1980,1982; Arnaud and Welsch 1980; Tang-Liu and Riegelman 
1983; Tang et al. 1983). It is now well accepted that in man 
caffeine is metabolised by a series of sequential and parallel 
reactions (Fig. 1.2), the initial stages of which may be 
summarised as follows:
A. 3-N demethyl ation to yield 1 ,7-dimethylxanthine
(paraxanthine).
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B. 1-N demethylation to yield 3,7-dimethylxanthine
(theobromine >.
C. 7-N demethylation to yield 1,3-dimethylxanthine
(theophylline).
These 3 reactions are probably catalysed by one or more of 
the cytochromes P-450 and yield formaldehyde as a secondary 
product. It has been estimated (Arnaud and Welsch, 1981) that 
approximately 95% of caffeine metabolism proceeds by an 
initial demethylation via these three reactions.
D. Hydroxylation of caffeine at the C-8 position to yield
1.3.7-trimethyluric acid which may also exist in its urate 
(salt) form. This reaction is again probably catalysed by one 
or more of the cytochromes P-450.
E. Hydration of caffeine at the 8,9 position to yield
1.3.7-trimethyldihydrouric acid and reversible ring opening to 
form 6-amino-5N-CformyImethy1amino]-1,3-dimethyluraci1. The 
enzyme(s) catalysing these reactions is not yet defined.
Although the reactions A-E all involve caffeine as a 
substrate, it is generally accepted that analogous reactions 
occur with the primary or secondary metabolites of caffeine.
In order to assess the importance of each of the three 
demethylation pathways, Arnaud and Welsch (1981) administered 
oral doses (4 mg/kg) of unlabeled paraxanthine, theobromine 
and theophylline to six non-smoking volunteers and quantitated 
the resulting urinary metabolites. Their report concluded that 
the quantitative importance of the initial demethyl ation 
reactions, in terms of metabolite recoveries were: 3-N 72%,
- 13 -
7-N 20% and 1-N 8%. A summary of the results of these findings
is shown in Fig.1.2. In a cross over study involving the
14 14administration of oral doses of 1- methyl- Cl-and C2- Cl 
caffeine to 8 normal male subjects, Callahan et al (1982) were 
able to account for 81% of the total dose of caffeine 
administered. Although their chromatography system was unable 
to resolve 7-methylxanthine from 1-methyluric acid, 
theophylline from paraxanthine and 3,7-dimethyluric acid from 
1-methylxanthine, their urinary profiles were similar to those 
reported by Arnaud and Welsch (1981). Faecal excretion of 
methylxanthines (where biliary metabolites could be included) 
accounted for less than 2% (± 1.7%) of the administered dose. 
One of the major urine metabolites found in this study 
corresponded to 5-acetylamino-6-amino-3- methyl uracil (AAMU), 
a urinary pyrimidine initially identified by Fink et al. in 
1964 as an excretion product elevated after oral intake of 
caffeine. The excretion of this metabolite showed great 
interindividua1 variability, with recovery values ranging from 
between 7% to 35% of the administered dose (mean 14.7% ±
6.4%). Another radiolabelled polar metabolite called A2 was 
also detected (3% ± 1%) but this unidentified compound was 
found to be unstable in methanol solution left at room 
temperature, transforming to AAMU. The possibility that AAMU 
was also an artefact of isolation was later investigated by 
Tang et al. (1983) who, in confirming this hypothesis, 
isolated and identified 5-acetyl amino-6-f ormyl amino^- 3-methyl 
uracil (AFMU) as a major metabolite of caffeine. Although this 
opened-ring metabolite of caffeine was initially isolated in
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the urine of a volunteer fed 1-methylxanthine (Arnaud and 
Welsch, 1981), its urinary excretion has recently been found 
to be more rapid and quantitatively more important following 
paraxanthine administration. It is however possible that its 
first identification as a 1-methylxanthine metabolite could be 
a result of an incomplete clearance of caffeine due to an 
inadequate period of abstention from dietary xanthines prior 
to the study.(Fig 1.3)
The formation of AFMU has been shown to be mediated by the 
polymorphic N-acetyltransferase enzyme (Grant et al., 1983a) 
which is responsible for the acetylation of a number of 
endogenous substrates and drugs including isoniazid and 
sulfamethazine. Furthermore, it has been shown that the molar 
ratio of AFMU to 1-methylxanthine excreted in 24 hour pooled 
urine samples following the ingestion of 300 mg caffeine 
provides a simple index of acetylator status (Grant et a l ., 
1983b).
In a comparative study of caffeine metabolism following an 
14oral dose of C2- Cl-ca f f e m e  in a 1:1 mixture of unlabelled
15 13caffeine and Cl,3— N-8- Cl-caffeine, Callahan et al. (1983)
reported that the biotransformation of caffeine was similar in 
groups of normal males, ovulating females and females 
receiving oral contraceptives, despite a slower plasma 
clearance rate for caffeine in the latter group. Possible 
variations in the biotransformation of caffeine resulting from 
increasing age or its route of administration has recently 
been investigated by Blanchard et al., (1985), by comparing 
urinary metabolite profiles in a group of seven healthy young
- 16 -
men (aged 18-29 years) and in a group of five healthy elderly 
men (aged 66-71 years) following 5 mg/kg doses of caffeine, 
either as an aqueous oral solution or an intravenous infusion. 
The metabolite profiles in both groups showed no substantial 
variation with either the route of administration or age, with 
the exception that significantly greater amounts of 1-methyl­
uric acid, 7-methyluric acid and 1,7-dimethyluric acid were 
excreted by elderly subjects.
1.3. PHARMACOLOGICAL PRQPERT 1ES
The dietary xanthines have several pharmacological actions 
in common but differ markedly in the intensity of their 
actions. They stimulate the central nervous system, 
respiration, cardiac muscle and skeletal muscle; act on the 
renal tubules to produce a diuresis; relax smooth muscle, 
notably bronchial muscle and they cause coronary dilation.
A structure/activity relationship exists between the three 
compounds. Methyl substitution on position 1 is associated 
with central nervous system (CNS) stimulation, diuretic 
effects are linked to the 3-methyl groups and cardiac 
stimulation with the methyl group at position 7. Caffeine 
therefore shows all three effects whilst theobromine possesses 
relatively weak CNS activity and theophylline has increased 
cardiac stimulant properties. All three compounds produce a 
diuresis from the presence of the 3-methyl group.
1.3.1. Central n ervous system (CNS).
Caffeine and theophylline stimulate the CNS at all levels, 
the cortex being affected first folllowed by the medulla,
- 17 -
whilst the cord is stimulated only by very large amounts. 
Theobromine is virtually inactive in terms of CNS stimulation. 
Stimulation of the cortex occurs following the administration 
of 150-250 mg of caffeine, resulting in a more rapid and 
clearer flow of thought with less drowsiness and fatigue 
(Goldstein et al. 1965; Bruce et al. 1985). Caffeine also 
produces an increased capacity for sustained intellectual 
effort, decreased reaction time, and a more perfect 
association of ideas. Comparable effects of theophylline have 
not been carefully investigated. At higher doses, methyl- 
xanthines produce nervousness, restlessness, insomnia, 
tremors, hyperesthesia and other signs of CNS stimulation 
(Rail, 1980).
Caffeine and theophy11ine stimulate medullary respiratory, 
vasomotor and vagal centres but only in the presence of high 
blood levels. Following the administration of large amounts of 
caffeine or theophylline, the spinal cord may also be 
stimulated resulting in increased reflex excitability and 
lower motor centres may be directly excited. This may produce 
focal and generallised convulsions although in man, the toxic 
dose of caffeine is so large (over 10g) that human fatality 
from the consumption of caffeinated drinks is unlikely (McGee, 
1980).
1.3.2. Cardiovascular system.
Caffeine and theophylline have prominent actions on the 
circulatory system although they are complex and sometimes 
antagonistic. The resulting effects depend largely on the 
conditions prevailing at the time of their administration and
- 18 -
the dose used.
Direct stimulation of the myocardium, particularly by 
theophylline, causes an increase in the force of contraction 
and cardiac output with an accompanying decrease in the venous 
filling pressure. Until recently, theophylline was used in the 
treatment of congestive heart failure but, the unpredictable 
absorption and distribution of theophylline in patients with 
compromised circulatory function frequently led to serious CNS 
toxicity (Piafsky et al. 1977).
At therapeutic plasma concentrations (10-20 mg/1) theophy­
lline produces a modest increase in heart rate in normal 
individuals (Ogilvie et al. 1977). Similar effects for 
caffeine have been reported by Robertson et al. (1978) who 
also observed that noradrenaline, adrenaline and renin levels 
were significantly raised at 1 and 3 hours following the oral 
ingestion of caffeine (250 mg). However their release does not 
appear essential to the pressor effect of caffeine, since 
patients lacking a functioning autonomic nervous system have a 
normal or even exaggerated pressor response. After large 
doses, both methylxanthines produce definite tachycardia and 
sensitive individuals may experience other arrhythmias, such 
as premature ventricular contractions.
By direct action on the vascular musculature, the xanthines 
dilate the coronary, pulmonary and general systemic blood 
vessels although they may also contract blood vessels by 
stimulation of the medullary vasomotor centre. Dilation of the 
coronary arteries increaes coronary blood flow and the ablity 
of the heart for work, but the overall effect of the xanthines
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on the systemic blood pressure is unpredictable. In the 
cerebral circulation, the xanthines increase vascular 
resistance thus decreasing cerebral blood flow and the oxygen 
tension of the brain. This vasoconstriction, rather than a 
decrease in cerebrospinal fluid pressure, may be responsible 
for the relief of hypertensive headaches by the xanthines 
(Rail, 1980).
1.3.3. Smooth muscle.
Xanthines, especially theophyline, relax the smooth muscles 
of the bronchi and are of value in the treatment of bronchial 
asthma. They may also overcome spasm of the biliary tract, 
produced in man by the injection of morphine or other opioids 
(Grubb and Burks, 1975), and theophylline containing compounds 
have been employed in the treatment of biliary colic.
1.3. 4. Ske 1 e t a_l _musc 1 e_.
Xanthines strengthen the contraction of isolated skeletal 
muscle, possibly by electrical stimulation or by an increased 
release of acetycho1ine. Caffeine increases the capacity for 
muscular work although it is argued that this may be due to 
stimulation of the central nervous system.
1.3.4. Gastric secretion
In man, moderate oral or parenteral doses of caffeine cause 
secretion of both acid and pepsin (Debas et a l ., 1971). In
experimental animals pathological changes and ulcer formation 
have been shown to occur following high doses. Evidence 
suggesting that caffeine potentiates secretion of acid, 
induced by histamine or alcohol, is not convincing but careful 
attention should be made to the ubiquitous use of caffeinated
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beverages in the pathogenesis and management of patients with 
peptic ulcers. Other ingredients of coffee have been shown to 
elevate plasma gastrin response in humans (Berkowitz et a l . / 
1974) suggesting that coffee may be a more potent cause o fj
stomach activity than caffeine alone. However, in a more /
/
recent study (McArthur et al., 1982), no single property of a 
variety of caffeinated beverages (including pH, caffeine 
content, osmolality, caloric content, buffering capacity and 
ionized calcium level) was found to be an adequate predictor 
of gastric acid secretion in humans.
 Carbohydrate and lipid metabolism.
It is generally believed that caffeine raises blood sugar 
levels, possibly by the accumulation of cyclic AMP. Coffee has 
been shown to increase glucose tolerance in normal subjects 
(Feinberg et al., 1968) and to reduce it diabetics. Although 
no explanation for this has been proposed, caffeine inhibits 
glucose metabolism and antagonises the effects of insulin, 
which may lead to increased blood glucose levels when insulin 
production is faulty.
Caffeine elevates free fatty acid levels.in plasma by 
stimulating cyclic AMP mediated lipolysis in adipose tissue 
(Bellet et a l . 1968). This effect can be blocked by insulin
and nicotininc acid and appears to be greater in young 
subjects perhaps indicating some degree of tolerance with 
increasing age. Tea drinking is negatively correlated with 
serum lipid levels in heart disease patients suggesting that 
it may contain a substance that counteracts the lipolytic 
effects of caffeine (Little et al. 1966). The prevalence of
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atherosc1erois appears to be higher among coffee-drinking than 
among tea-drinking populations (Young et al . 1967).
1.3.6. Other biochemical effects.
The xanthines, particularly theophylline have a well known 
diuretic effect which may be due to increased renal blood flow 
or a direct effect on the renal tubule. However, caffeine has 
also been shown to cause water retention (Ross, 1971) possibly 
from synergism between the action of antidiuretic hormone and 
eye lie A M P .
Caffeine readily permeates the liver and may alter the 
activity of drug metabolizing enzymes in the liver. In vitro, 
it has been shown to inhibit and reduce platelet aggregation 
induced by adenosine diphosphate but its effects on blood 
clotting are unknown. It depresses the formation of urea from 
ammonium salts and promotes creatinuria.
High doses of caffeine in rats produce an endocrine stress 
syndrome (Spindel and Wurtman, 1984) characterized by 
decreased serum TSH levels, suppressed pulsatile secretion of 
growth hormone, and elevated serum levels of corticosterone
following 500 mg doses but it is unlikely that these effects 
would be produced with normal patterns of coffee consumption. 
However, a non-coffee drinker who suddenly chose to drink
Similar responses have been shown in man
large amounts of caffeine containing beverages or analgesics
might we 1-4— be^expected to experience transient endocrine
changes.
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1.4. CELLULAR BASIS FOR THE ACTION OF THE METHYLXANTHINES
In spite of the widespread use of the methylxanthines as 
food constituents and as drugs, the molecular mechanisms 
mediating their pharmacological actions are not well 
understood. In order to explain their diverse effects, three 
basic cellular actions of methylxanthines have been studied, 
which in order of increasing sensitivity to methylxanthines 
are:
a) Translocation of intracellular calcium. 
b> Inhibition of cyclic AMP phosphodiesterase, 
c) Competitive antagonism of cell surface adenosine 
receptors.
Although caffeine has been shown to increase calcium levels 
in mammalian smooth muscle, heart muscle and skeletal muscle; 
the threshold for observations related to alterations in the 
permeablity to or binding of calcium in intracellular 
organelles, appears to be consistently greater than the 
maximal therapeutic concentrations for methylxanthines (Rail,
1980). Until recently, it was widely held that caffeine and 
theophylline acted in vivo by inhibiting phosphodiesterase and 
subsequently increasing levels of cyclic AMP. However, in 
intact animals, even relatively high doses of methylxanthines 
fail to increase tissue cAMP levels (Burg and Warner, 1975) 
and some inhibitors of phosphodiesterase that are 100-1000 
times more potent than caffeine, fail to show similar 
behavioral effects (Snyder, 1984).
The past decade has produced considerable evidence to 
suggest that the observed behavioral and physiological effects
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of caffeine may involve competitive antagonism at cell surface 
adenosine receptors (Fredholm, 1980; von Borstel and Wurtman, 
1984; Snyder, 1984). In animals, adenosine produces sedation, 
bradycardia, hypotension, hypothermia, dilation of coronary 
and cerebral arteries, inhibition of platelet agregation, and 
suppression of locomotor activity. It also modifies the 
responses of the heart, vasculature, adipose tissue, and 
kidney to sympathetic stimulation. These effects, which are 
mediated through specific adenosine receptors located on the 
external surfaces of the plasma membranes of cell <Daly et al.
1981), are competitively antagonised by methylxanthines at 
concentrations similar to those found in plasma after the 
consumption of one to three cups of coffee <5-30 uM; Rail
1980).
The first biochemical analysis of adenosine receptor 
activity by Sattin and Rail <1970), showed that adenosine can 
increase the accumulation of cyclic AMP in brain slices by 
direct action on extracellular receptors which may be blocked 
by theophylline. The effects of adenosine on the enzyme 
adenylate cyclase, reveal two distinct sub-types of adenosine 
receptors which have been designated Al and A 2 . These 
receptors show opposing effects in that adenosine, at micro­
molar concentrations, inhances adenylate cyclase activity via 
A2 receptors .whilst at nanomolar concentrations, it decreases 
adenylate cyclase activity through Al receptors. There are 
also structure-activity differences between the receptors, the 
most striking being the marked stereospecificity in the 
effects of phenyl-isopropy1adenosine <PIA) at Al receptors,
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with L-PIA being much more potent than D-PIA. At A2 receptors 
the two isomers have relatively similar effects.
Although most xanthines have similar potencies in blocking 
both Al and A2 receptors, some exceptions exist between 
affinities for adenosine receptors and behavioral effects 
(Snyder, 1984). For example, 3-isobutyl-1-methylxanthine 
(IBMX) has about the same affinity as caffeine for adenosine 
receptors, but does not display locomotor enhancement at any 
dose examined. In addition, biphasic effects have been 
observed for some xanthines eg. at lower doses caffeine 
decreases locomotor activity whilst at higher doses it 
enhances it. IBMX decreases activity at all doses whilst 7-(p 
-hydroxyethy1)theophy11ine enhances locomotor activity at all 
doses evaluated.
The long term blockade of adenosine receptors by caffeine 
makes the cardiovascular system more sensitive to adenosine 
and also increases brain adenosine receptor density (von 
Borstel and Wurtman, 1984). It is possible that the onset of 
headaches and jitteriness associated with caffeine withdrawl 
(Goldstein et al., 1969) might reflect enhanced tissue 
sensitivity to endogenous adenosine which is a potent dilator 
of the cerebral vasculature. Although the effects of 
adenosine on cardiovasular tissues have generally been thought 
to be restricted to the particular tissue in which the 
adenosine was formed and released (Fredholm, 1980), it is 
possible that circulating adenosine might also function in a 
hormone-like role affecting vascular dynamics in tissues 
throughout the body (von Borstel and Wurtman, 1984).
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1 .5 . MEASUREMENT OF CAFFEINE AND ITS METABQLITES^Jl-^JLOLQCLLCAL.
FLU 1 US
Procedures for the measurement of caffeine in biological 
fluids have, in general, paralleled the development of ./ 
analytical technology and have utilised ultraviolet 
spectrophotometrty, paper chromatography, thin layer 
chromatography <TLC>, gas-liquid chromatography (GLC), high 
performance liquid chromatography (HPLC) and radioimmunoassay 
<RIA>. The progress in methodology has not only increased the 
sensitivity, specificity and ease of determinations but has 
also permitted the measurement of metabolites.
1.5 .1. Ultraviolet spectrophotometry
Ultra-violet spectrophotometry was first utlised by Ishler 
et al.(1948> for the measurement of caffeine in coffee, a 
procedure later adapted by Fisher et al.<1949) for monitoring 
caffeine levels in the urine of greyhounds and horses. Prior 
to this, the determination of caffeine involved extraction 
with chloroform followed by a nitrogen estimation or the 
application of a non-specific colorimetric method. The first 
definitive method for the determination of caffeine in 
biological fluids was described by Axelrod and Riechenthal 
(1953). Caffeine was extracted with benzene from a biological 
matrix saturated with sodium chloride at pH 7-8 and then back 
extracted with 5N HC1 before direct measurement of its 
absorbance at 273 nm. Problems related to the effects of 
benzene in altering the spectral absorbance curve of caffeine 
were later overcome by Routh et al.(1969) using a differential
//
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absorption method at 285 nm, in which the same extract at two 
different pH values was used for the sample and reference 
solutions. However, U.V. spectrophotometric procedures are 
time consuming, require large sample volumes and are prone to 
interference from caffeine metabolites and co~administered 
drugs.
1.5.2. Immunoassay techniques
A radioimmunoassay for the measurement of caffeine in 
serum, described by Cook et al.(1976> offered many advantages 
in terms of sensitivity and specificity. An antiserum, 
prepared by immunizing rabbits with 7-[5~carboxypenty11-1,3- 
dimethylxanthine-bovine serum albumin conjugate, was incubated 
with serum samples for 2 hours in the presence of a [8- H3 
caffeine radioligand, before separation of bound and unbound 
ligand with dextran-coated charcoal. The requirement for a 
sample volume of only 20 pi and a detection limit of 20 ng / m l , 
led to the procedure being used in several kinetic studies.
Non-isotopic immunoassays for the measurement of caffeine 
have received limited attention. An enzyme multiplied 
immunoassay technique <EMIT) has been developed for 
theophylline (Syva Inc.), using an antiserum produced in a 
manner similar to that described for RIA. The enzyme-1abe11ed 
drug is made by coupling theophylline at the 8-position with 
g lucose-6-phosphate (Gunshaw et al.,1977), the activity of 
which is monitored spectrophotometrica1ly by the reaction 
between NAD and g lucose-6-phosphate. Although a similar 
system could be adopted for the measurement of caffeine, the
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manufacturers have declined to develop the assay in view of 
its limited application. A substrate labelled fluorescent 
immunoassay (SLFIA) has been described by Biggs et al.(1985) 
although the anti serum used in the procedure showed extensive 
cross reactivity with theophylline.
1.5.3. Thin layer chromatography
Thin layer chromatography techniques have been employed in 
both therapeutic monitoring and, in combination with the use 
of radiolabelled caffeine, for studies of the biotransformation 
of caffeine. A procedure for the measurement of caffeine and 
theophylline in serum, saliva or urine was described by 
Reichert <1978) for monitoring the treatment of neonatal 
apnoea with methylxanthines. Using a Keiselgel 60 F254 
chromatography plate, samples were applied directly onto a wet 
ethanol spot and developed using a solvent system of 
ethylacetate: methanol: 25% ammonia. A detection limit of 
about 1 yig/ml was achieved by measuring the UV absorbance with 
a dual wavelength scanner, in a reflection mode using a sample 
wavelength of 273 nm and a reference wavelength of 315 nm.
Two dimensional chromatography of radiolabelled caffeine, 
using a silica gel plate (Merck F254, 0.25 mm thickness) was 
used by Arnaud (1976) to resolve the various metabolites of 
caffeine in urine. The sample spots were developed first with 
chloroform: methanol <4:1, v/v) and then with chloroform: 
acetone: n-butanol: concentrated ammonium hydroxide <3:3:4: 1, 
v/v). Using this procedure, the chromatographed compounds may 
be identified using a radioscanner and/or autoradiography, or
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by scintillation counting following removal of the spots by 
scraping or cutting of the plate. A one dimensional procedure 
with chloroform: acetone: n-butanol: concentrated ammonium 
sulphate <3:3:2:0.5, v/v) described by Ferrero and Neims 
<1983) separated theophylline, theobromine, 1,7-dimethyl- 
xanthine, 1,3,7-trimethyluric acid and 6-amino-5-CN-formy1- 
methylaminol-1,3-diaminouraci1.
1.6.4. Gas-liquid chromatography
The application of gas chromatography to the measurement of
caffeine in plasma was first described by Grab and Reinstein
in 1968. Samples were prepared by an alkaline extraction with
chloroform, using hexobarbital as an internal standard, before
injection onto a 3% 0V17,Chromosorb W 100-120 mesh AW/DMCS
0
column at an operating temperature of 200 C. The effluent was
o
monitored using a flame ionization detector at 260 C.
In recent years, the introduction of alkali flame
ionization detectors, specific for nitrogen/phosphorus 
containing compounds, has resulted in the development of 
methods showing significant improvements in both sensitivity 
and specificity (Cohen et a l ., 1978; Bonati et al, 1979;).
These have included a procedure for the measurement of 
caffeine in urine utilizing solid phase extraction columns 
(Delbeche and Debackere, 1983). However, these methods have
received only a limited application to studies on the kinetics
of caffeine, due mainly to their inability to measure 
metabolites. In addition, a comparison between the use of GLC 
using nitrogen-phosphorus detection and high performance
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liquid chromatography techniques (Bonati et al., 1979) showed 
that HPLC gave linear responses over a wider concentration 
range with improved precision at lower concentrations and 
subsequently lower limits of detection.
The combination of GLC with mass spectrometry has provided 
a valuable system for the identification of metabolites of 
caffeine (Merriman et al., 1978).
 H igh per formance liqu id chromatography
The present understanding of the disposition of caffeine is 
largely attributable to the application of high performance 
liquid chromatographic techniques which have permitted the 
simultaneous measurement of both caffeine and its methyl- 
xanthine metabolites. Procedures have been described for the 
measurement of caffeine in piasma/serum, urine, saliva, milk, 
cerebrospinal fluid, semen, amniotic fluid, aqueous humour, 
and a variety of tissue affusates, perfusates and extracts. 
Measurement of caffeine and its d imethvlxanthine metabolites 
in serum and saliva.
The various methods described for the measurement of 
caffeine in serum are summarized in Table 1.1. They differ 
mainly with regard to their chromatographic conditions and 
mode of sample preparation. Although normal phase systems have 
shown adequate resolution and specificity for both caffeine 
(Van der Meer and Hass, 1980) and its metabolites (Arnaud and 
Welsch, 1982, Wahl lander et al., 1985), most procedures have 
favoured the improved reliability and simplicity of reverse 
phase systems (Desiraju et a l ., 1977; Foeander et al., 1980;
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Blanchard et al., 1982; Pickard et al., 1986). However, the 
inability of reverse phase systems to adequately resolve 
theophylline and 1,7-dimethylxanthine has impeded their 
application to metabolite studies. Recent procedures for the 
measurement of theophylline, have shown that these problems of 
specificity may be improved by the incorporation of 
ion-pairing reagents, such as tetrahydrofuran (Miksic and 
Hodes, 1979) or tetrabutyl ammonium chloride (Farrish and
Wargin, 1980), into the mobile phase.
Sample preparation has been achieved either by the use of 
organic extraction or deproteinization techniques, involving 
precipitation with acetonitrile solutions (Blanchard et al., 
1980; Christensen and Neims, 1985) or ultrafiltration 
(Desiraju et a l ., 1977). Organic extraction with dichloro-
methane or chloroform/isopropanol mixtures has been mainly 
adopted in preference to deproteinization techniques in order 
to overcome problems encountered with peak distortion (Jowett,
1981) and interference from cephalosporin antibiotics (Kelly 
et al., 1978). More recently solid phase extraction columns, 
containing reversed-phase octadecylsilane bonded silica 
(Bond-Elut C18), have been used for both the measurement of 
caffeine and theophylline in serum (Pickard et al., 1986; 
Hartley et al., 1986). Whilst their use reduces analysis time 
by eliminating the need for solvent evaporation and 
reconstitution in the mobile phase, these advantages are 
offset by their high cost.
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b ) Measurement o f m ethvlxanthine metab o lites in u rine
The techniques used in early studies of the metabolism of 
caffeine and theophylline (Brodie et al., 1952; Cornish and 
Christman, 1957) were very cumbersome, involving anion- 
exchange chromatography followed by paper chromatography; 
then, spectrophotemetry and colorimetry. Quantitative analysis 
of these metabolites was not achived until 1974 when, Thompson 
et al. <1974) separated theophylline metabolites using an 
Aminex A-5 cation exchange resin. However, the sample 
preparation was extremely time consuming and laborious since 
it involved an initial prefractionation of the urine into 
methylxanthine and uric acid fractions using a Dowex 2-X8 
anion exchange resin <C1- form, 50-100 mesh). These fractions 
were then injected separately onto the ion-exchange column.
Aldridge et a l . (1979) determined caffeine metabolites
using a simple gradient elution system <1.5%-7.5% aceto- 
nitrile in 0.5% glacial acetic acid) on a reversed phase 
column <p Bondapak C-18) following organic extraction of urine 
samples by means of chloroform/isopropanol (85:15). However, 
although the procedure was used by Callahan et al. (1981) and 
Arnaud and Welsch (1981) for studies on the metabolism of 
caffeine, it failed to resolve 7-methylxanthine from 
1-methyluric acid, theophylline from 1,7-dimethylxanthine or
3,7-dimethyluric acid from 1-methyl xanthine. In addition, 
extraction recoveries were consistently low for 1-methyluric 
acid (36.3%), 7-methyluric acid (55.6%) and 3,7-dimethyluric 
acid (58.5%).
Recently, it has been shown that the recovery of methyl
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xanthines from urine may be significantly improved by the 
formation of an ion-pair complex prior to extraction (Tang-Liu 
and Riegelman (1982). The sample, internal standard (^-hydroxy 
- ethy1theophy11ine), 0.1M tetrabutylammonium hydrogen 
sulphate, and 0.01M sodium carbonate buffer, pH 11.0, were 
mixed for 30 seconds before and after the addition of about 1 
gram ammonium sulphate. This mixture was then extracted with 
ethylacetate: chloroform: isopropanol (45:45:10) and,
following centrifugation, the organic layer was evaporated to 
dryness under nitrogen. The residue was then reconstituted in 
an aqueous solution of 50mM tetrabutylammonium hydrogen 
sulphate and 10mM sodium acetate, pH 4.9. Chromatoraphy was 
then performed using a 5 yim Ultrasphere ODS column and a 
gradient elution sytem consisting of Solvent A, the 
aforementioned reconstitution solution, and Solvent B which 
consisted of solvent A mixed with an equal volume of 50% 
methanolj pH adjusted to 4.8 with glacial acetic acid. A 
gradient increase of 0-45% increase in solvent B resolved 15 
methylated xanthines and uric acids within 30 minutes, the column 
effluent being monitored at 280 nm. However, the retention of 
7-methylxanthine was found to be sensitive to trace amounts of 
methanol retained in the stationary phase of the column, and a 
re-equilibration period of 30 minutes was necessary to resolve 
7-methylxanthine from 3-methyluric acid.
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2. MEASUREMENT OF CAFFEINE AND ITS DIMETHYLXANTHINE
METABOLITES IN SERUM AND SALIVA USING HIGH PERFORMANCE
LIQUID CHROMATOGRAPHY
In recent years, high performance liquid chromatography 
(HPLC) has been extensively applied to the specific analysis 
of theophylline or caffeine, but the simultaneous measurement 
of caffeine and its dimethylxanthine metaboltes has received 
little attention. Foenander et al.(1980) described a procedure 
wherein dichioromethane extracts of serum were chromatographed 
on a octadecy1si1ane column using 12% acetonitrile in acetate 
buffer, pH 4, as a mobile phase. However, dichioromethane 
extraction produced a low recovery and the chromatography 
system was unable to resolve theophylline from 1,7-dimethyl- 
xanthine (paraxanthine), a metabolite of caffeine often 
present in significant concentrations in biological fluids. 
Improved specificity was shown in a normal phase procedure 
adopted by Arnaud and Welsch (1981) for the measurement of 
theophylline, theobromine, paraxanthine and caffeine in serum 
and saliva. Samples were extracted using a chloroform/ 
isopropanol mixture but their results showed considerable 
variation in recovery between xanthines. Moreover, normal 
phase systems are prone to rapid column deterioration.
The specificity problems encountered with reverse phase 
systems for the measurement of methylxanthines may be improved 
by the incorporation of tetrahydrofuran (Miksic and Hodes,
1979) or tetrabutylammonium chloride (Farrish and Wargin,
1980) into the mobile phase. This report describes the
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development of a procedure, designed initially for the 
simultaneous measurement of caffeine, theophylline and 
theobromine in serum and saliva but later modified to permit 
the estimation of 1,7-dimethylxanthine, the primary metabolite 
of caffeine found in serum and saliva. The correlation between 
caffeine levels in serum and saliva is investigated and the 
results obtained by HPLC analysis are compared with those 
obtained using a radioimmunoassay procedure.
2.1. Materials and Equ ipment
Caffeine was purchased from BDH Chemicals Ltd. Poole, 
England; theophylline, 7^-hydroxypropy1theophy11ine 
(proxyphyl1ine), 1-methyluric acid, and 1,7-dimethylxanthine 
from Sigma Chemical Company Ltd., Poole, Dorset, England; 
7-methyluric acid, 7-methylxanthine, 3-methylxanthine,
1-methylxanthine, 1,3-dimethyluric acid, 1,7-dimethyluric acid 
and 1,3,7-trimethyluric acid from Adams Chemical Company,
Round Lake, Illinois, USA.
Stock solutions (200 mg/1) of the xanthines were prepared 
in distilled water. The working standards of caffeine, 
theophylline, and theobromine were made by further diluting 
the stock solution in horse serum (Wellcome Reagents Ltd. 
Beckenham, England) to give concentrations of 5-30 mg/1.
Analar grade chloroform, isopropanol, tetrahydrofuran (BDH 
Chemicals Ltd., Dorset, England) and HPLC grade acetonitrile 
(Rathburn Chemicals Ltd., Walkerburn, Scotland) were used 
throughoutvthe study.
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HPLC Equipment
Initial studies were performed using an Applied 
Chromatography Systems (ACS) twin headed reciprocating pump 
(Model 750/03). This was later replaced by an ACS model 300/02 
single headed, dual channel, reciprocating pump. Both pumps 
were adjustable to provide a constant flow rate of 0.1 to 9.9 
ml/min.
Eluted peaks were detected using an ACS 750/1 IE UV monitor 
fitted, with an 8 pL flow cell, and integrated using a Spectra 
Physics Model 4270 computing integrator. Samples were injected 
via a Rheodyne loop injector fitted with a 50 pL loop.
Chromatography was performed using stainless steel columns 
(100 x 4.5 mm id.) packed, by a slurry techniqe, with 5 pm 
Hypersil octadecy1si1ane (Shandon, London, England). Methanol 
(AR) was used as the packing solvent. The packing material 
(1.8g) was added to a stainless steel column packing reservoir 
which was then filled to capacity (50 ml) with methanol and 
the contents mixed continuously on a magnetic stirrer for 
approximately 5 minutes. A.fter securing the reservoir lid in 
place, the solvent inlet line was attached to a constant 
pressure air pump and the reservoir outlet line attached to an 
empty column containing a 2 pm frit on the outlet end reducing 
union. The packing pump was then started and the air regulator 
adjusted to produce a pressure of 4,000 psi which was 
maintained until the solvent flow from the outlet end of the 
HPLC column had ceased. After allowing the pressure to return 
to zero, the column was disconected fron the packing system, 
installed into the analytical HPLC system and primed with the
- 38 -
appropriate solvent system for at least 30 minutes before 
injecting a standard mixture. The suitability of the column 
for use in analytical studies was assessed by inspection of 
peak symmetry and calculation of the number of theoretical 
plates. For the latter, a minimum value of 40,000 per metre 
was required.
2.2. Separation and identification of caffeine and its 
d imethvlxanthin e m etabolites by reverse phase HPLC.
The optimal chromatography conditions for the separation of 
an aqueous standard (10 mg/1) containing caffeine, 
theobromine, theophylline and 1,7-dimethylxanthine 
(paraxanthine) was investigated using a series of solvent 
systems consisting of acetonitrile or methanol solutions, 
prepared in distilled water or acetate buffer, as described in 
Table 2.1. The eluted peaks were detected using a UV monitor 
set at a previously established optimum wavelength of 280 nm. 
In order to improve the resolution between 1,7-dimethyl- 
xanthine (paraxanthine) and theophylline, and thus eliminate 
previously described problems of specificity (Miksic and 
Hodes, 1979; Farrish and Wargin, 1980), the use of mobile
phases incorporating tetrahydrofuran and tetrabutylammonium 
chloride as ion-pairing reagents were investigated.
Results
The separation of methylxanthines, using reverse phase high 
performance liquid chromatography, was found to be highly 
sensitive to changes in both the pH and polarity of the mobile
- 39 -
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1
mins
F i9 2.1 Chromatography of an aqueous solution of methylxanthines ( 10mg/l )
Chromatographic conditions as described in te x t.
Peaks; 1 = T h e o b r o m i n e  2 = 1 , 7 - d i m e t h y l x a n t h i n e
3 « T h e o p h y l l i n e  k = C a f f e i n e  5 = P r o x y p h y l l i n e
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Compound Capacity 
factor (k')
Retention 
time (min)
Theobromine 2.3 2.0
Theophylline 4.2 3.1
Caffeine 7.8 5.3
Proxyphylline 9.8 6.3
7-methyluric acid 0.5 0.9
7-methylxanthine 1.0 1.2
1-methyluric acid 1.3 1.4
3-methylxanthine 1.7 1.6
1-methylxanthine 1.8 1.7
1,3-dimethyluric acid 2.0 1.8
1,7-dimethyluric acid 3.2 2.5
1,7-dimethylxanthine 3.8 2.9
1,3,7-trimethyluric acid 5.0 3.6
paracetamol - -
Phenobarbitone - -
Primidone - -
Phenytoin - -
Trimipramine 1.0 0.6
Table 2.2 Chromatography retention data for the separation of
methylxanthines using a solvent system of 4% acetonitrile: 1%
tetrahydrofuran in 40mM acetate buffer, pH 4.0.
Indicates that the compound did not chromatograph under the 
conditions used.
r
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phases (Table 2.1.). The addition of tetrahydrofuran or tetra­
butyl ammoniumhydrogen hydrogen chloride produced similar and 
significant improvements in the resolution of theophylline and
1,7-dimethylxanthine. Optimum chromatographic conditions, in 
terms of resolution and retention time, were achieved using a 
moblie phase of 1% tetrahydrofuran/4% acetonitrile (v/v) in 
acetate buffer, pH 4. The use of this eluent at a flow rate of 
1.5 ml/min produced a pressure drop of 60 bars. The separation 
of an aqueous standard solution using this system is shown in 
Fig. 2.1.
The specificity of the chromatography system was examined 
by injecting aqueous preparations of methylxanthine metabol­
ites and a number of potentially interfering compounds, the 
retention times of which are shown in Table 2.2.
2.2.1. Electrochemical detection of methylxanthines
The suitability of direct current (dc) amperometric 
detection for the measurement of caffeine, theobromine and 
theophylline was assessed using an EDT Model LCA 10 detector 
fitted with a glassy carbon electrode and operated at an 
oxidizing potential of +1.3 volts. The electrochemical 
responses of the methylxanthines were monitored following the 
chromatographic separation of an aqueous standard solution 
using a solvent system of 12% acetonitrile in acetate buffer, 
pH 4.0, at a flow rate of 1 ml min.
Results
Chromatograms comparing the amperometric detection of a 100 
ng injection of aqueous standard solutions with detection by
/'
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a) Electrochemical detection. b) U.V. detection.
m  ins m  ins7
F i g  2 . 2  M o n i t o r i n g  of an e l u t e d  me thy 1 x a n t h i n e  s o l u t i o n  
( l O O n g )  u s i n g  a) e l e c t r o c h e m i c a l  d e t e c t i o n  a n d 
b) UV m o n i t o r i n g  at 2 8 0  nm.
C h r o m a t o g r a p h i c  c o n d i t i o n s  as d e s c r i b e d  in text.
1 - theobromine, 2 - theophylline, 3 - caffeine
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UV at 280nm are shown in Fig.2.2. At an operating potential of 
+1.3 volts only theophylline was detected using dc ampero­
metric detection. Although it has been shown that caffeine and 
theobromine are detectable using differential pulse ampero- 
metry (Lewis and Johnson, 1978), these facilities were not 
available and subsequently further use of amperometric 
detection was considered unsuitable.
2.3. The extraction of methylxanthines from serum.
In order to eliminate the previously reported specificity 
problems associated with deproteinization techniques (Jowett, 
1981; Kelly et al., 1978), an organic extraction procedure was 
investigated for sample preparation. The extraction efficiency 
of a series of organic solvent systems were examined by 
estimating the recovery of caffeine, theophylline, theobromine 
and 1,7-dimethylxanthine from two pooled serum samples, 
labelled A and B, which had been spiked with 4ug/ml and 8ug/ml 
amounts of aqueous standard. The extraction solvent sytems 
investigated were a) dichloromethane, b) chloroform, c) 
chloroform/isopropanol <85:15 v/v), d) ethylacetate and e) 
ether/dichloromethane <60:40 v/v)
100 pi serum, 200 pi 0. 2M HC1 and 5 ml of extraction solvent
were vortexed mixed for 30 seconds in a stoppered tube and
then centrifuged at 2,000 rpm (approx. 1500 g) for 5 minutes.
4 ml of the organic phase was then transferred to a clean tube
and evaporated to dryness under a stream of air in a water 
o
bath at 40 C. The residue was dissolved in 100 pi of the
-45 -
mobile phase and 50 ul injected onto the HPLC column. The 
recovery of the methylxanthines from serum was calculated by 
comparing the peak heights with those obtained from the 
injection of an unextracted aqueous standard solution 
(200ng/50ul>.
Results
The recovery data for each of the solvent systems studied 
is shown in Table 2.3. Optimum recovery was achieved using a 
chloroform/isopropanol mixture <85:15 v/v) which produced 
recovery values in excess of 90% for each methylxanthine. 
Chromatograms of serum samples extracted using this system are 
shown in Fig.2.3. Although dich1oromethane extraction was used 
in a procedure described by Foenander et al. (1980), these 
results suggest that recovery using this solvent is low, and 
in the case of caffeine, extremely variable.
2.3.1.The recovery of methylxanthines from saliva and aqueous 
J/ut^ons^ 
Using the procedure previously described for serum, the 
suitability of chloroform/isopropanol (85:15) extraction for 
the measurement of methylxanthines in saliva was investigated 
by determining the recovery from two saliva samples, spiked 
with 4 mg/1 and 8 mg/1 amounts of an aqueous standard. For 
comparison, aqueous solutions of similar concentrations were 
extracted in the same manner.
Results.
The recovery of methylxanthines from saliva was similar to 
that found for serum (Table 2.3.), thus confirming the 
suitability of the procedure for the extraction of methyl-
- 46 -
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oui
CO
mins
(a) 10
mins
0 10
(b)
Fig 2 .3 Chromatography of extracted serum samples collected 
a) before and b) 4 hours following an oral dose of 
caffeine (400 mg).
Chromatography conditions as described in text. 
Peak identification as in Fig 2.1
- 48 -
xanthines from saliva. In addition, the close agreement 
between aqueous recovery values and those obtained using 
serum/saliva matrices suggests that standardization of the 
procedure may be achieved using aqueous solutions.
2jJLJL Selection of an internal standard
In order to minimize any loss of precision, through either 
variations in extraction recovery or volume of injection, the 
use of an internal standard was adopted. Selection was based 
on examining the retention data of internal standard solutions 
(200 mg/1) used in previously described HPLC procedures for 
caffeine and theophylline. These included, 8-chlorotheophy1- 
line (Adams et al., 1976; Foenander et al., 1980), 7-hydroxy- 
propy1theophy11ine (Evenson and Warren, 1976; Naish et al., 
1979; Blanchard et al., 1980) and carbamazepine (Van der Meer 
and Hass, 1980).
Using a solvent system of 12% acetonitrile in acetate 
buffer, pH 4.0, at a flow rate of 1 ml/min 8-chlorotheophyl1- 
ine was unresolved from theophylline and carbamazepine was not 
detected. However, 7-hydroxypropy1theophy11ine was suitably 
resolved from all the standard methylxanthines. Following 
extraction by the previously described procedure, the recovery 
of 7-hydroxypropyl theophylline was found to be 95.4%, 
confirming its suitability for use as an internal standard.
2.3.3. Standardizat ion and detect ion limits.
A series of standard solutions (range 1-30 mg/1) contain­
ing theobromine, theophylline, paraxanthine and caffeine, were
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O  - Theobromine
•  - Theophylline2.0*
A  - 1,7-dimethylxanthine
- Caffeine
1.0'
0.5‘
100 2 4 6 8
Methylxanthine concentration (ag/1)
Fig 2.4 Standard curves for theobromine, theophylline, 1,7-dimethyl 
xanthine and caffeine following extraction of spiked serum 
samples.
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prepared using horse serum as a diluent. Duplicate extractions 
of these solutions, using proxyphy11ine <800 ng/tube) as an 
internal standard, were chromatographed and standard curves 
prepared by plotting the methylxanthine/proxyphyl1ine peak 
height ratios against concentration. The detection limit for 
each methyl- xanthine was established by determining the 
minimum concentration of a standard solution, which, when 
extracted, produced a signal to noise ratio of 4:1 at 0.01 
absorbance units full scale <AUFS). A blank extraction of the 
horse serum was also chromatographed in order to detect the 
presence of any interfering peaks.
Results
For each methylxanthine, the standard curves showed a 
linear response over the range investigated. Linear regression 
analysis showed corresponding coefficient of variation values 
<r> for theobromine, theophylline, paraxanthine and caffeine 
of 1.000, 1.000, 0.998 and 0.999 respectively. Standard curves
covering the normal expected range <1-10 mg/1) of these 
methylxanthines are shown in Table 2.4. Limits of detection 
were established as 100 ng/ml for theobromine, theophylline 
and paraxanthine and 200 ng/ml for caffeine. The extract of 
horse serum itself showed no significant interference.
2.3.4. R eproducibility of method
The within batch precision of the method was assessed by 
chromatographing replicate extractions of serum and saliva 
samples sjpiked with 4 mg/1 and 8 mg/1 amounts of an aqueous 
standard <200 mg/1). Between batch precision was studied by
- 51 -
Sample Theobromine Theophylline Paraxanthine Caffeir
Serum A 4.41 4.37 4.01 6.73
4.78 4.74 4.00 7.67
4.84 4.78 3.97 7.13
4.98 4.86 4.09 7.73
5.04 4.86 4.28 7.66
Mean 4.81 4.72 4.07 7.38
S.D. 0.25 0.2 0.13 0.44
CV% 5.13 4.3 3.08 5.9
Saliva A 4.35 4.25 4.21 5.20
4.49 4.38 4.58 5.17
4.38 4.25 4.00 4.76
4.49 4.29 4.13 5.37
4.38 4.3 4.20 4.96
Mean 4.42 4.29 4.22 5.09
S.D. 0.07 0.05 0.22 0.24
CV% 1.49 1.24 5.11 4.72
Serum B 7.6 7.59 7.31 7.84
8.08 8.16 8.00 7.97
7.99 8.0 8.26 8.0
8.06 7.91 8.30 8.13
8.06 7.94 8.18 8.3
Mean 7.96 7.92 8.01 8.05
S.D. 0.20 0.21 0.41 0.17
CV% 2.55 2.62 5.09 2.2
Saliva B 7.68 7.79 8.14 11.16
8.34 8.4 8.00 11.47
8.0 8.09 8.27 11.45
7,9 8.0 8.23 11.32
7.9 8.0 7.66 10.71
Mean 7.96 8.06 8.06 11.22
S.D. 0.24 0.22 0.25 0.31
CV% 3.02 2.75 3.06 2.78
Table 2.4 Within batch precision for measurement of 
methylxanthines in serum and saliva.
- 52 -
Sample Day Theobromine Theophylline Paraxanthine Caffeine
Serum A 1 4.83 4.38 4.48 4.49
4.74 4.26 — 4.58
2 4.88 4.52 4.30 4.83
4.79 4.53 - 4.81
3 5.14 4.74 4.76 4.13
5.00 4.51 — 4.42
4 4.94 4.55 4.33 4.80
4.75 4.74 - 4.93
Mean 4.89 4.53 4.47 4.65
S.D. 0.12 0.15 0.21 0.27
CV % 2.5 3.3 4.7 5.8
Serum B 1 8.29 7.89 8.24 11.88
8.17 7.78 — 1 1 . 1 1
2 8.31 8.22 7.72 11.72
8.21 8.22 - 11.88
3 8.43 8.17 8.41 12.24
8.50 8.22 — 12.39
4 8.18 8.18 8.16 12.10
8.69 8.77 - 12.44
Mean 8.35 8.19 8.13 11.97
S.D. 0.12 0.26 0.29 0.39
nrr Q. \~V 'O i a 3.2 3,6 3.3
Table 2.5 Between batch precision for the measurement of
methylxanthines in serum
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the repeated analysis of two serum samples "A" and "B" which 
had been spiked in a similar manner. For quantitation, the 
ratio of peak heights of the xanthines to those of the 
internal standard were compared with those obtained for 
appropriate working standards processed in a similar manner. 
Results
The results summarized in Table 2.4 and Table 2.5 showed 
good precision for both within and between batch analysis. 
Within batch analysis of serum samples produced overall 
coefficient of variation values for theobromine, theophylline,
1,7-dimethylxanthine and caffeine of 3.8%, 3.5%, 4.1% and 4.2% 
respectively. Similar results were shown for saliva samples 
with corresponding values of 4.7%, 2.0%, 4.1% and 3.8%. The 
mean coefficients of variation for serum samples A and B 
showed respective values of 2.0%, 3.3% and 4.6%, confirming 
that the precision of the method was maintained for between 
batch analysis.
2.4y  .Correlation between caffeine concentrations in serum and 
saliva.
A series of serum and saliva samples, collected simultan­
eously from 52 hospital staff and outpatient volunteers were 
assayed for caffeine by the procedure previously described.
For the collection of saliva samples, volunteers were 
requested to rinse their mouths out with tap water, and about 
5 minutes later, collect approximately 2 ml of saliva into a 
plastic container. In order to overcome sample contamination 
with sputum, volunteers were requested not to "clear their
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Concentration of caffeine in serum (mg/1)
Fig 2 .5 .  C o rre la tio n  between c a ffe in e  le v e ls  in  serum and s a liv a .
\
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8
6
2
0 1 086k2
HPLC (mg/1)
Fig 2.6* Correlation between serum caffeine estimations by HPLC and RIA 
( y =1.04 X - 0.063 ; r = 0.962 )
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throats" during collection.
Results
The relationship between results obtained for caffeine 
concentrations in serum and saliva is shown in Fig. 2.5*
Linear regression analysis showed a coefficient of correlation 
<r> of 0.941 with a regression line, y= 0.710 x - 0.018; where 
y is the value for saliva and x is the value for serum. These 
results indicate that the analysis of caffeine in saliva can 
be used to reflect concentrations in serum.
2 . 5 . .Corre lation between serum caffeine measurement by HPLC 
and radioimmunoassay.
In a collaborative study with St Luke’s Hospital, Guildford, 
a comparison was made between the results of caffeine 
determinations made on 42 serum samples using a radioimmuno­
assay procedure (Cook et al., 1976) and values obtained using 
the described HPLC procedure.
A scattergraph of the results obtained by each procedure is 
shown in Fig. 2.6. The correlation coefficient <r>, calculated 
by linear regression analysis, was 0.962 with a regression 
line, y= 1.04x - 0.063 where y is the value obtained by RIA 
and x the value by HPLC. These values confirm a good 
correlation between the two procedures.
DISCUSSION
Spectrophotometric methods for the measurement of caffeine, 
theophylline and theobromine in biological fluids (Schack and 
Waxier, 1949; Axelrod and Reichenthal, 1953; Fellenberg and
- 57 -
Pollard, 1979) require large sample volumes and are non­
specific whilst gas chromatography procedures (Cohen et al., 
1978; Schwertner, 1979; Chambers, 1979) have long analysis 
times and low sensitivity. The use of radioimmunoassy (Cook et 
al., 1976) and enzyme immunoassay techniques may be used to 
overcome some of these limitations but they are unable to 
provide simultaneous determinations of the methylxanthine 
metabolites of caffeine.
The method described in this study utilises the simplicity 
and reliability of reverse-phase HPLC which overcomes the 
problems of column deterioration often encountered with normal 
phase procedures. The incorporation of tetrahydrofuran into 
the mobile phase resulted in improved specificity by resolving 
theophylline from 1,7-dimethylxanthine thus permitting the 
simultaneous determination of caffeine and its dimethyl- 
xanthine metabolites. Sample preparation using organic 
extraction was adopted in preference to the more rapid 
deproteinization techniques in order to overcome associated 
problems encountered with peak distortion (Jowett, 1981) and 
interference from cephalosporin antibiotics (Kelly et al., 
1978). Optimum conditions for extraction were obtained using a 
chloroform/ isopropanol mixture (85:15 v/v) at pH 4. The 
recovery values and precision using this extraction procedure 
was shown to be very satisfactory and results suggest that 
aqueous standards may be suitably employed as an alternative 
to those prepared in drug free serum. Direct injection of 
saliva samples, diluted 1:4 with the internal standard, showed 
good reproducib1ity and results of caffeine analysis
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correlated well with those obtained using organic extraction 
<r = 0.995). However this technique resulted in a rapid 
deterioration of column performance and subsequently organic 
extraction is recommended for routine use.
The good correlation obseved between caffeine levels in 
serum and saliva indicates that analysis of saliva can be used 
to reflect concentrations in serum. The non-invasive nature of 
saliva sampling is of considerable advantage in therapeutic 
drug monitoring and pharmacokinetic studies, and the ability 
to perform at least 25 analyses in one working day makes this 
HPLC procedure highly suitable for these applications. In 
addition the procedure may also be used to determine methyl- 
xanthine concentrations in beverages by direct injection of 
diluted samples into the HPLC system.
Experience has shown that the procedure described is robust 
and economical with no significant problems of late eluting 
peaks, column deterioration or interference from other drugs.
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MEASUREMENT OF THE URINARY METABOLITES OF CAFFEINE BY 
HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
3. MEASUREMENT OF THE URINARY METABOLITES OF CAFFEINE BY HIGH
PERFORMANCE LIQUID CHROMATOGRAPHY.
The methods currently available for the measurement of 
caffeine metabolites in urine have been reviewed in section 
1.5.5. However most studies involving the analysis of methyl- 
xanthine metabolites have utilised the procedure described by 
Aldridge et al. (1979) in which urine is extracted with a 
chloroform/iso-propanol mixture (85:15 v/v) before chromato­
graphing the metabolites on a C-18 |j-bondapak column (Waters 
Associates) using a concave gradient of 1.5%-7.5% aceto- 
nitrile in 0.5% acetic acid. However, a significant limitation 
of this method is its inability to resolve 7-methylxanthine 
from 1-methyluric acid, theophylline from 1,7-dimethyl- 
xanthine or 3,7-dimethyluric acid from 1-methylxanthine. In 
addition, extraction recoveries are low for 1-methyluric acid 
(36.3%), 7-methyluric acid (55.6%) and 3,7-dimethyluric acid 
(58.5%).
In order to overcome these limitations, a procedure has been 
developed which offers a significant improvement in both 
recovery and specificity and facilitates the separation and 
quantitation of thirteen metabolites within a 20 minute 
period. In an attempt to optimize sample preparation a 
critical comparison is made between results obtained from the 
direct injection of diluted urine samples with those produced 
following ion-pair extraction using a procedure similar to 
that previously described by Tang-Liu and Riegelman (1982).
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CHROMATOGRAPHIC CONDITIONS 
3.1. Materials and equipment
The HPLC equipment, reagents and caffeine metabolites were 
similar to those described in section 2.2. Additional reagents 
included tetrabutylammonium hydrogen sulphate <Sigma Chemicals 
Ltd. Poole, Dorset); disodium tetraborate, 1M phosphoric acid, 
ethyl acetate, sodium carbonate, sodium bicarbonate and 
ammonium sulphate (Analar grade, BDH chemicals Ltd. Poole, 
Dorset) .
For the provision of elution gradients an Applied 
Chromatography Systems (ACS) 750/36 decilinear programmer was 
used. Chromatographic columns of 5 yim Hypersil octadecyl- 
silane 250 x 4.5 mm i.d. (Shandon, London), slurry packed by 
the procedure previously described, were used throughout.
A stock metabolite standard solution was prepared according 
to the procedure described by Thompson et al. (1974). Each 
xanthine metabolite (10 mg) was dissolved in approximately 35 
ml of 0.08M disodium tetraborate, Na^ B^ 0y , 10 H20; the pH was
then adjusted to 7 with 1M phosphoric acid before diluting to 
100 ml with distilled water.
3.2.Separation and identification of caffeine and its 
metabolites by reverse phase HLPC.
a) Isocratic separation of methylxanthines 
The suitability of isocratic reverse phase chromatography 
systems (incorporating acidic acetonitri1e/water mixtures as 
mobile phases), for the separation of caffeine and its 
dimethylxanthine metabo1ites, has been clearly established in
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Section 2. However the use of a similar mobile phase <4% 
acetonitri1e /1% tetrahydrofuran in acetate buffer pH 4.0) for 
the separation of a complex mixture of methylxanthines 
resulted in poor resolution of the early eluted, high polarity 
metabolites. The subsequent application of a less polar 
isocratic system, consisting of 2.5% aqueous acetonitri1e , 
improved the resolution of the more polar metabolites at the 
expense of a prolonged retention time for caffeine and an 
inability to resolve 1,7-dimethylxanthine from theophylline 
(Table 3.1). These findings confirmed the limitations of 
isocratic chromatography systems in separating metabolite 
mixtures of varying polarity, clearly indicating the 
requirement for a technique involving gradient elution, 
b) Gradient elution chromatography
The optimisation of chromatography conditions for the 
separation of an aqueous solution (50 mg/1) containing 
caffeine and eleven of its metabolites, was investigated using 
a variety of elution gradients consisting of acetonitrile 
mixtures in acetate buffer. In addition, the resolution of 7(2 
-hydroxypropy1 theophylline (proxyphy11ine) was examined to 
assess its suitability for use as an internal standard. The 
effects of variations in pH and ionic strength of the mobile 
phase were investigated and also the addition of the 
ion-pairing agent, tetrahydrofuran.
Results
The initial optimistion of chromatography conditions and 
many of the early metabolite studies were performed using a 
pre-packed Hypersil ODS column (Column A), commercially
RE
TE
NT
IO
N 
TI
ME
 
(m
in
s)
SO
LV
EN
T 
SY
ST
EM
 
7M
U 
7M
X 
1M
U 
3M
X 
1M
X 
13
MU
 
37
MX
 
17
MU
 
17
MX
 
13
MU
 
13
7M
U 
13
7M
X
- 63 -
ro in CN in
r - CO r - 00 x>
i—i i—1 ■—i i—i i—1 1—1 i—i 1—1
ro
CN O i—1 CTi o o r - ■ o o o .• • • • • • • • • • Cn
O VO 00 VO r - 00 (J1 •H
IT) CN CN 1—1 1—1 ■—i 1—1 i—i 1—1 1—1 0 Pm
44
•H C
rH •H
CN r- in in r-- CN VO VO o• • • • • • • • • XI c
CN VO in in 0
CN 1—1 i—i ■—i i—i i—1 1—1 1—1 i—i 44 o0 -C
£ CG
ID i—1 o in r - ro VO VO ro 0 0• • • • • • • « • • G 54
O O in ro ro ro ro ro •rH 0
CN CN i—i i—i i—i rH i—l ■—i i—i i—1 43
4-J(—
ID i—1 o i—I 00 ro 00 CN CN ■—I c3 0• • • • • • • • • • :* 4-J
O O in ro ro ro CN ro ro rH CG
CN CN •—i i—1 i—I i—I i—1 ■—I i—l i—I >1 >1
x : CO
44
00 ro o VO O ro CN o a> 44
• • • • • • • • • £ G
00 ro CN ro CN CN CN CN ro 0
1—1 i—1 i—1 i—i 1-4 i—1 i—1 i—1 i—I 44 •H
o nj0
00 00 VO in o r - in 0 54• • • • • • • • » • 44 cn
i—1 VO 1—1 o •—i O O o o i—I 0
i—1 1—1 1—1 i—i i—i 1-4 i—1 iH i—i ■—l <V 44
c
V4
o CO
CN CN 00 ro O r-~ cn r-~ in •H 1—1• • • • • • • • • 44 •H
in o cn o O cn cn cn . o G 0rH 1—1 i—i i—1 ■—i 0 44
44 0
0 Q
CN ro 00 00 o r— o 00 54• • • • • • • • •
CN 00 00 00 cn 00 cn 00 cn >1 •
rH ro
a
0 0
o O in 00 o VO o r - in 54 cn• • • • • • • • • cn 0
VO i—1 t-" e'­ r— 00 r— 00 00 o Qa
iH 44
0 o
£ 44ro <n CO en CN ■—i CN o in o
• * • • • • • • • • 54 54
CT> VO r - r - r - r - r - -C 0V 44
0• 54
cn r-~ 00 00 O r - o m 1—1• • • • • • • • • • CG
1 Cn VO VO VO r - VO r-> VO r - ro Go
0 •H
i—l 44
i—1 00 1—1 CN CN o o cn CN XI 0• • • • • • • • • 0 •H
1 00 in VO VO VO VO VO m VO E4 >mU/
54
X !
X I
0
o o o o CN CN 00
G s  • S  • sg • ££ • J2 • 2  • s  • S  • O
*i-l £  ^ e  ^ 6  ^ e  ^ e  ^ £ .< • £  ^ £  ^ £  ^ 4-J
0  54 o  rn O  44 °  5 o o  tc o  EC °  5 o  tc o  EC >1i—1 0 in  a in  O j iH  {Hi in  a rH £1| in  O i rH d) m Qa in  04 0
•H 4-J
54 (0 G u G 54 G 54 G 54 C  54 G 54 G  54 G  54 G 54
44 £ •H 0 •H 0 •H 0 •H 0 ■H 0 •H 0 •H 0 •H 0 ■H 0 54
•H 4-1 44 44 44 44 44 44 44 44 O
G  T3 i—1 4-1 CN 44 ro  44 ro  44 ro  44 ro  44 ro  44 ro  44 ro  44 Pm
O 0 3 3 3 3 3 3 3 3 3
4-J <—1 4-J X I 4-J X I 44 X I 44 X I 44 XJ 44 JH 44 X I 44 X I 44 -Q
0  rH G G G G G C G G G
U -H 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
<C 4-J •H 4_) •H 44 •H 4J ■H 44 •H 44 •H 44 •H 4-» •H 44 •H 44
co T5 0 TJ 0 T3 0 T5 0 TJ 0 T3 0 43 0 T5 0 43 0
<#P -H 0  4-J 0  44 0  44 0  44 0  44 0  44 0  44 0  4-> 0  44
ID  T3 54 0 54 0 54 0 54 0 54 0 54 0 54 0 54 0 54 0
• u q o o o q U  U O q O q O q O q O q
CN < < < < < < < >< <
- 64 -
a*C4
ron
sr-ro
ro
W
SM
EH
Z0M
EH
1wPi
ro
ro
G>
S
D
(5
cn CN cn o
• . . .
CO r - VO f "
i—i i—i 1—1 ■—i
r^- CN r - CO
• . . . CQ
in VO in in CD
«—i 1—1 ■—i i—i 4-J
•H
r—!
o
O'! ro CO r-~-
■8
ro ro ro 4-J
•—i t—l i—l ■—i (D
E
CD
r - CN r-* CO G• . . . •H
CM ro CN CN X
i—1 ■—l i—1 i—1 4-J
c
cn •
oo ro O O X ro. . . . <—i
1—1 CN CN CN >i CD
1—1 i—1 i—1 i—1 X cn
4-J co
0 C4
CO <J\ in O E. . . . O
i—H i—1 ■—i i—1 44 44
i—1 r—1 ■—i i—1 O G
CO
i—1 CN i—1 4-J 44
• • . • co CD
cn cn cn cn XS Vh
G CQ
O G
•rH O
n - CN o i—i 44 •rH• • . . G 44
CO cn cn cn CD (0
44 •rH
CD >
G CD
ro in in V4. • . . ' > i X
r - r - r-" r"- X X
Q a co
CO
VH o
00 CN •—i ■—i
g
44
in VO VO VO 44 >1
CD
£ M
O
r-~ cn CN u V4
• . . . X O
in in in in V p-t
X*
CO o o cn i—1
in in ro
CD
i—1
VO in CN X!
. . . • CO
EH
>4
0
4-1
44
3
X!
(1)
4-J
CO
4-J
0U
CO
G
• r H
0 i—I 
•r-J »4 
4-J 
•rH
co
0
cW>
CO
I
03
o VO 00 CDg  . 2  . S  * E  . X
E ^ E  ^ E  N1 E w
> i
CQ°  51—1 fit
o  m
rH fit °  5rH fit °  93rH fl|
•—i
i \
G U G U G V4 G U
-4—'
G
-4—'
G
•H CD •H CD •H CD •H CD CD 0
44 44 44 44 •rH •rH
ro  44 ro  44 ro  44 ro  44 X ! XJ
3 3 3 3 CO CO
X  X X  X X  X X  X E
G
CD CD
G
CD CD
G
CD CD
G
CD CD
cn O
•H 44 •H 44 •H X •H 44 o
TD CO 
CO X
XS CO 
CO X
XJ CO 
CO X
X3 CO 
CO X
X
G CD V-i CD Vh CD V4 CD
u  o o o O  U o u 0
< << < <
Gr
ad
ie
nt
 
2 
- 
3.
8-
73
.8
% 
Ac
et
on
it
ri
le
 
in 
ac
et
at
e 
bu
ff
er
 
(v
/v
)
Gr
ad
ie
nt
 
3 
- 
0-
12
.8
% 
Ac
et
on
it
ri
le
 
+1
% 
Te
tr
ah
yd
ro
fu
ra
n 
in 
ac
et
at
e 
bu
ff
er
 
(v
/v
)
- 65 —
obtained from Shandon U.K. Ltd. However, as result of a 
gradual deterioration in performance, it was eventually 
replaced by a "in-houseH slurry packed column (Column B) which 
showed characteristic changes in optimal chromatogrphic 
conditions. These were mainly reflected by variations in pH; 
the optimum value for column A being pH 4.0 compared to levels 
varying between pH 4.6-4.8 for the columns prepared "in- 
house" . In order to demonstate these effects, data is reported 
in Table 3.1 and Table 3.1b. for the use of columns A and B 
respectively.
For column A, optimum separation of the metabolite standard 
solution was achieved using a gradient elution system of
0-12.5% acetonitrile in 1% tetrahydrofuran, pH 4.0. The eluent 
for pump A consisted of 1% tetrahydrofuran in 10 mM acetate 
buffer, pH 4.0, and for pump B, 15% acetonitrile and 1% 
tetrahydrofuran in 10 mM acetate buffer, pH 4.0. Solvent A was 
pumped for 5 minutes before introducing a stepwise gradient of 
5%, 10%, 2% increase in B per minute, using a segment interval
of 5 minutes. A flow rate of 1.5 ml per minute was maintained 
throughout. Similar conditions were found to be optimal for 
column B with the exception that both solvents were prepared 
in 1OmM acetate buffer pH 4.6. Chromatograms showing the 
separation of an aqueous solution of methylxanthines using 
columns A and B are shown in Fig. 3.1 and 3.2 respectively.
Whilst variations in ionic strength <10mM-50 mM) and slight 
differences in the acetonitrile concentration resulted in 
minimal effects on the resolution of methylxanthines, the pH 
of the mobile phase was found to be critical in obtaining
613
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12
mins 20
Fig 3.1 Chromatography of an aqueous methyl xanthine standard solution (50mg/l) 
using Hypersil ODS Column A. ( Chromatography conditions as described 
in text)
PEAKS: 1= 7 - m e t h y l u r i c  acid, 2= 7 - m e t h y l x a n t h i n e ,  3= 1 - m e t h y l u r i c  ac id,
4= 3 - m e t h y l x a n t h i n e ,  5= 1 - m e t h y l x a n t h i n e , 6= 1 , 3 - d i m e t h y l u r i c  ac id ,
7= t h e o b r o m i n e ,  8= 1 , 7 - d i m e t h y l u r i c  acid, 9= 1 , 7 - d i m e t h y l x a n t h i n e ,
10= t h e o p h y l l i n e  H -  1 , 3 , 7 - t r i m e t h y l u r i c  acid, 12= c a f f e i n e ,
13= p r o x y p h y l l i n e  ( i n t ern al s t a n d a r d )
0-2 
A
U 
F
S
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10
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m i n s 20
Fig 3.2 Chromatography of an aqueous methyl xanthine standard solution 
(50mg/1) using Hypersil OPS, Column B.
Chromatographic conditions are described in tex t.
Peak identif ication  as in Fig 3.1.
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maximum separation of the early eluted peaks. For example, an 
increase from pH 4.0 to pH 4.4 when using column A, resulted 
in an almost total loss of resolution between 7-methylxanthine 
and 1-methyluric acid, whilst for column B, a slight reduction 
in pH from 4.6 to 4.4 led to an inability to resolve 1-methyl­
uric acid from 3-methylxanthine and 1,7-dimethyluric acid from
1,7-dimethylxanthine. In agreement with the findings of 
Section 2., the addition of tetrahydrofuran to the mobile 
phase was found to be essential in achieving optimal 
separation of theophylline and 1,7-dimethylxanthine. A period 
of 5 minutes, pumping solvent A only, was found to be an 
acceptable period of re-equilibration beween gradient runs.
SAMPLE PREPARATION
3.3. Direct Injection
Urine samples were centrifuged and then diluted 1 in 10 
with an aqueous solution of the internal standard, 
proxyphyl1ine (10 mg/1). An aliquot <50 pi) of the diluted 
sample was then injected directly onto the column without 
further preparation. For q u a n t i t a t i o n t h e  peak height ratios 
of eluted metabolites were compared with those obtained from 
the injection of an aqueous standard solution (50 mg/1) 
processed in a similar manner.
An assessment of detector response linearity was made by 
measuring the peak heights of eluted peaks following the 
injection of standard solutions ranging from 25-200 mg/1. 
Within batch precision was studied by replicate analysis <n=4) 
of a 24 hour urine sample collected from a volunteer receiving
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a controlled dietary intake of 600 mg (Urine A) and a urine 
sample collected from a Mormon volunteer spiked with 
methylxanthine metabolites to a concentration of 25 mg/1. 
Between batch precision was investigated by analysis of a 
similar spiked urine sample on 3 consecutive days.
The specificity of the procedure was investigated by
chromatographing a series of random urine samples, collected
from a Mormon population on a strict caffeine free diet. The
results obtained were expressed in terms of mg/g creatinine;
urine creatinine levels being determined using the alkaline
✓
picrate reaction described by Jaffe.
The suitability of urine "clean-up" procedures was studied 
using C-18 Sep-pak cartridges (Walters Associates), micro­
columns containing kieselguhr (Extrelut, Merck Ltd), and 
ultrafiltration using the Amicon Micropartition System. The 
procedures adopted for use with these systems are descibed in 
Appendix 1. They were evaluated by estimating the post 
treatment recovery of a methylxanthine standard and their 
ability to eliminate non-specific substances present in a 
urine sample collected from a Mormon volunteer.
Results
Detector linearity was found to be acceptable over a 
concentration range of 25-200 mg/1 (mean coefficient of 
correlation, r = 1.0) confirming the suitability of a one 
point calibration. Within batch precision data is summarized 
in Table 3.2. The mean coefficient of variation for the within 
batch precision of diluted urine samples was 8.64% (SD. 5.11)
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with values ranging from 4.4% <1-methyluric acid) to 19.7%
<7-methyluric acid). Between batch precision, studied by 
analysis of a spiked urine sample on 3 consecutive days, 
showed an overall mean coefficient of variation of 8.58 <S.D. 
4.39) with corresponding ranges of 1.5% (caffeine) to 15.5%
<7-methyluric acid).
The methylxanthine levels determined in urine samples from 
Mormon volunteers on a strict caffeine free diet are shown in 
Table 3.4. Significant blank values 0 3  mg/1) were obtained 
for 7-methylxanthine, 1-methyluric acid, 1,3- dimethyluric 
acid 3-methyl xanthine, 1-methylxanthine, and theobromine, 
although the latter three were affected by detection of an 
interfering peak on a single occasion.
Whilst the use of Sep-Pak cartridges as a sample "clean-up" 
procedure showed complete recovery of all the methylxanthines, 
interfering peaks were still present on post extraction 
chromatograms of urine. Similar results were obtained 
following the use of the ultrafiltration technique. Although 
the recovery values following "Extrelut" extraction were 
acceptable for caffeine and the dimethylxanthines (93-105%), 
low recoveries were found for the mono-methylxanthines 
(25-75%) and the uric acid metabolites (both mono- and di-) 
were almost totally retained on the column.
3 .4. Organic extraction of methylxanthines
In view of the limitations of the direct injection 
procedure, imposed by the finding of high blank values, 
attempts to improve specificity were made by investigating the
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use of organic extraction techniques. The following solvent 
systems were assessed for their suitability by calculating the 
recovery of an aqueous methylxanthine standard <100 mg/1) 
following extraction.
a) Chloroform/isopropanol with acetate buffer pH 4.0.
b) Ethylacetate/chloroform/isopropanol with acetate buffer 
pH 4 . 0 , 7 . 0 , 1 1 . 0 .
c> Ion-pair extraction using tetrabutylammonium hydrogen 
sulphate.
Metabolite recovery values were calculated by comparison of 
peak height values with those obtained by direct injection of 
unextracted aqueous standard.
3.4.1 .Organic extraction using a ) chloroform/isopropanol 
(85:15 v/v) and b) ethvlacetate/chloroform/isopropanol 
(45 :45:10 v/v ) .
Aqueous standard solution <100 pi), 50 pi of internal 
standard (proxyphyl 1ine, 200 mg/1), 100 pi of buffer solution
were placed in a stoppered tube and vortex mixed for 1 minute 
following the addition of 5 ml extraction solvent. After 
centrifugation at 2000 rpm (1500 x g) for 5 minutes, a 4ml 
aliquot of the organic layer was transferred to a clean tube 
and evaporated to dryness at 45 C under a stream of air. The 
residue was reconstituted with 500 ul of 1% tetrahydrofuran in 
acetate buffer, pH 4.0, and then injected onto the HPLC 
column.
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3.4.2. Ion -pair extraction
Aqueous standard solutions (200 pi), 50 pi of internal 
standard solution <proxyphyl 1ine, 200 mg/1 ), 200 pi 0.1M 
tetrabutylammonium hydrogen sulphate and 100 pi of pH 11 
buffer solution (0.1M sodium carbonate/0.1M sodium bicarbonate 
90:10 v/v), to produce a resulting pH of approximately 6.5, 
were placed in a stoppered tube. The contents were vortex 
mixed, before and after the addition of approximately 0.5g of 
ammonium sulphate, and then extracted by vortex mixing with 5 
ml of a solution containing ethylacetate/chloroform/ iso­
propanol <45:45:10 v/v) for at least 1 minute. After 
centrifugation for 5 minutes at 2,000 rpm <1500 x g), a 4 ml
aliquot of the organic layer was transferred to a clean tube
©
and evaporated to dryness at 45 C under a stream of air. The 
residue was dissolved in 500 pi of 1% tetrahydrofuran, pH 4.8, 
50 pi of which was injected onto the column.
Results
The recovery values for each of the solvent systems 
investigated are summarized in Table 3.3. Significant 
differences in recovery between these systems, were present 
for only 7-methyluric acid and 1-methyluric acid. In 
comparison with chloroform/isopropanol extraction, the use of 
ethylacetate/chloroform/isopropanol, without the presence of 
an ion-pairing agent, gave an overall lower recovery, 
especially at an alkaline pH. However, a significant advantage 
of the latter solvent system was that the organic layer formed 
the upper phase after centrifugation, thus eliminating the 
requirement for removal of the aqueous phase prior to
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sampling. The recovery of 7-methyluric and 1-methyluric acid 
was significantly improved by the addition of tetrabutyl 
ammonium hydrogen sulphate (TBAS) and subsequently this system 
was adopted for further investigation. Slight variations in 
the concentration of TBAS (0.05M-0.2M) produced only minimal 
differences in recovery values.
3.4.3. Standardization
As a result of the close correlation in recovery values for 
aqueous solutions and spiked urine samples using the ion pair 
extraction procedure, standardization using aqueous solutions 
was adopted. A series of standard solutions, covering a range 
of 0-100 mg/1, were prepared in distilled water and extracted 
in duplicate using proxyphy11ine <1 ug/tube) as an internal 
standard. The reconstituted extracts were then chromatographed 
and standard curves prepared by plotting the metabolite/ 
proxyphy11ine peak height ratios against concentration.
Results
The relationship between concentration and the 
peak height ratios were linear for each metabolite. The mean 
coefficient of correlation <r), calculated using least squares 
regression analysis, was 0.988 (range = 0.992-0.999).
3.4.4. Reproducibility and specificity
The within batch precision of the procedure was studied by 
replicate analysis <n=4) of a 24 hour urine sample collected 
from a volunteer receiving a controlled daily intake of 600 mg
- 76 -
1
m i ns 2 00
Fig 3.3 Chromatography of an extracted urine sample from a Mormon volunteer.
Chromatography conditions as described in text for column A.
Pe ak s: 1 = Uric acid 2 = P r o x y p h y l l i n e
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(Urine A) and a urine sample collected form a Mormon volunteer 
spiked with methylxanthine metabolites to a concentration of 
25 mg/1. Quantition of the metabolites (Table 3.2.) showed 
mean coefficient of variation values of 8.12% (SD = 6.65) with 
corresponding ranges of 2.75% (1-methyluric acid) to 15.81%
(1,3-dimethyluric acid). Between batch precision, studied by 
analysis of a spiked urine sample on three consecutive days, 
showed an overall mean coefficient of variation of 8.04% with 
corresponding ranges of 3% (1-methylxanthine) to 12.2% (1,7- 
dimethylxanthine).
Specificity was examined by measurement of methylxanthine 
levels in urine samples obtained from Mormon volunteers on a 
strict caffeine free diet. Values of less than 1.5 mg/g 
creatinine were found for each metabolite (Table 3.4), 
demonstrating a considerable improvement in specificity over 
the direct injection procedure. A chromatogram of a Mormon 
urine extract is shown in Fig. 3.3
3.5.COMPARISON OF URINARY METHYLXANTHINE METABOLITE PROFILES 
BY DIRECT INJECTION AND ION-PA1R EXTRA C T ION PROCEDURES.
A comparative study of the two procedures was made by
analysing urine samples, collected from normal volunteers
receiving a controlled dietary intake of caffeine (300, 450 or
600 mg) in the form of pre-weighed aliquots of instant coffee.
Following a 24 hour period of equilibration to the restricted
caffeine intake, the volunteers collected two consecutive 24
hour urine samples of which the volumes were recorded and
o
aliquots stored at - 20 C until analysis. The controlled
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caffeine intake was maintained throughout the study and all 
other forms of caffeine were excluded from the diet.
In order to assess the suitability of the procedures for 
monitoring metabolite excretion following administration of 
other methylxanthines, urine samples were also collected and 
analysed from hospital inpatients receiving theophylline 
therapy.
Results
The analysis of 24 hour urine samples from patients 
receiving oral doses of theophylline (16 mg/kg/day) produced 
peaks corresponding to theophylline, uric acid, 1-methyluric 
acid, 3-methylxanthine and 1,3-dimethyluric acid (Fig 3.4). 
Urinary excretion products identified from individuals 
receiving a controlled intake of caffeine included the 
compounds named above plus caffeine, 7-methyluric acid, 7- 
methylxanthine, 1-methylxanthine, theobromine, 1,7-dimethyl-
uric acid, 1,7-dimethylxanthine and 1,3,7-trimethyluric acid 
(Fig 3.5). The methylxanthine levels obtained using both 
procedures are summarized in Table 3.4.
Statistical analysis of the results obtained for each 
procedure was made using a Student t-test and linear 
regression analysis. A favourable correlation was found for 
the major metabolites, 1-methyluric acid (r = 0.067, P <0.1),
1-methylxanthine (r = 0.930, P <0.05), and 1,7-dimethyluric 
acid (r = 0.783, P <0.1), although the direct injection 
procedure results showed a slight positive bias. For the 
remaining metabolites, the correlation between the two 
procedures decreased in proportion to concentration although a
• I All F
S
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a) Direct injection technique. b) Ion pair extraction.
ro
inj •nj
0 mins 18 o mins 18
Fig 3.4 Chromatograms of urine sample received from a subject receiving 
theophylline therapy assayed by a) direct injection technique,
b) ion pair extraction.
Chromatographic conditions as described in text for Column A.
V
PEAKS: 1» uric acid, 2- 1-nethyluric acid, 3- 3-nethylxanthine,
1,3-diaethyluric acid, 5- theophylline, 6- proxyphylline (internal 
standard).
0-2 
A
U
F
S
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C7
20mins
Fig 3.5 Chromatogram of a urine sample collected 0-24h following oral 
ingestion of 500mg caffeine (ion pair extraction technique). 
Chromatographic conditions as described in text for Column B. 
Peak identification as in Fig 3.1.
CA
FF
EI
NE
 
IN
TA
KE
 
CO
NC
EN
TR
AT
IO
N 
IN 
UR
IN
E 
(m
g/
g 
cr
ea
ti
ni
ne
)
AN
D 
AS
SA
Y 
PR
OC
ED
UR
E 
7M
U 
7M
X 
1M
U 
3M
X 
1M
X 
13
MU
 
37
MX
 
17
MU
 
17
MX
 
13
MU
 
13
7M
U 
13
7M
X
- 81 -
GO•H
Xo0•l~>
c
X
8
X
•i— lQ
ro in CO in .—i CN O O  CO ro co ro in o  co
cr> rH ro r- o ro c» h 4 in r- ro O  i— 1 ro in• # • • • • • • • • • • • • • •
r- co cn r- H 4 rH o  o r- ro in cn r-~ ,h o  o
+ +
+ +
G •
0  P  0 •£ W
in CN H 4 O  CO in co
00 iH ro .H r- o o  t— OO CO r- h 4 ro ro
05 ro co • • • • • • • •
• • • • • • CN O rH  O CN O o  o
CO CN
C •
0  P  
0 •
e w
ro o o  o
CO CO O  .—1 00 CO ro cn co ro ro co CN O
CO .H a\ in H 4 CO h 4 r- rH CN CO rH H 4 CO• • • • • • • • • • • • • •
1—1 1—1 O i—1 i—1 CN rH ro cn CN rH i— 1 i— 1
ro ro CO CN in in CN CO in co H 4 CO in rH CO CO
CO o O  CN CO CO cn r- r- o 05 CO 05 O r- in• • • • • • • • • • • • • « • •
■—i co in O  rH o  o in cn in rH 05 i—1 o •—i
i—1 i—i CN i— i 1— 1 1—1
O  CN 00 05 O  00 05 in oo r- CO 00 ro r-> in in
i— 1 i— 1 05 CN H 4 in r- OO 05 t"- 00 05 CD ro ^• • • • • • • • • • • • • • • •
t-~ 05 H 4 CO in rH o  o h 4 r- h 4 r-~ o  co o  o
CN CN ro CN CN ro
ro co CO CN ro oo 05 r- in rH CO o o  ro r- ro
iH CO 05 CO CO H 4 ro oo ro cn O  05 I"- in ro r-• • • • • • • • • • • • • • • •
CN CN CO CN ro co ro in in rH co ro CO rH o  o
ro ro CN CN ro
. G • •pH c • C •
P 0 Q X 0 Q 0 Q
0 • o (1) • 0 •
W £ W 0 £ W) £ C/3
CQ
X
CQ
X
CQ
X 04
X X X 3
___ — H 4
O  r—  
x  ro
CN cn in CN CN 05 '— 1
\ II \  II \  II II
CP G dj c G C
£ — ' £ Q '—'
o o O X
o in O O
ro CO s
X
4->X
0
X•rH
(U
91GoH
c •
0 p
1 cn
o  ro
CO i— 1 H 4 05 O  rH CO CO i—i in 00 05 co r-» CN ro
05 CO rH rH ro o  ro • • • • • • • •
CN ro
• •
r- rH 05 CN ro cn
in  cn in  o CO o o o
O  rH co o r- co CO H 4 oo ro CN 05 o  CO CO 05
CN O co in oo r- rH CO CO CO in h 4 05 O o  o
• • • • • • • • • • • • • • • •
o  r-~ 00 05 CN H 4 in h 4 oo r- r- 05 h 4 in r— i i— i
ro H 4 CO CN H 4 in
ro ro O  H 4 r -  ro rH CN ro  co o  r - 00 o CN CN
■—l 05 r -  o H 4 ro CO 00 05 in co o H 4 ^ CO r-• • • • • • • • • • • • • • • •
ro H 4 ro  in
rH
o  in
i— i
ro  cn r- rH CN CN
i— 1
i— 1 i— 1 
i— 1
o o
o  in h 4 in o  o CO 05 cn in H 4 o  o 05 CO
05 CO CN CO CO CO CO 00 ro  r- rH 00 cn ro r- co
• • • • • • • • • • • • • • • •
rH CO o  r» o  CO CN rH O  H 4 in 05 00 rH o  o
in 00 CN CN CN in i— i r -  ro 05 rH
Q O  w LO u ) rH CN ^  rH 00 vo p* ro
<J\ CN KO ^ 00 o rH ro cn in ro vo in oo t— 1• • • • • • • • • • • • • • • •
o r—1 ^  CN 00 vo ro ro O  CN r- cn r- rH o o
«— I i— 1 1— 1 i— 1 *— I 1— 1
ro o O  05 in ro CO CN ro 05 CO rH o  r- in cn
r- ro H 4 O co in co r- H 4 CN cn ro i— i i— i r-~ 05
• • • • • • • • • • • • • •
H 4 ^4 H 4 CN i— 1 i— 1 o  o in rH H 4 rH in rH o  o
Q
cn
CQ CQ CQ
X X X 04
X X X 3
O
H4 —- H 4 — H 4 x  ro
CN H 4 cn in CN CN 05 rH
\  II \  ll \  II II
t?  G d i G d> c G G
£ — £ £ Q —
o o o X
o in o O
ro H 4 CO s
cq
Xo0
•ro
X !
3
CQ
x
4-) i—i 
0 
0 
X
G
•rH
CQ 
0 
4-J 
•H 
r—Io
■s
4->
0G
•rH
X
4-J
SX
rH
£
0e
4-1o
co
•rH
4->0
XuX
5-4
0G
•rH54D
ro
0
CP
0
04
O
4-J
X
0
44
0
54
CQ
§ •H 
4-J 
0 
•i— I 
>  
0 
>4XX)
0
o
4-J
0
.v:
54oDm
0 i—IX
0
543
CQ
0
U
4-Jo
G
4-J3 
X !
4->C
0
CQ(it
54
04
I
+
G
O
54 -H
X  4->
0
H 4 54 
CN O  
X
O  0
" §
- 0
cq e
4-J
U  0  
0  X  
•ro 4j 
X  ,
3  44 
CQ O
0  G  
X  O  
4-J -H 
X  
44 0  
O  3
i— I
X  0  
CQ >
0  0  
54
54 
0  O  
X  44
4-1 X  
X  0  
X  CQ
3= 3 
0  
• 3
X  i— I 
U  0  
0 >
¥ &
CQ 0  X
X  0  
O  >
0  0  
0
0  
X  X  
O  X  
44
TJ 
T5 * G  
0  0  
X
O  >i 
0 i—I 
i—I 0 
i— I X  
O  0  
O X ' -'0 in 
CQ 04 0 0 x
£  CQ O
C 0  ^
S 0  -CQ CN•rH
U H  II
n \ rr<
2j C G 
CQ 0  — '
e  x  04 
O  G  3  
X  0  O  
G  >4
0 0  DJ  
X  0  
X  X
0  u  o  
G  0  0
O  H  - n
•H X  
- 0 3
04 O  CQ 
3
O  0  0  
X  X  >  
CP 0  -H 
5  X  C O
O  CQ 
£ 0 
54 i—I
0  CQ 0  
X  X
X  0  X  
G
X  -H X  
0 X 0  
3 4 4
- 82 -
significant difference was only observed for unchanged 
*
caffeine.
D ISCUSSION
Whilst reverse phase chromatography techniques have made a 
significant contribution to the present understanding of the 
biotransformation of caffeine they have been generally non­
specific. This has been mainly reflected by their inability to 
resolve 7-methylxanthine from 1-methyluric acid, theophylline 
from 1,7-dimethylxanthine or 3,7-dimethyluric acid from 1- 
methylxanthine. In contrast the procedure described herein 
eliminates most of these problems of non-selectivity.
In order to optimise sample preparation in terms of 
selectivity, precision and preparation time, an assessment has 
been made of the use of direct injection of diluted urine and 
a procedure involving the formation and extraction of an 
ion-pair complex. The extraction procedure described shows 
excellent selectivity and much improved recovery from previous 
techniques based on chloroform/isopropanol extraction. 
Variations in recovery are relatively insignificant using the 
direct injection technique and, with a much reduced 
preparation time, it has obvious advantages over extraction 
techniques. Also the requirement of peak height correction 
using the internal standard was found to be minimal. However, 
it is apparent that the technique has limitations due to high 
blank values and the occasional presence of an interfering 
peak. These problems were not resolved by the use of 
ultrafi1tration or purification using C-18 Sep-Pak (Water's
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Associates) cartridges prior to injection. The use of 
"Extralut" columns for sample purification was rejected due to 
low recovery values for certain metabolites.
The chromatography procedure described achieves separation 
of the xanthine metabolites within 20 minutes, and a re­
equilibration period of only 5 minutes permits the analysis of 
approximately twenty samples within one working day or more if 
automatic sampling is used. The short period of equilibration 
can be largely attributed to the use of acetonitri1e , in 
preference to methanol as a solvent component, since reports 
have shown (Muir et a l ., 1980) that, in order to ensure
adequate resolution of the early eluted peaks when using 
methanol based solvents, all traces of methanol must be 
removed from the stationary phase of the column between 
injections. This necessitates re-equilibration periods of at 
least 30 minutes using a flow of buffer solutions only. In the 
absence of an ion-pairing agent, the retention of some of the 
methyluric acids was inadequate for acceptable resolution. The 
addition of tetrahydrofuran as a counterion to the solvent 
system resulted in a considerable increase in retention of 
these metabolites despite the fact that the pH of the mobile 
phase was lower than their pKa values (about 5.5). The effects 
of pH were most noticeable with the retention times of 
1-methyluric acid and 1,3-dimethyluric acid. For example, in 
using column B, the lowering of the pH to 4.4 resulted in a 
marked reduction in the retention and resolution of these 
compounds, presumably by reducing the fraction of these 
molecules in the ionic state which are capable of ion-pairing.
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Increasing the pH to 5.0 resulted in the opposite effect where 
the retention times of 1-methyluric acid and 1,3-dimethyluric 
acid were increased by virtue of the higher equilibrium 
concentration of the paired, neutral species. Whilst the 
resolution of 1,3-dimethyluric acid and theobromine was 
relatively poor using Column B, these represent only minor 
metabolites of caffeine metabolism and for theophylline 
metabolites studies, theobromine interference in the 
measurement of 1,3-dimethyluric acid levels is negligible.
Slight variations in the resolving properties of different 
batches of HPLC packing materials are not uncommon (unpublish­
ed observations). Whilst the differences observed in this 
report could be the result of variations in packing 
techniques, ie commercial vs "in-house", this is considered 
unlikely. Following consultation with Shandon U.K. and 
subsequent examination of a series of Hypersil ODS batches, it 
was clearly established that such marked effects were 
infrequent; optimum resolution being generally obtained at pH 
4.6. It was concluded that the altered selectivity in Column A 
may have been due to previous applications using octyl 
-sulphonic acid, clearly indicating the disadvantages of using 
HPLC columns for multifunctional analysis.
The use of an ion-pair extraction procedure considerably 
improved the recovery of the methyluric acid metabolites. At 
pH 6.5, uric acids are in an ionized form which permits them 
to form an ion-pair with the tetrabutylammonium counter ion. 
This can then be effeciently extracted using the solvent 
system described. Extraction was enhanced by the addition of
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ammonium sulphate to the system to produce a salting out 
effect. The effects of pH and concentration of ion-pairing 
agent were in agreement with those previously described by 
Tang-Liu and Riegelman (1981). Using this extraction procedure 
a batch of twenty samples may be processed for chromatography 
in appproximately 1 hour.
Both the direct injection and ion-pair extraction 
procedures have proved robust in use with no problems of late 
eluting peaks and minimal deterioration of column performance. 
When required, peak resolution may be rapidly restored by 
repacking the top few millimetres of the column and the use of 
a guard column is considered unnecessary. The use of direct 
injection offers a slight improvement in the within-batch 
precision when compared with the extraction procedure, but for 
the major metabolites, both procedures show satisfactory 
reproduc ib i1i t y .
In summary both the procedures described in this study have 
some value in investigating the pharmacokinetics and 
metabolism of methylxanthines. In studies where a precise 
determination of values is required, the extraction procedure 
described is the method of choice. However, experience has 
shown that, providing suitable cut-off values are applied to 
compensate for the potentially high blank values, the 
convenience of direct injection of diluted urine is of value 
where quantitation is only required for the major metabolites. 
Applications include screening for toxicity or the detection 
of alterations in the pattern of metabolite excretion 
resulting from diseased states such as chronic liver disease.
HUMAN CONSUMPTION OF CAFFEINE
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4. HUMAN CONSUMPTION OF CAFFEINE
4.1. Introduc tion
The consumption of caffeine from natural sources has been 
enjoyed throughout the world for centuries. Historical records 
show that tea has been popular in the Orient since about 350 
A.D. where initially its raw leaves were infused with water to 
produce a medicinal potion. However, tea was first brought to 
Europe in 1559 by the Venetian traveller Gian Battista 
Ramusio, and found its way to England during the early 17th 
century. The East India Company brought its first consignment 
from China in 1664. Although coffee was similarly introduced 
to Europe in the seventeenth century, the earliest mention of 
coffee beans being consumed as a hot beverage was in the tenth 
century. However coffee for use as a food may have been culti­
vated in Ethiopia in early 575 A.D. Cocoa and other caffeine 
containing chocolate products also have a long history. 
Chocolate drinks became popular first in Spain where, in 1519, 
the Spanish conquerors were served a sweetened chocolate drink 
by the Aztec Emperor Montezuma. A way of making milk chocolate 
bars was invented in Switzerland in 1876.
The major ingredient use of caffeine is as flavouring 
component in cola-type soft drinks which originated around the 
beginning of this century (Dr Pepper in 1885, Coca-cola in 
1886, Pepsi-cola in 1896 and Royal Crown cola in 1912). To a 
lesser extent, caffeine is also used as a flavouring in baked 
foods, dairy deserts, puddings and fillings, and in some 
sweets. Caffeine was first chemically isolated in 1820 and has
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since been used therapeutically in neonatal apnoea, acne and 
other skin disorders, migraine headaches and as a bronchial 
and cardiac stimulant. Caffeine also occurs in various "over 
the counter” products used as analgesics, diuretics, slimming 
aids, allergy relief preparations and mild stimulants.
4.2. Sources . levels and consumption estimates of caffeine
Estimates of the caffeine content of various food products 
have shown considerable variations (Burg, 1975), especially 
with reference to tea and coffee (Table 4.1). The differences 
may be partially explained by non-standardization of 
analytical procedures and reference volumes (ie.”cup” size), 
although they may also be influenced by the plant variety and 
growing conditions of the natural product. The largest 
variation occurs with brewed coffee where levels depend on the 
form (eg. ground roasted vs instant), the method of brewing 
(eg. percolator vs filter), the amount of coffee used and the 
brewing time.
Representative values for each of the major sources were 
standardized by Barone and Roberts (1981) for consumption 
estimates in American populations. The selected values were:
Cof f ee
a) Ground roasted 85 mg per 5 oz cup
b) Instant 60 mg per 5 oz cup
c> Decaffeinated 3 mg per 5 oz cup
Tea
a) Leaf or bag 40 mg per 5 oz cup
b) Instant 30 mg per 5 oz cup
Product Volume caffeine content (mg) Reference 
or weight_______Range Average________________
Roasted and ground coffee 
(percolated)
Instant coffee
Roasted and ground coffee 
(decaffeinated)
Instant coffee 
(decaffeinated)
Roasted and ground coffee 
(drip)
Instant coffee 
(percolated and drip)
Tea
Bagged tea
Leaf tea
Instant tea
Cocoa - African
- South American
Cocoa
Chocolate bar 
Milk chocolate
Chocolate milk 
Baking chocolate
Regular colas 
Decaffeinated colas 
Diet colas
Decaffeinated diet colas
5 oz 60-124 83
5 oz - 74
5 oz 40-108 59
5 oz - 66
5 oz - 66
5 oz 2 - 5  3
5 oz - 2
5 oz 2 - 8  3
5 oz - 112
5 oz 29-176
5 oz 8- 91 27
5 oz - 42
5 oz 28- 44
5 oz 30- 48 41
5 oz 24- 31 28
5 oz - 6
5 oz - 42
5 oz - 5
5 oz <40
5 oz 2 - 7  4
30 g - 20
1 oz - 6
1 oz 1- 15 6
8 oz 2 - 7  5
1 oz - 35
1 oz 18-118 60
6 oz 15- 23
6 oz trace
6 oz 1- 29
6 oz trace
Burg (1975) 
Gilbert (1981)
Burg (1975) 
Gilbert (1981) 
FDA (1980)
Burg (1975) 
Gilbert (1981)
Burg (1975)
Gilbert (1981)
Gilbert (1981)
Gilbert (1981)
Burg (1975)
FDA (1980)
Burg (1975)
Burg (1975)
Burg (1975)
Burg (1975)
FDA (1980)
Gilbert (1981)
Zoumas et al. (1980)
Gilbert (1981)
FDA (1980)
Zoumas et al. (1980) 
Zoumas et al. (1980) 
FDA (1980)
Zoumas et al. (1980)
NSDA (1982)
NSDA (1982)
NSDA (1982)
NSDA (1982)
Table 4.1 Caffeine content of food products (Barone and Roberts, 1984)
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Cola (except caffeine free) 18 mg per 6 oz glass
Cocoa, hot chocolate 4 mg per 5 oz cup
Chocolate milk 5 mg per 8 oz glass
A survey by the Market Research Corporation of America 
reported a mean daily caffeine intake for all adults as being 
2.6 mg/kg. This compared favourably with previous surveys by 
Graham (1978) and Gilbert (1981) which reported respective 
daily consumption estimates of 206 mg and 200 mg per adult. 
Data from a nationwide food consumption survey (NFCS), which 
included only consumers of caffeine containing products, 
reported a total mean consumption of 345 mg for all groups. 
Respective average daily caffeine intake values from coffee, 
tea and cola flavoured drinks were 233 mg, 76 mg and 25 mg. 
Caffeine intake from various chocolate products was less than 
6 mg per day. Whilst consumption, estimates for children (under 
18 years of age) are more variable than those for adults, the 
mean daily intake of caffeine for all American children is 
estimated to be 1 mg/kg.
Bruce and Lader (1986) have reported that of 51 
prescribable analgesic preparations available in the UK, 12 
contain caffeine; the mean content being 26 mg (SD = 15 m g , 
range 7.5-50 mg). For "over the counter” (OTC) preparations of 
systemic analgesics, 32 out of 89 forms listed in the OTC 
Index, 1985, were reported to contain caffeine. The mean 
content was 35 mg (SD = 21 mg, range 7.5- 95 mg).
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4_^_3:_. A study of caffeine consumption in the United K ingdom
In view of the absence of reports on the dietary intake of 
caffeine in the U.K., a limited study <n= 174) was made to 
assess the nature and quantity of caffeine consumption in a 
random population. Subjects were requested to complete a 
questionnaire (Appendix 2 ) giving details of their age, sex, 
daily consumption of caffeinated beverages, smoking habits, 
current drug therapy and information on any adverse effects 
experienced through caffeine consumption or withdrawl. In 
addition, the caffeine content of various commercial brands of 
coffee, tea, cola and drinking chocolate was determined using 
the HPLC procedures previously described. Aqueous dilutions of 
the beverages were directly injected onto the analytical 
column and the peak heights compared with values obtained from 
injection of aqueous standard solutions.
R esults
A summary of the caffeine concentrations of the various 
beverages analysed in this study is shown in Table 4.2. In 
agreement with previous estimates (Table 4.1), the values 
showed considerable variation, especially for the caffeine 
content of percolated and filter coffee extracts. With the 
exception of chocolate drinks, where significant amounts of 
theobromine were present (43-209 mg/200 ml), the levels of 
other methylxanthines were minimal.
In order to provide an accurate comparison with previously 
reported studies, consumption estimates were calculated using 
the standardized values selected by Barone and Roberts (1982). 
The results are summarized in Table 4.3 and shown as a histo-
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CONCENTRATION (mg per 200 ml cup) 
PRODUCT__________ CAFFEINE THEOPHYLLINE THEOBROMINE
Coffee
a)Instant coffee
Nescafe' 75 -
Gold Blend 62 -
b) Percolated coffee
Various blends 74-263
Safeways Kenya 120
c) Filter coffee
Kenco continental 52 -
Safeways original 77 -
d) Decaffeinated
Cafe Hag 1
Gold Blend
Coffee Beans 6 -
Tea
a) Bagged tea
Tetley 40 - -
Quick Brew 39 -
Co-operative 99 48 1.2 4.8
Marks and Spencers 49 -
extra strong
b) Leaf tea
Typhoo 51 - -
Co-operative 99 85 1.2 6.4
PG tips 193
China 38 -
c) Instant
Nestea 60 -
d) Decaffeinated
St James * 3 — —
Luaka 4 -
Cola flavoured drinks
Coca-cola 18 - -
Pepsi-cola 13 -
Safeways 10 -
Chocolate drinks
Cadbury's drinking choc. - 58
Sainsbury's hot choc. 2 - 43
Sainsbury's chocolate 8 - 209
Table 4.2 Methylxanthine levels of common beverages
Beverages were prepared using manufacturers recommended amounts ie. 
one teaspoonful of coffee per 200ml cup, one teabag per 200ml cup, and 
one teaspoonful of leaf tea per 200ml. Tea preparations were allowed 
to brew for 5 minutes before sampling
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30
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Caffeine consumption (mg/day)
1000 1200
Fig 4.1 D i e t a r y  i n t a k e  of  c a f f e i n e  in a U.K.  p o p u l a t i o n .
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gram in Fig 4.1. Although there appeared to be a trend for 
increased dietary intake with increasing age, the difference 
in total caffeine intake between the highest <61-80 years) and 
lowest <10-20 years) consumption groups was not statistically 
significant <P <0.2). However the increased consumption in 
smokers <421 ± SD. 248), compared to non-smokers <329 + S D . 
152) was significant <P <0.01).
In terms of mean estimates for the total population 
studied, coffee drinking was found to be the major source of 
dietary caffeine, accounting for 55% of per capita intake. The 
consumption of tea accounted for 44% whilst caffeine intake 
from chocolate and and cola flavoured drinks was minimal <less 
than 0.4%). The contributions of the various sources to the 
total caffeine intake were constant for all age groups, with 
the exception of subjects aged 61-80 years, where, caffeine 
intake from the consumption of tea <63%) was significantly 
higher than that from coffee <37%). The increased caffeine 
intake in smokers was not related to an increased consumption 
of a particular beverage since the ratio of coffee versus tea 
consumption was similar for both groups.
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DISCUSSION
Previous surveys involving American and Canadian adult 
populations have reported mean daily caffeine intakes of 2.6 
mg/kg (Market Research Corporation of America, 1977), 206 mg 
(Graham, 1978), 200 mg (Gilbert, 1981) and 345 mg (Nationwide 
Food Consumption Survey-NFCS, 1982). The mean caffeine intake
for children of all ages from 5-18 years, on a body weight 
basis, has been estimated to be approximately 1 mg/kg (Morgan 
et al., 1982). However with the exception of reports by 
Galliano (1982) and Bruce et al. (1986), which reported 
respective mean values of 621 mg (SD = 210) in 20 adults and 
426 mg (SD = 146) in nine adults, estimates of caffeine 
consumption in the U.K. based on large samples are not 
ava i1ab 1e .
Since the caffeine content of food products may vary 
considerably according to the type, source, "cup-size", method 
of brewing and plant variety, consumption estimates based 
solely on retrospective questionnaires have many limitations. 
Whilst a more accurate estimate may be made by concurrent 
analysis of the actual beverages consumed, this approach is 
technically difficult when dealing with a large population. 
However from the data obtained in this survey certain 
generalised observations can be made. The consumption 
estimates suggest that the caffeine intake in the U.K. is 
significantly higher than that reported for American or 
Canadian populations. Although the NFCS of America reported a 
similar mean total caffeine intake, the study only included
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habitual consumers of caffeinated beverages. The indications 
that caffeine intake is higher in smokers than non-smokers is 
in agreement with the conclusions made by Istvan <1984) 
following a review of previous studies, which primarliy 
involved male subjects, of the intei— relationships between 
tobacco, alcohol and caffeine. The report also found a 
positive relationship between the consumption of alcohol and 
coffee although it was mainly limited to those reporting heavy 
use of either substance.
In agreement with reports from the USA and Canada, the data 
from this survey suggests that the combined consumption of 
coffee and tea account for the vast majority of per capita 
caffeine intake in the U.K. However whilst the proportion 
attributed to the consumption of coffee appears to be similar . 
(appprox 60%), the consumption of tea is significantly higher 
<44% versus 15-30%) whilst caffeine intake from chocolate and 
cola flavoured drinks is lower. This was particular evident in 
the age group, 61-80 years, where the consumption of tea was 
the major dietary source of caffeine. Although the total 
caffeine intake, calculated on the basis of number of clips 
consumed, was marginally higher for this group, this may 
represent an overestimation since elderly people often prefer 
weaker brews of tea and coffee <unpublished observation).
Since it has been suggested that coffee consumption may 
increase as the caffeine content decreases <Koslowski, 1976), 
it is possible that a similar relationship may exist for this 
age group with respect to tea.
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5. PHARMACOKINETICS AND METABOLISM OF CAFFEINE IN 
NORMAL SUBJECTS
/- 99 -
5_^  PHARMACOKINETICS AND METABOLISM OF CAFFEINE IN NORMAL
SUBJECTS
5. 1 .Pharmacok i.net ics o f caffeine in serum and saliva following 
oral administration.
The first reported study on the pharmacokinetics of 
caffeine was in 1953 when Axelrod and Reichenthal reported 
elimination half life values ranging from 2.5-4.5 hours in 
normal subjects following an oral dose of 7 mg/kg. However the 
present understanding of the pharmacokinetics of caffeine is 
mainly attributable to studies performed in the last decade.
In 1978 Parsons and Neims compared the salivary elimination 
curves of caffeine in groups of healthy smokers <n=13) and 
non-smokers <n=13). The mean half-life in smokers <3.5 hr) was 
significantly less than that in smokers (6.0 hr) with 
corresponding clearance values of 155 ± 16 ml .kgr^ hr,~l and 94 ± 
18 ml . kg.-^hrT^ - Since no significant differences were found 
between the apparent volumes of distribution for the smoking 
(720 ± 67 ml.kgf^) and non-smoking <610 £ 80 ml.kg.-l) groups, 
the increased clearance of caffeine in smokers was attributed 
to an induction of hepatic aryl hydrocarbon hydroxylase 
activity Additional studies on the half-life of caffeine 
have reported mean values of 4 hours in seven subjects (Cook 
et al., 1976) and 5.5 ± 2.6 hours in thirteen males following 
a 250 mg oral dose of caffeine (Patwardhan et a l ., 1980).
The effects of increasing doses <50-750 mg) on the plasma/ 
salivary pharmacokinetics of caffeine was investigated by 
Newton et a l . (1981). The apparent first-order elimination
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rate constant decreased linearly with dose whilst total body 
clearance was unaffected (mean value 0.98 ± 0.38 ml . kg- ^ mirT^ ' > . 
There was a trend towards increasing apparent volume of 
distribution with increasing dose. A linear relationship was 
observed between the area under plasma concentration vs time 
curves and dose; dose and dose normalised plasma concentration 
vs time plots were superimposab1e suggesting that caffeine 
obeys linear pharmacokinetics over the dose range invest­
igated. In 5 subjects kinetic data obtained following an oral 
dose of 300 mg on 3 occasions showed good reproducibility. The 
overall saliva/plasma concentration ratio was 0.74 ±  0.08.
The noninvasive nature of saliva sampling and the ability 
to obtain multiple samples without loss of blood or exposure 
of paediatric or geriatric patients to discomfort and 
potential skin irritation and infection makes it ideal for 
pharmacological investigations. In addition, for many drugs, 
concentrations in saliva reflect the free fraction of the 
drug, whereas data obtained from plasma concentrations 
represents both the free and protein-bound forms of the drug. 
In plasma, The ratio of free to protein-bound drug varies with 
age and disease state and may also be affected by alterations 
in albumin concentrations and the presence of compounds that 
can displace the drug from its binding site on albumin. As 
pharmacological effects are generally attributed to the free 
form of a drug, measurements of drug concentrations in saliva 
should therefore be, therapeutically more meaningful.
An earlier study in this thesis (Section 2.3.5) showed a 
favourable correlation between caffeine levels in serum and
- 101 -
saliva <R = 0.941). However, before saliva samples can be used 
with confidence in pharmacokinetic studies it is essential to 
establish that data obtained from saliva is a true reflection 
of serum kinetics. The reports by Parsons and Neims <1978) and 
Newton et a l . (1981) provide only limited information to
substantiate this relationship. In the following studies, the 
suitability of salivary caffeine determinations is further 
investigated by comparing pharmacokinetic data, derived from 
caffeine levels measured in samples of serum and saliva, 
collected simultaneously following oral doses of caffeine. In 
addition, an assessment is made of caffeine levels in a random 
non-pregnant population. Approval for this study was obtained 
from the Bromley Health District Ethics Committee.
5.1.1. Study 1.
Following an overnight abstention from all forms of
caffeinated beverage, samples of serum and saliva were
collected from 4 normal volunteers for estimation of basal
caffeine levels. The subjects then received either 2 cups of
strong coffee (equivalent to 180 mg of caffeine) or a gelatine
capsule containing 200 mg anhydrous caffeine. Additional
samples of serum and saliva were collected at 20 m i n s , 40
mins, 1 hr, 2 hr, 4 hr and 6 hr post caffeine dose. Blood
samples were centifuged and samples of serum and saliva were 
o
stored at - 20 C until required for analysis. Prior to 
analysis, the thawed saliva samples were centrifuged at 2,000 
rpm for approximately 5 minutes to remove mucoid particles. 
Following analysis by the previously described techniques.
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serum and saliva caffeine concentrations were plotted 
semi 1ogarithmica1ly as a function of time and the slope of the 
descending curve (elimination constant,k) was calculated by 
least squares linear regression analysis. The concentration of 
caffeine at zero time (Co) was calculated by extrapolation of 
the regression line. It was assumed that the kinetic data 
conformed with first order kinetics of a one compartment model 
(Newton et al., 1982). The area under the plasma (AUC-p) and 
saliva (AUC-s) concentration/time curves from 0 to infinity 
were estimated by the trapezoidal method. Pharmacokinetic data 
was determined using the following equations: T 1 /2 = 0.693/k, 
apparent volume of distribution = dose/Co, and total plasma 
and saliva clearance (Cl) = dose/AUC. Student's t test was 
used for analysis of data.
Results
A summary of the pharmacokinetic data obtained from this 
study is shown in Table 5.1 (N1-N4). Additional data is also
included from a volunteer (N13) who received an oral dose of 
400 mg as described in study 2 of this section. The estimated 
values for caffeine in serum and saliva showed a linear 
agreement throughout. Least squares regression analysis of the 
levels for each subject showed a mean coefficient of 
correlation of 0.982 (SD = 0.005); the overall mean for the 
combined values for the 5 subjects was 0.965. The mean 
salivasserum caffeine concentration ratio was 0.82 (SD =
0 .1 0).
A comparison of pharmacokinetic data derived from serum 
caffeine determinations versus data obtained from salivary
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measurements showed good correlation. Respective coefficient 
of correlation values for elimination half life, elimination 
constant, volume of distribution, area under curve and 
clearance were 0.760, 0.755, 0.982, 0.974 and 0.759. The mean 
values for these parameters were similar for both serum and 
saliva. Whilst values for apparent volume of distribution were 
consistently higher in saliva than in serum, an analysis of 
the results using a paired Student’s t test showed that the 
difference was not statistically significant (P <0.9).
5.1.2. Study 2.
Whilst the number of subjects involved in Study 1 was too 
small for an accurate statistical evaluation, the correlation 
between kinetic data in serum and saliva was considered 
sufficiently acceptable to permit further kinetic studies to 
be performed using saliva samples only. In order to provide 
reference ranges of pharmacokinetic data for future studies, 
additional groups of volunteers were investigated. The study 
was performed using the same conditions as for Study 1 with 
the exception that the administered oral dose consisted of 
either 200 mg or 400 mg of anhydrous caffeine contained in a 
gelatine capsule. For subjects N5-N12, saliva samples were 
collected at times 0, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 10 and 12
hours following oral caffeine whilst for the subjects N13-N21 
samples were collected at times 0, 0.5, 1, 2, 3, 4, 6, 16, 16
o
and 24 hours. Samples were stored at -20 C until required for 
analysis. Salivary caffeine determinations were made using the 
previously described techniques and, for subjects N13-N21,
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measurements were also made of the dimethylxanthine 
metabolites of caffeine (theobromine, theophylline and 
paraxanthine). For subjects N5-N12, a comparison was made of 
pharmacokinetic data obtained by linear regression analysis 
with data obtained from a computer based non-linear kinetics 
programme. The computer system consisted of an intelligent 
user interface linked to the "NONLIN" programme supplied by 
Upjohn Ltd. Using this system, a polyexponential equation is 
used to fit concentration-time data by a weighted iterative 
non-linear least-squares regression algorithm.
Results
A summary of the subject characteristics, caffeine doses 
and kinetic parameters, calcul4ted from salivary caffeine 
determinations, is shown in Table 5.2. Only one subject (N12) 
was a smoker and the volunteers were all free from any form of 
medication, including oral contraceptives.
The mean values for elimination half life (4.35 ± SD 1.95), 
elimination constant (0.185 ± SD 0.07) and total salivary 
clearance (1.605 ± SD 0.555) were in agreement with those 
previously reported by Parsons and Neims (1978) for a non­
smoking population. A wide variation was found for elimination 
half life values (2.6-9.1 hours). For one subject (N12) the 
enhanced clearance could be attributed to the inducing effects 
of smoking on the microsomal enzyme, aryl hydrocarbon hydroxy­
lase, whilst in contrast, the impaired clearance observed for 
subject N7 may possibly have been related to an habitual 
abstinence in the consumption of caffeinated beverages.
A statistical comparison, using Student’s t-test, of the
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6
3
TINE (hoursV
1 Mean caffeine (O ) and 1,7-dimethylxanthine ( v )  levels in saliva follow­
ing oral dose of caffeine (400mg).
Vertical line represents one standard deviation.
- 1:08 -
kinetic data calculated using linear vs non-linear kinetics 
showed no significant differences between values for 
elimination constant (P <0.9) and volume of distribution (P 
<0.9). Whilst the values for elimination half life were 
statistically different (P <0.001) this was mainly 
attributable to the wide variation observed in values for 
subject N 7 .
A plot of the mean salivary levels of caffeine and para- 
xanthine for subjects N13-N21 is shown in Fig 5.1. Peak levels 
of paraxanthine (mean = 1.9 mg/1 ± SD. 0.7) were obtained 5.4 
hours (SD = 2.87) following oral caffeine administration (400 
mg). The levels of theobromine and theophylline were similar 
throughout to those found in basal samples (less than 1 mg/1).
5.2.Measurement of caffeine levels in a non-pregnant 
populat i on
In order to provide a "reference range" for caffeine levels 
in a normal non-pregnant population, serum caffeine 
determinations were made on a series of samples obtained at 
.random from both normal volunteers and patients attending 
hospital out-patient clinics (n = 202). Since some of the 
symptoms of chronic anxiety states and thyrotoxicosis mimic 
those associated with caffeine toxicity eg. tachycardia, 
anxiety, nervousness, tachypnoea and gastrointestinal 
disturbances, the relationship between circulating caffeine 
levels and the occurence of these symptoms was investigated in 
a group of congruent patients.
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Results
A summary of the caffeine levels, determined in samples of 
serum obtained from the participants of this study, is shown 
in Fig. 5.2. The overall mean caffeine level was 2.42 (SD = 
1.59) with values ranging from 0 to 9.2 mg/1. In agreement 
with the findings of previous report by Smith et a l ., (1982),
6% of the population studied showed caffeine levels in excess 
of 5 m g / 1.
The mean serum caffeine level for 72 patients with symptoms 
related to caffeine toxicity was 2.44 mg/1 (SD = 1.72); a 
result similar to that found for the total population studied. 
Significantly elevated levels of 9.2 and 8.2 mg/1 were found 
in two subjects. Although requests were made to obtain repeat 
samples, and information on their normal dietary caffeine 
intake, a return was only received for the former subject. The 
"follow-up” serum caffeine level on this patient was 3.9 mg/1 
with an estimated daily caffeine intake of 320 mg.
5.3.Urine metabolite profiles of caffeine in normal subjects
On commencing this study in 1981, literature reports on the 
metabolism of caffeine were limited to those described by 
Brodie et al. (1956), Arnaud and Welsch (1980) and Callahan et 
al. (1980) which have been summarised in Section 1.2. By 
administering radiolabelled caffeine to healthy normal 
sublects, the latter two studies clearly established that the 
metabolic fate of caffeine primarily involves demethyl ation 
and oxidation in the liver before excretion by the kidneys; 
unchanged caffeine accounted for only 1-3% of the administered 
dose. However analytical limitations prevented the resolution
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of 7-methylxanthine from 1-methyluric acid, 1,7-dimethyl- 
xanthine from theophylline, and 3,7-dimethyluric acid from 
1-methylxanthine.
In this study, the more specific methodology described in 
Section 3 was used to evaluate the rate of appearance and 
recovery of caffeine metabolites in urine samples collected 
from normal healthy subjects following oral administration of 
unlabelled caffeine. Cummulative data was then used to 
establish a reference range for metabolite excretion in 
subjects receiving a single bolus ingestion.
5.3.1. Study 1
Four healthy male subjects, aged 20-55 years, were enrolled 
for this study after a careful explanation of its require­
ments. The subjects were all non-smokers and receiving no 
prescibed or non-prescribed forms of medication. Following a 
24 hour period of abstention from all forms of caffeinated 
beverages and chocolate, urine samples were collected to 
establish basal levels of caffeine and its metabolites. An 
oral dose of anhydrous caffeine (200 or 400 mg) contained in a 
gelatine capsule was then administered to each subject with 
approximately 200 ml of water. Further urine samples were then 
collected for periods of 0-2 hr, 2-4 hr, 4-6 hr, 6-8 hr, 8-10
hr, 10-12 hr, and 12-24 hr. The volumes of the urine samples
o
were recorded and aliquots stored at -20 C until assayed using 
HPLC. Prior to analysis the samples were diluted 1:10 with the 
internal standard (Proxyphy11ine, 10 mg/1) and then injected
directly onto the column without further preparation.
- 1 1 2  —
0-2 hr
M e a n 0
S.D. 0
2-4 hr
M e a n 0
S.D. 0
4-6 hr
M e a n 0
S.D. 0
6-8 hr
M e a n 0
S.D. 0
8-10 hr
M e a n 0
S.D. 0
i—
• 0 1 i—•
 
to hr
M e a n 0
S.D. 0
12-24 :hr
M e a n 0
S.D. 0
0-24 hr
M e a n 2
METHYLXANTHINE EXCRETION (% administered dose)
7MU 7MX 1MU 3MX TMx 13DU 37MX 17DU 17DX 13MU 137MU 137MX Total
3.15
0.96
4.36
0.71
6.0
2.71
7.36
1.40
7.41
1.99
0.04 0.04 6.46
0.06 0.05 0.84
0.20 0.16 24.31
0.26 0.20 5.06
4.94 18.98 2.72 11.09 1.98 2.24 6.88 3.37 0.20 0.79 0.89 56.50
S.D. 0.54 1.00 4.92 0.41 1.24 0.68 0.95 0.51 1.87 0.21 0.62 0.41 4.19
Table 5.3 Mean metabolite excretion following an oral dose of caffeine
(200 or 400 mg)
For key to abbreviations refer to page 3
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Results
The urinary recoveries of caffeine metabolites for the 
specified time intervals are summarised in Table 5.3. Despite 
a variation in the administered dose, the total recovery for 
the 24 hr period was similar for each subject (mean value 
56.5% ±. SD 4.2) . These values are compared in Table 5.4 with 
data obtained from the previous studies of Arnaud and Welsch 
(1981) and Callahan et a l . (1982).
The major metabolites excreted in the urine during the 24 
hr period were 1-methyluric acid (18.98% ± SD 4.92), 1-methyl 
xanthine (11.09% ± SD 1.24) and 1,7-dimethylxanthine (3.37% ± 
SD 1.87). Unchanged caffeine accounted for only 0.89% of the 
administered dose. The overall mean value of metabolites 
present in the basal urine was 5.49 mg/1 with values ranging 
from 0.93 mg/1 for theophylline to 13.7 mg/1 for 1-methyluric 
acid. Whilst significant amounts of metabolite were recovered 
during the time interval 12-24 hr, the periods of maximal 
output were 2-4 hr for caffeine; 6-8 hr for 1-methylxanthine, 
7-methylxanthine and 1,7-dimethyluric acid; and 8-10 hr for 
1-methyluric acid.
5.3.2. Study 2
A group of normal volunteers consisting of 4 male subjects 
(aged 26-42 yrs) and 5 female volunteers (aged 24-28 yrs) were 
enrolled for this study after explanation of the protocol. All 
subjects were non-smokers and receiving no medication with the 
exception of 2 females who were receiving oral contraceptives. 
Since the subjects were all habitual consumers of caffeine 
(mean daily intake = 280 mg) they were requested to abstain
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CAFFEINE METABOLITE EXCRETION (% OF ORAL DOSE ADMINISTERED)
7MU 7MX 1MU 3MX 1MX 13U 37X 17U 17X 13X 137U 137X Total
N.S.
0-24 hr 
24-48 hr
1.0
1.0
3.2
2.2
16.7
10.6
1.3
1.8
13.0
5.2
0.8
1.3
0.5
1.5
7.8
3.6
6.2
1.9
0.7
0.6
1.5
0.2
1.1
0.4
53.8
30.3
A.A.
0-24 hr 
24-48 hr
2.0
0
2.4
0
■ 8.6 
1.7
1.4
0.6
5.5
1.0
1.8
0.6
1.5
0.5
5.2
0.4
3.8
0
1.3
0
2.2
0
4.4
0
40.1
4.7
G.M.
0-24 hr 
24-48 hr
0.4
0.4
1.9
1.2
17.2
3.0
0
0.3
9.3
1.5
1.3
0.6
2.3
0.6
7.0
0.8
3.3
0.3
0.3
0
0.6
0
1.3
0.3
45.1
8.9
M.H.
0-24 hr 
24-48 hr
0.3
0.3
3.1
1.6
19.0
5.9
1.1
0.7
10.8
1.1
0.7
0.3
1.4
0.7
5.7
1.0
4.5
0
0.4
0
1.2
0
3.9
0
52.0
11.5
Me.H. 
0-24 hr 
24-48 hr
0.6
0
2.4
1.2
14.8
4.1
1.2
1.3
3.8
2.5
0.8
1.1
2.0
0.6
5.4
1.7
4.7
0.4
0
0.4
0
0
1.7
0
37.3
13.3
F.L.
0-24 hr 
24-48 hr
0.9
0.9
1.8
0
12.0
4.2
0.8
1.0
11.6
1.8
0.8
1.0
1.7
1.3
6.9
1.9
1.2
0.8
0.3
0.5
0.7
0
1.8
0
40.3
12.5
M.P.
0-24 hr 
24-48 hr
1.0
0.3
1.1
1.2
30.3
3.0
1.1
2.1
15.8
1.4
0.7
0
2.9
0.2
6.7
0
2.4
0
0.2
0
0.4
0.4
0.5
0
62.7
8.5
B.P.
0-24 hr 1.4 2.5 13.2 1.1 3.2 0.6 1.5 4.5 2.5 0.7 0.3 1.0 32.2
W.B.
0-24 hr 
24-48 hr
0.5
0.2
2.0
1.8
6.3
1.9
0.6
0.6
4.0
1.7
0.6
0.3
1.1
0.4
3.9
0.9
1.7
0.6
0.3
0
0.3
0.1
0.5
0.1
21.8
8.6
Mean metabolite excretion
0-24 hr 
S.D.
0.9
0.5
2.3
0.7
15.3
6.9
1.0
0.4
8.6
4.6
0.9
0.4
1.7
0.7
5.9
1.3
3.4
1.6
0.5
0.4
0.8
0.7
1.8
1.4
42.8
12.3
0-48 hr 
S.D.
1.2
0.6
3.4
1.2
19.9
8.5
2.0
1.0
11.3
4.9
1.6
0.6
2.4 • 
0.6
7.4
2.0
4.0
2.0
0.6
0.5
1.0
0.7
2.0
1.4
56.5
16.4
Table 5,4 Methylxanthine metabolite excretion of normal volunteers 
following an oral dose of caffeine (400 mg)
For key to abbreviations refer to page 3
METABOLITE METABOLITE EXCRETION (% DOSE ADMINISTERED)
Arnaud + Welsch1 
(1981)
Callahan 2 
(1982)
Study A 3 
(Re: page 113)
Study I 
(Re: page
1-methyluric acid 11.7 14.8 i 19.9 19.7
1-me thylxanthine 11.7 18.1 11.3 11.6
1,7-dimethyluric acid 9.0 5.4 7.4 7.3
7-me thylxanthine 6.4 9.9 3.4 ' 3.8
1 ,7-dimethylxanthine 6.0 5.9 4.0 4.9
3,7-dimethylxanthine 2.6 1.9 2.4 1.8
3-methylxanthine 2.6 4.1 2.0 2.7
1,3-dimethyluric acid 2.6 1.8 1.6 1.6
1 ,3-dimethylxanthine 0.7 0.9 1.6 0.7
7-methyluric acid * * 1.2 1.5
1,3,7-trimethyluric acid 2.0 1.3 1.0 0.6
1,3,7-trimethylxanth ine 1.0 1.2 0.8 2.1
Table 5.5 Summary of studies on caffeine metabolism in man
1. Total metabolite excretion for 48 hour period following an oral ingestion of 
unlabelled caffeine (8 mg/kg).
2. Total metabolite excretion for 48 hour period following an oral dose of 
[2- 14c]-caffeine (5 mg/kg).
3. Total metabolite excretion for 48 hour period following an oral dose of 
unlabelled caffeine (400 mg).
4. Mean metabolite excretion of two consecutive 24 hour periods for subjects 
receiving a controlled dietary intake of caffeine (300-750 mg/24h).
- 115 -
from all forms of dietary caffeine for a 24 period before the
study and for its duration. On day 1 of the investigation, a
400 mg bolus dose of anhydrous caffeine, contained in a
gelatine capsule, was administered orally to each subject.
Total urine outputs were then collected for the time intervals
0-24 hr and 24-48 hr; urine volumes were recorded and aliquots 
©
stored at -20 C until required for analysis. Methylxanthine 
metabolite levels were determined by HPLC using the previously 
described ion-pair extraction procedure.
Results
The urinary methylxanthine metabolite profiles for each 
subject invstigated are summarized in Table 5.4 and Fig 5.5. 
The overall mean recovery of the administered dose for the 48 
hour period of urine collection was 56.5% <SD = 16.4). In 
agreement with the results of study 1, the principal urinary 
products of caffeine were shown to be 1-methyluric acid (19.9 
± SD 8.5), 1-methylxanthine <11.3 ± SD 4.9) and 1,7-dimethyl-
uric acid (7.4 t. SD 2.0) ; unchanged caffeine accounted for 
only 2% (± SD 1.4) of the administered dose. Although the mean 
total metabolite recovery for the first 24 hour period was 
lower than the mean value found for a similar period in study 
1 (56.5 ± SD 4.19 vs 42.8 +, 12.3), the difference was not
statistically significant. Since the total recovery values for 
study 1 were obtained using combined data from serial urine 
collections, assayed using the less specific direct injection 
technique, the difference probably reflects a cummulative 
b 1ank effect.
The metabolite profiles showed no variations related to the
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individuals sex or the concurrent use of oral contraceptives. 
For one subject <U8), the total metabolite recoveries were 
consistently low, although the pattern of distribution was
unaltered. Whilst this low recovery may be explained in terms
of incomplete urine collection, this was considered unlikely 
since the subject was familiar to research techniques.
The results of this study are in agreement with two
previous reports (Arnaud and Welcsh, 1981; Callahan et al., 
1982) of metabolite recoveries obtained following 
administration of radiolabelled caffeine. The lower recovery 
of 7-methylxanthine in the present study, with a corresponding 
increase in the recovery of 1-methyluric acid, is probably 
explained by the improved specificity of the HPLC procedure in 
terms of its ability to resolve 7-methylxanthine from 1-methyl 
uric acid. A similar explanation may be made for the variation 
in recovery values for 1,7-dimethylxanthine and theophylline, 
which were also poorly resolved in the HPLC procedures used 
for the earlier studies.
D ISCUSSION
The primary objective of the studies described in this 
section has been to establish suitable reference ranges, using 
the previously developed analytical procedures, for the 
pharmacokinetic and metabolic aspects of caffeine metabolism 
in normal healthy volunteers. The data obtained agrees 
favourably with results of previous studies thus confirming 
its reliability for use in future studies on the disposition 
of caffeine.
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The non-invasive nature of saliva sampling and the ability 
to obtain multiple samples prompted further investigation into 
the suitability of saliva measurements for obtaining pharmaco­
kinetic data. The close correlation between caffeine levels in 
serum and saliva confirms that salivary determinations may be 
used to accurately reflect the concentration of caffeine in 
serum. Thus the same pharamacokinetic principles applied to 
blood can be used when salivary drug concentrations are 
measured. This concept is supported by a recent study by 
Zylber-Katz et a l . (1984) which reports a similar ratio (0.79
±  SD 0.02) and degree of correlation for caffeine levels in 
saliva versus plasma. For comparison, the mean saliva: plasma 
caffeine ratios in seven neonates (Khanna et a l ., 1980) and in
six healthy nursing mothers (Hi 1denbrandt et al., 1983) have 
been reported as 0.71 and 0.73 respectively.
The transfer of drugs from plasma to saliva is mainly a 
passive, pH dependent process; drug concentrations in saliva 
generally representing the free fraction of the drug. Since 
pharmacological effects are produced only by the free form of 
the drug, salivary concentrations are more meaningful. For 
acidic drugs with pKa values greater than 8.5 and basic drugs 
with pKa values of 5.5 or less no correction is required for 
the salivary pH. However, since caffeine is a weak base (pKa 
14), there is a tendancy for it to accumulate in saliva in 
accordance with the pH partition theory. Evidence for this 
has been shown by Zylbei— Katz et al. (1984) who demonstrated 
that the actual ratio for salivary caffeine concentration 
versus the free fraction in S^rom was 1.47 (SD = 0.05).
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Determination of the fraction of drug bound to plasma proteins 
(Fb) may be obtained using the following equation described by 
Dvorchik and Vesell (1976).
Fb = 1-K [Saliva]
[Plasma]
where K is a proportionality factor which takes into 
account plasma and salivary pH as well the pKa of the drug 
(Martin et al. 1974).
For bases, K = 1 +1 0~ (pHp-pKa) / 1 +1 o~(pHs-pKa)
For caffeine the calculated values for K at salivary pH 6.5 
and 7.0 are 0.126 and 0.399 respectively.
The urine metabolite data derived from this study shows 
that the majority of the metabolites of caffeine are recovered 
within the first 24 hours after dosing. The distribution of 
metabolites is in agreement with the previous reports by 
Arnaud and Welsch (1981) and Callahan et a l . (1982) which 
indicates that the metabolic fate of caffeine is primarily de- 
metnyiation and oxidation in the liver with unchanged caffeine 
accounting for only 1-3% of an administered dose. In man, the 
increasing stability of the methyl groups is 3-N, 1-N, and 7-N 
and although the initial demethyl ation may occur at any of 
these three positions, yielding formaldehyde as a secondary 
product, the reported quantitative importance of the reactions 
are 3-N demethylation, 72%; 1-N demethyl ation, 20%; and 7-N 
demethyl- ation, 8% (Arnaud and Welsch, 1982). Subsequently 
the majority of administered caffeine undergoes 3-N
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demethylation to produce 1,7-dimethylxanthine, the primary 
metabolite found in serum. The major metabolites excreted in 
urine are 1-methyl- uric acid, 1-methylxanthine and 
1,7-dimethylxanthine.
Since the completion of these studies, further reports on 
the biotransformation of caffeine have been made by Callahan 
et al. <1983), Branfman et a l . (1963), Tang et al. 1983, and 
Blanchard et al. (1985). Data form these studies agree 
favourably with the metabolite recovery values found in this 
report. Whilst it has not been possible in this study to 
measure the acetylated uracil metabolites of caffeine, such as 
5-acetylamino-6-amino- 3-methyluraci1 (AAMU) and 5-acetylamino 
-6-formylamino-3-methy1 uracil (AFMU), it is probable that the 
unaccounted metabolites for the normal volunteers <ca. 44%) 
represents the formation of such compounds.
Symptoms associated with the withdrawl of caffeine were 
experienced by many of the volunteers participating in these 
studies. The reported effects included headaches, drowsiness, 
lethargy and severe muscle aching in the thighs and legs. In 
agreement with previous reports by Driesbach and Pfieffer 
(1943) and Greden et al. <1980), the most commonly reported 
effect to the abstention of caffeine was a withdrawl headache, 
mainly occuring after a period of approximately 12 hours. In 
all cases the withdrawl effects were eliminated by the 
ingestion of caffeine. Adverse effects associated with the 
intake of caffeine included mild tachycardia, light headiness 
and insomnia.
Although it has been reported that anxiety states may in
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some cases be attributed to "caffeinism" (Greden, 1974; Greden 
et al., 1978; Uhde et al., 1984), no relationship could be 
found in this study between serum caffeine levels and the 
presence of symptoms associated with caffeine toxicity.
However recent reports by Boulenger et al. (1984) and Lee et 
al. (1985) have suggested that anxiety disorder patients may 
have an increased sensitivity to caffeine which leads to a 
decrease in consumption. Since this in turn would lead to a 
reduction in circulating caffeine levels, it can be concluded 
that the random monitoring of caffeine levels in serum or 
saliva is of minimal clinical value in detecting caffeine 
related anxiety states.
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6. THE ELECTROPHYSIOLOGICAL AND PSYCHQPHARMACOLOGICAL 
EFFECTS OF CAFFEINE IN NORMAL HEALTHY HUMANS
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6. THE ELECTROPHYSIOLOGICAL AND PSYCHQPHARMACOLOGICAL EFFECTS
OF CAFFEINE IN NORMAL HEALTHY HUMANS
INTRODUCTION
The pharmacological and physiological effects of caffeine 
in normal subjects have been reviewed in Section 1. Reports on 
the acute effects of caffeine (Robertson et al., 1978, 1981)
have shown that following an oral dose of caffeine (250 mg) 
systolic blood pressure is significantly increased, plasma 
adrenaline levels are doubled and nor-adrena1ine levels may be 
increased by 75%. A small, but significant decrease in heart 
rate has also been observed. Levels of dopamine and 
unconjugated 3-methoxy-4-hydroxy-pheny1-ethyleneglyco1 (MHPG) 
are reported to be unaltered (Robertson et al., 1981; Charney 
et al., 1984). The ability to develop tolerance to the humoral 
and haemodynamic effects of caffeine is well established 
(Robertson et al., 1984; Ammon et al., 1983). Whilst 
significant increases in plasma cortisol levels have been 
recorded in subjects receiving large doses (750 mg) of 
caffeine (Unde et al., 1983), such effects are probably 
behavioral since the neuroendocrine reponse to caffeine is 
reported to be minimal (Spindel et al., 1984).
The ability of caffeine to improve both motor and mental 
efficiency was first demonstrated in 1912 by Ho11ingworth. The 
administration of 150-250 mg of caffeine increases alertness, 
stimulates attention and restores performances degraded by 
factors such as fatigue and boredom (Weiss and Laties, 1962; 
Goldstein, 1965). At higher doses caffeine produces nervous­
- 123 -
ness, restlessness, insomnia, tremors, hyperesthesia, 
tachypnoea, tachycardia and gastrointestinal disturbances 
(Greden, 1974; Gilbert, 1976). Withdrawl of caffeine in 
habitual users may produce severe headaches, nausea, vomiting, 
fatique, mental depression and rhinorrhoea (Dreisbach and 
Pfeiffer, 1943).
Clinically, the symptoms associated with excessive caffeine 
consumption ("caffeinism") are difficult to distinquish from 
those found in anxiety disorders (Greden, 1974). However, 
whilst there is a strong positive correlation between caffeine 
consumption and scores of trait-anxiety, as a group, patients 
with anxiety disorders consume no more caffeine than controls 
(Boulenger and Uhde, 1982). This suggests that an increased 
sensitivity to the effects of caffeine may exist in anxious 
patients through altered pharmacokinetic (Levy and Zylbei—  
Katz, 1983) and/or pharmacodynamic responses.
The aim of this study was to establish baseline pharmaco­
kinetic and psychopharmacological values for responses to 
single doses of caffeine in healthy human subjects. In 
collaboration with Professor M. Lader and Dr M. Bruce of the 
Institute of Psychiatry, Denmark Hill, London, the effects of 
caffeine (250 mg or 500 mg) and placebo on physiological, 
psychological measures and subjective feelings were studied in 
a double blind, cross over study in normal healthy volunteers. 
Each subject was tested on three different occasions, at least 
one week apart. The psychophysio1ogica1 test sequences were 
performed by Dr M. Bruce using where possible an on line 
PDP-12A computer for the rapid and accurate aquisition,
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storage and analysis of data.
METHODS
Approval for this investigation was obtained from the 
Ethics Committee (Research) of the Institute of Psychiatry. 
Nine normal healthy adult volunteers, 4 males and 5 females, 
were enrolled for this study after a careful explanation of 
the protocol. All were habitual caffeine users; the mean daily 
intake as assessed by retrospective questionnaire was 428 mg 
(SD = 146), range 230 - 670 mg. Instructions were given to 
abstain from caffeine and alcohol for a 24 hour period prior 
to each test day and to have a light breakfast.
On arrival in the laboratory at about 12 noon, a cannula
was inserted into a forearm vein and kept patent with heparin.
Electroencephalogram (EEG) scalp electrodes were applied and
electrodes were also attached to the forearm and thumb to
measure skin conductance. Following the collection of a basal
blood sample, the subjects were asked to provide a sample of
urine and then collect all subsequent urine passed for the 5
hour duration of the investigation. A pre-drug test sequence
was then performed before administering a capsule containing
either 250 mg or 500 mg of caffeine or placebo in matching
capsules, using a randomised design. Test sequences were
repeated at 1,3 and 5 hours later, details of which are
summarized in Appendix 3• At hourly intervals throughout the
test period, 5 ml samples of venous blood were collected and
centrifuged with minimum delay. Total urine volumes were
recorded and aliquots (30 ml) were stored along with the
o
samples of plasma at -20 C for later analysis of caffeine and
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its metabolites by HPLC.
An appraisal of the psychophysio1ogica1 data was made by 
calculating a four-way analysis of variance, the main sources 
of variance being subjects, drugs, occasions and times. 
Differences between drugs were obtained from the drugs x times 
interaction. Differences between means were assessed using the 
0.05 critical difference.
RESULTS
a ) Plasma levels of caffeine and its dimethvlxanthine
m etabo1i tes
The absence of methylxanthines in pre-drug blood samples 
confirmed that each subject was adequately decaffeinated. 
Following the oral administration of caffeine, plasma levels 
of the drug rose rapidly producing peak values at 1-2 hours 
(Fig 6.1). The levels of theobromine and theophylline showed 
only a minimal increase over basal levels whilst plasma 
concentrations of paraxanthine rose steadily to the 5 hour 
point. Pharmacokinetic data, calculated using a computer based 
non-linear kinetics programme is summarized in Table 6.1. 
Whilst precise calculation of pharmacokinetic parameters was 
impeded by the limited number of sample points, the overall 
mean values for half-life (4.62 + SD = 2.17), elimination 
constant (0.193 + SD = 0.08) and volume of distribution (29.3 
+ SD = 5.55) were similar to those reported in Section 5. for 
saliva samples obtained from normal volunteers. The close 
correlation between values obtained following 250 mg versus
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0
Fig 6.2 Mean methylxanthine metabolite values (mg/g/creatinine) in basal urine 
samples (— ) and in samples collected for a 5h period following oral 
ingestion of caffeine (500mg).
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Fig 6.3 Mean methylxanthine metabolite ouput in urine samples 
(— ) collected for a 5hr period (mg/5-h vol) from 
normal subjects following an oral dose caffeine (500mg) 
This is compared with output from normal subjects (mg/ 
24 _h vol) following an oral dose of 400mg caffeine.
For key to abbreviations refer to page 3.
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500 mg caffeine is consistent with a report by Newton et al. 
(1981) confirming that caffeine obeys linear pharmacokinetics.
b ) Urine metabolite excretion
The limited period of urine collection resulted in a low 
recovery of methylxanthine metabolites; the mean recovery for 
the 5 hour period following the ingestion of 500mg caffeine 
being only 8.3% <SD = 2.9) of the administered dose. However, 
in comparison with pre-drug values, methylxanthine metabolite 
levels (expressed as mg/g creatinine) in urine samples 
collected during this period showed significant increases in
1-methylxanthine, caffeine, 1,7-dimethylxanthine, 1-methyluric 
acid, 1,7-dimethyluric acid, 1,3,7-trimethyluric acid, 1,3- 
dimethyluric acid, theobromine and theophylline (Fig 6.2 and 
Fig. 6.3). The patterns of excretion were similar to those 
found previously (Section 5.) for 24 hour urine collections 
obtained from normal subjects, receiving either a single bolus 
dose of caffeine (400 mg) or a controlled daily dietary 
caffeine of 450 mg.
c) Physiological measurements
E lectroencephalogram. Log "theta" power was decreased by 
caffeine in a dose-related manner (Fig. 6.4), with the effect 
persisting to 5 hours, especially with the high dose. Log 
"alpha” power was also decreased (Fig. 6.5), the doses 
initially having similar effects but the lower dose wearing 
off quicker. Log "beta" showed paradoxical effects, the 500 mg 
dose having less effect than the 250 mg dose (Fig. 6.5). The 
total power however, reflects drug effects on the slower
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frequencies <Fig. 6.4).
Skin condu ctance. Caffeine was associated with a significant 
dose-related increase in skin conductance level (sweat gland 
activity) (Fig. 6.6), the effects persisting over the five 
hour period. There was no drug effect on the number of 
fluctuations.
Pulse and blood pressure were unaffected by either dose of 
caffeine.
Critical flicker fusion. Caffeine tended to increase CFF as 
compared with placebo but this effect marginally failed to 
reach significance (P <0.052).
Tremor Caffeine produced a non-significant increase in the 
amount of tremor,
d ) Psychological m easures.
Tapping rate, reaction time, digit-symbol substitution 
(DSST), symbol copying (SCT) and number cancellation time (CT) 
all failed to show significant differences between the drug 
and placebo. 
e ) Self ratings
Mood rating scale. Caffeine was associated with a signif­
icant dose-related increase in alertness which persisted for 5 
hours (Fig 6.7). The significant sub scales were: alert-drowsy 
(P <0.01); energetic-lethargic (P <0.02); quick witted- 
mentally slow (P <0.03); and attentive-dreamy (P <0.04). In 
general, the effects were dose-related; they began within the 
first hour, and tended to diminish thereafter, except on the 
alert-drowsy sub scale where the effect persisted. Other mood 
factors did not significantly-distinguish drug from placebo.
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CD
1 .24
-0.5-
PRE 1 , 3 5
TIME (hours)
Fig 6.6  Mean skin conductance leve ls  fo l lowing placebo ( v ) ,
250mg ca f fe ine  and 500mg c a f fe in e  ( • ) .
CD=cri t ical  d i f fe rence  at  the 0.05 level  of p r o b a b i l i t y .
(See Fig 6.4)
Reproduced by kind permission of Dr M Bruce, Institute of Psychiatry, London.
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ALERT
30
25
20
15
10
5
0
5
10
DROWSY
PRE 1 3 5
TINE (hours)
Pig 6.7 Mean mood ra t in g  f o r  "alert -drowsy" a f t e r  placebo ( V ) ,  
250mg c a f fe in e  (O) and 500mg c a f fe in e  { •  ) .
CD=cri t ical  d i f fe rence  at the 0.05 leve l  of p r o b a b i l i t y .
Reproduced by kind permission of Dr M Bruce, Institute of Psychiatry, London.
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SHAKING or TREMBLING
30
25 '
20 '
CD
PRE 1 3 5
TIME (hours)
Fig 6.8 Mean bodi ly symptom ra t in g  "shaking or t rembl ing"  
‘ fo l lowing placebo ( v ) ,  250mg, caf f  ei ne ( O  ) and 
500mg c a f fe i  ne ( •  ) .
CD=cr i t ica l  d i f fe rence  at the 0.05 level  of p r o b a b i l i t y .  
(See Fig 6.4)
Reproduced by kind permission of Dr M Bruce, Institute of Psychiatry, London.
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Bodily symptoms. The subjects reported more severe shaking 
and trembling (Fig. 6 .8 ), maximal at one hour, and diminishing 
rapidly thereafter. There were also fewer complaints of 
headache (P <0.05) and less tiredness (P <0.01) after caffeine 
than after placebo. State anxiety inventory failed to show any 
difference between drug and placebo effects.
DISCUSSION
The precise calculation of pharmacokinetic data for his 
study was impeded by the limited number of subjects and the 
short period of sample collection. In addition there was a 
lack of control of relevant factors such as dietary caffeine 
consumption, the amount of smoking, female menstrual status 
and the taking of oral contraceptives. However the calculated 
values for elimination half-life and apparent volume of 
distribution were consistent with those found previously for 
normal healthy volunteers (Section 5.) In a study of random 
caffeine levels in hospital outpatients (Smith et al., 1982), 
5% of the population were shown to have values in excess of 
5.6 mg/1. This level is comparable to the average peak 
caffeine level following the 250 mg dose of caffeine. The 
gradual increase in 1 ,7-dimethylxanthine (paraxanthine) levels 
during the period of investigation is consistent with previous 
studies (Callahan et al., 1983; Arnaud 1986) indicating that 
within two hours following caffeine intake, the formation of 
this metabolite by 3-N demethylation accounts for 75% of the 
administered dose.
The limited period of urine collection resulted in a low
- 138 -
recovery of methylxanthine metabolites. However, the pattern 
of excretion after the 500 mg dose resembled closely the 
metabolite output estimated in normal subjects receiving a 
controlled dietary caffeine intake of 450 mg/24 hours. In 
agreement with data from previous studies (Callahan et al., 
1983, Blanchard et a l ., 1985), the principal urinary
metabolite were 1-methyluric acid, 1-methylxanthine and
1,7-dimethyluric acid.
An important consideration in this study was the 
effectiveness of quantitative EEG measuremnts as empirical 
dose/time markers of the reputed stimulant effects of 
caffeine. Evidence for the stimulatory action of caffeine was 
provided by the highly significant dose-related decrease in 
the slow-wave (theta) activity and a similar, but not dose 
related, decrease in alpha wave activity. The paradoxical 
responses observed with fast wave (beta) activity suggest 
that, whilst caffeine may have a similar direct (but dose 
related) effect in decreasing EEG power, a concomitant 
dose-related increase in beta activity may occur as a direct 
result of the stimulant action. Similar complex effects are 
occasionally observed in the opposite directions with 
sedatives such as premazepam (Golombok and Lader, 1984)*
The failure to show significant changes in both systolic 
and diastolic blood pressures is in contrast with a report by 
Robertson et al. (1978) which showed an increase of 14/10 mm 
Hg one hour after a single dose of caffeine (250 mg). Although 
their subjects were normally abstainers of caffeine, the 
significance of this factor is doubtful since similar, but
- 139 -
less pronounced increases have been recently shown in habitual 
caffeine consumers (Smits et al., 1985).
The dose-related increase in skin conductance indicated an 
increase "arousal" in accordance with the known stimulatory 
effects of caffeine (Veleber and Templer, 1984). This was also 
demonstrated by the self-rating mood scale where the effects 
of caffeine included increased measures of alertness, energy, 
quick wittedness and attentiveness. Self rating bodily symtoms 
also indicated less tiredness. Whilst increases were observed 
in the measure of tremor by the accelerometer and the degree 
of shaking and trembling by the bodily symptom scales, only 
the latter showed significant changes. This would suggest that 
tremulousness is mainly subjective in nature.
Although the sensitivity of the psychological tests used in 
this study has been previously established in studies on the 
depressant effects of a wide range of psychotropic drugs, no 
significant effects were observed for this study. However, it 
is probable that the subjects were well motivated and 
performed the tasks to their maximum abilities thus leaving 
limited scope for drug induced improvements. Since the effects 
of caffeine will counter decline in repetitive performance 
tasks, the use of longer term tasks such as a standard 
vigilance task should be more sensitive.
As a result of the ubiquitous nature of caffeine 
consumption, often in almost toxic doses, prolonged periods of 
withdrawl are required before true baseline readings can be 
attained. In agreement with earlier reports (Section 5), the 
period of caffeine withdrawl for this study was in some
- 140 -
instances associated with the onset of headaches similar to 
those previously reported by Dreisbach and Pfeiffer (1943) and 
Greden et al. (1980). The effectiveness of a caffeine load in 
counteracting this effect was confirmed by a decrease in the 
self rating bodily symptom of caffeine.
The aim of this study was essentially of a pilot nature to 
assess the suitability of the test battery for use in 
assessing the psychophysiological effects of caffeine. The 
results obtained generally support the effectiveness of these 
investigations for use in future studies of this complex 
drug-subject interaction. The state anxiety inventory in 
normal subjects has previously been shown not to distinquish 
high caffeine consumption (Boulenger and U h d e , 1982); this is
supported by the findings of this study.
Since the pharmacological properties of the dimethyl- 
xanthine metabolites of caffeine are reported to be similar to 
those of caffeine (Williams et al., 1978), the presence of 
significant plasma levels of paraxanthine may potentiate the 
effects of caffeine. The application of this battery of tests 
in monitoring the psychophysio1ogica1 responses to a 
paraxanthine load would therefore be of considerable interest.
- 141 -
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7. CAFFEINE IN PREGNANCY AND ITS EFFECTS ON THE NEWBORN INFANT
7.1 INTRODUCTION
7.1*1 THE METABOLISM OF CAFFEINE DURING PREGNANCY
Studies on the elimination of caffeine in pregnancy have 
consistently shown a substantial and progressive decrease in 
its clearance during the second and third trimesters (Aldridge 
et al.,1981; Knutti et a l ., 1982). A study of the salivary 
kinetic profiles, following an oral dose of caffeine (177 mg) 
in the form of instant coffee, in eight subjects during and 
after pregnancy (Aldridge et a l ., 1981), showed that the mean
clearance of caffeine fell from 69.6 ml/hr/kg at 11 weeks 
gestation to 23.5 ml/hr/kg at 36 weeks. Corresponding salivary 
elimination half-life values increased fourfold from 5.3 to
18.1 hours. These changes disappeared within a few days post 
partum. The reductions in clearance were reflected more by 
changes in the elimination constant than in the apparent 
volume of distribution. Kinetic profiles of caffeine during 
the first trimester of pregnancy were similar to that of 
non-pregnant women not receiving oral contraceptives. These 
findings were confirmed by Knutti et al. (1982) who, in a 
study involving 15 pregnant women, found no correlation 
between the delayed clearance of caffeine and age, body 
weight, consumption of caffeinated beverages or changes in 
smoking habits.
Similar impairements in the elimination of caffeine have 
been observed in women receiving oral contraceptives.
Following oral administration of radio1abe11ed caffeine to 
three non-smoking populations, Callahan et al. (1983) observed
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that women taking oral contraceptives for at least 6 months 
had a lower mean plasma clearance (37 ml/hr/kg) compared to 
normal male subjects (83 ml/hr/kg> and ovulating females (109 
ml/hr/kg). Respective caffeine elimination half life values 
were 10.4 hr (SD = 2.4), 4.5 hr (SD = 1.1) and 3.1 hr (SD = 
0.9). The reduced plasma clearance of caffeine and its 
extended half-life in women receiving oral contraceptives were 
mainly reflected in lower amounts of metabolites in urine and 
a slower rate of metabolite formation. However, the pattern of 
metabolite excretion was similar for all three groups, the 
major urinary metabolites being 5-acetylamino-6-amino-3- 
methvluraci1, 1-methyluric acid and 1-methylxanthine. In 1980, 
Patwardhan and colleagues used similar groups of subjects in a 
study restricted to the clearance of caffeine from plasma. 
Although their results showed a significantly prolonged 
half-life for caffeine in 9 females receiving oral 
contraceptives (10.7 hrs SD = 3.0), the apparent volumes of 
distribution and levels plasma protein binding were similar to 
those observed in 9 control females not receiving oral 
contraceptives showed. In comparison with results obtained for 
13 healthy males, the pharmacokinetic data was similar with 
the exception that values for the apparent volume of 
distribution were significantly larger in both the female 
groups (P <0.05).
The impaired elimination of caffeine during pregnancy may 
be explained by changes in the hormonal milieu (increased 
oestrogens and progesterone) which decrease the hepatic 
metabolism of certain drugs (Patwardhan et al., 1980). The
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evidence that progesterone, oestrogens and their metabolites 
can induce, repress, or directly inhibit selective mono­
oxygenase catalysed processes is abundant (Feuer and Kardish, 
1975; Krauer and Krauer, 1977; MacKinnon et al., 1977).
However these investigatons have been mainly descriptive with 
little attempt to determine the cause of the changes in drug 
metabolism. In a study of factors affecting hepatic drug 
metabolism in the pregnant rat, Turcan <1981) showed that 
elevated levels of placental lactogen caused a significant 
decrease in maternal mixed function oxidase activity when 
expressed as per gram of liver. Drug enzyme activity, 
determined with the substrates aniline (p-hydroxy1ation), 
ethylmorphine (N-demethy1 ation) and p-nitrobenzoic acid 
(reduction) decreased progressively during gestation to 53-73% 
of the non-pregnant control level by day 20 of gestation. 
However, the total activity of the liver to metabolize drugs 
remained unchanged or increased because liver weight was 
elevated by up to 40% during pregnancy. The author concluded 
that, in the pregnant rat, changes in drug metabolism during 
gestation were not related to alterations in the concentration 
of cytochrome P-450. The rise in circulating steroids did not 
appear to be an important factor of mixed function oxidase 
activity. However it was suggested that oestrogens may induce 
hepatic growth hormone receptors which are important mediators 
of placental lactogen activity.
The low molecular weight of caffeine facilitates transport 
across the placenta (Goldstein and Warren, 1962) and evidence 
suggests that it may accumulate in foetal brain tissue (Galli
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et al . . 1975). Other facors which aid in placental transfer
include its high lipid solubility and its low ionization at 
physiological pH. Caffeine is also secreted into breast milk 
and enters gonadal tissue (Goldstein and Warren, 1962).
7.1.2. The metabolism of caffeine in the newborn
Caffeine is eliminated remarkedly slowly by both premature 
and full-term newborn infants (Parsons et a l ., 1976; Aranda et
al., 1981). The mean plasma caffeine half life approximates 
100 hours in the preterm newborn infant (Aranda et al., 1981) 
which represents a 16-fold prolongation relative to the 
non-smoking adult whose mean half-life is about 6 hours. In 
full term infants, there is an 11-fold decrease in the plasma 
clearance of caffeine relative to that of the non-smoking 
adult. The decreased clearance is mainly due to slow 
elimination of caffeine as the apparent volumes of 
distribution are similar for both neonate and adult. In a 
study of the maturation of caffeine elimination in infancy 
(Aranda et al.. 1979) the plasma clearance of caffeine at the 
age of 3 to 4 months was estimated to be 105 ml/hr/kg, a rate 
similar to that of the non-smoking adult value. No changes in 
caffeine elimination seemed to occur during the neonatal 
period itself. In addition, the clearance or half-life of 
caffeine during this period was not be related to indices of 
maturity such as birth weight, gestational age, and postnatal 
age.
The urine methylxanthine metabolite patterns in 10 infants, 
aged 8 days to 8 months, receiving therapeutic treatment with
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caffeine (Aldridge et al.. 1979) showed that during the first 
month of life, caffeine accounted for more than 85% of the 
identifiable products in urine. Caffeine remained the 
predominant component for the first 3 months before gradually 
decreasing to the adult value of less than 2% by the age of 7 
to 9 months. This coincided with the attainment of normal 
adult metabolite patterns. The data suggests that the impaired 
clearance of caffeine in the newborn is mainly the result of a 
generalised deficiency in the oxidative metabolism of drugs 
handled by the cytochrome P-450 mono-oxygenase system. In 
particular. Pelkonen et al. (1973) observed that human fetal 
liver is much more deficient in aryl hydrocarbon hydroxylase 
activity (2% of the adult value) than in other catalytic 
functions of the mono-oxygenase complex (25-50% of the adult 
values).
7.1.3. Dispos ition o f caffeine in human breast milk
Caffeine from dietary sources has long been known to enter 
milk from lactating mothers. Early studies by Irvin and 
Schumaker (i936) demonstrated the presence of caffeine in milk 
after tea or coffee consumption, with mean levels of approx­
imately 8.2 mg/1 being reached 4 hours after the ingestion of 
coffee containing 100 mg caffeine. However these studies used 
techniques lacking in specificity and sensitivity. Tyrala and 
Dodson (1979) studied the disposition of caffeine in maternal 
serum and milk in 4 lactating mothers from 4 to 12 months. 
Following oral ingestion of 150 mg caffeine sodium benzoate, 
peak levels in serum occurred by 60 minutes in all patients
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and ranged from 2.4-4.0 mg/1. Caffeine appeared in both serum 
and milk by 30 minutes and the milk/serum ratio was constant, 
the average ratio being 0.52. Since approximately 75% of 
caffeine in serum is free, this ratio is less than the 
theoretical value suggesting that additional factors other 
than free diffusion determines the distribution across the 
mammary alveolar cell into milk. On the assumption that the 
infants would nurse 90 ml at 1 and 2 hours after the maternal 
dose, the total amount of caffeine ingested by the infant was 
estimated to be 170 ug or 0.11% of the maternal dose.
In a similar study, Berlin et al. (1984) investigated the 
disposition of caffeine in milk and saliva following the 
consumption of a caffeine containig beverage equivalent to 
their usual amount (conc. range = 35-336 mg). Caffeine was 
detected by 15 minutes in both milk and saliva; peak levels in 
milk (2.09 - 7.17 mg/1) and saliva (1.24 - 9.22 mg/1) were 
reached within 1 hour. Respective elimination half-life values 
for milk and saliva were 6.1 (SD = 4.4) and 4.0 (SD = 3.7) 
hours. Using similar criteria to Tyrala and Dodson (1979), 
they estimated that the amount of caffeine available for 
infant absorption ranged from between 0.01-1.64 mg or 0.06% to 
1.5% of the maternal dose. In 1982, Bailey et al. monitored 
the caffeine concentration in milk of one woman over a 10.5 
hour period during which she drank 12 cups of weak coffee 
(33.2 mg caffeine per cup). The total amount of caffeine 
consumed was 398 mg. Concentrations in milk ranged from 0 to 
1.5 mg/1. A more recent study by Ryu (1985), which determined 
caffeine concentrations in milk of 9 lactating
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women, reported a mean value for 6 of the subjects of 3.8 
mg/1; the average values for the remaining 3 subjects were
13.4, 15.7 and 28.6 m g /1. However, whilst these values clearly 
indicate that breast fed infants may be exposed to high levels 
of caffeine, it is questionnab1e whether the results are 
representative of a normal pregnant population since the 
subjects were all receiving a high dietary caffeine intake of 
750 mg per day.
Although the above mentioned studies reflect minimal 
exposure to caffeine following the maternal consumption of 1-2 
cups of coffee, the delayed clearance in young infants may 
result in cumulative blood levels being reached.
7 .1.4. Caffeine levels in u m b ilical cord blood
In 1976 Parsons et al. determined the concentration of 
caffeine in cord blood samples collected from 15 full term 
infants in Montreal, using a RIA procedure specific for 
caffeine (Cook et al., 1976), and found a mean value of 1.4 
mg/1. Similar values were found by Soyka and colleagues (1981) 
in a more extensive study (n=30) of an infant population in 
Vermont USA (Soyka et al., 1981). Using the same analytical 
procedure they reported a median value of 1.0 m g /1 (range = 
0.01-5, n=329). This group also studied a population of 69 
infants born in Marburg, West Germany in which they found a 
mean value of 1.6 mg/I (range = 0.2-8.9). A report by V a n ’t 
Hoff (1981) suggests that cord blood caffeine levels in the 
United Kingdom may be somewhat higher than estimates from 
other countries. In a study involving 55 full term infants at
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Guy's Hospital, London, he observed cord blood caffeine levels 
up to 12.6 m g /1 .
7.1.5. Effects of caffeine consumption on the outcome of 
pregnancy
Concern about the possible harmful effects of caffeine in 
pregnancy have evolved mainly from animal studies which have 
associated caffeine intake with decreased intrauterine fetal 
growth, a lower birth weight and skeletal abnormalities. 
However, the implications of these findings in humans is 
unclear due to differences in the mode of exposure to 
caffeine, the amounts consumed and the species variations in 
metabolism of the drug.
In a retrospective survey by Weathersbee et al., (1977) the 
daily caffeine intakes of women who had recently been pregnant 
were estimated and analysed in relation to the outcome of 
pregnancy. In a subgroup of 16 women with a caffeine intake of 
a least 600 mg/day, 15 of the pregnancies ended in spontaneous 
abortion, stillbirth or premature births. However it is 
doubtful whether the consumption estimates accurately 
reflected the intake during pregnancy and the study failed to 
consider the effects of other risk factors such as age, 
smoking habits and alcohol consumption. More recently, Linn et 
al., (1982), in a study of the outcome of 12,205 pregnancies 
reported that lower birthweights and shorter periods of 
gestation occurred more often among the offspring of women who 
drank four or more cups of coffee per day. However, after 
controlling for smoking, alcohol consumption, demographic
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characteristics, and medical history by standard logistic 
regression, they concluded that coffee consumption was not 
related to low birth weight, short gestation, or the presence 
of malformations. Cigarette smoking was one of the more 
prominent risk factors for a birthweight of less than 2.5 kg. 
Additional support for this is found in a study by Kuzma and 
Sokol (1982) which was primarily concerned with evaluating 
alcohol consumption and birthweight. The report concluded that 
women who consume the caffeine equivalent of 6 cups of coffee 
a day prior to delivery gave birth to babies weighing 1.5 oz 
less than babies born to women who consumed virtually no 
caffeine. In contrast, the birthweight reductions for 
consumption of two-thirds of a can of beer a day and smoking 
one or more packets of cigarettes per day were, 3.7 oz and 6.4 
oz respectively.
The risk of congenital anomalies was evaluated by Rosenberg 
et a l . 1982) in a case controlled study of 2,030 malformed
infants. The focus of this study was two congenital anomalies 
which had been previously observed in rodents given high doses 
of caffeine. Cleft lip (with or without cleft palate) occurred 
in 299 babies, and isolated cleft palate was identified in 
another 120 babies. However, neither mothers who consumed more 
than 200 mg per day nor those who consumed more than 400 mg of 
caffeine per day were at significantly increased risk of 
delivering a baby with either of these clefts. Similar 
negative correlations were observed for infants with inguinal 
hernia, cardiac defects, pyloric stenosis and neural tube 
defects. The study concluded that caffeine has no major
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teratogenic effects.
In summary, the cumulative evidence derived from 
epidemiological studies suggests that caffeine consumption by 
pregnant women does not materially increase the risk of low 
birthweight, preterm birth or congenital malformations 
(Levi ton, 1984).
7.1.6. Adverse effects of caffeine in the newborn infant
The adverse reactions of caffeine in the newborn infant are 
mainly exaggerations of the known pharmacological effects. 
These include tachycardia, tachypnoea, seizures, opisthotonus, 
tremors, jitteriness, increased reflexes, hypertension and 
gastro-intestinal disturbances (Howell et al. 1981). Whilst 
these effects are most likely to result from excessive use of 
caffeine in the treatment of neonatal apnoea, the cumulation 
of caffeine due to excessive maternal consumtion should not be 
ignored.
7.1.7. Introduction to experimental work
The studies summarised in Section 7.1 have provided a 
significant amount of information on the pharmacokinetics and 
pharmacological properties of caffeine in maternal serum, cord 
blood and breast milk. This data, supplemented with 
information on the dietary consumption of caffeine during 
pregnancy, has enabled assessments to be made of the degree of 
foetal exposure to caffeine and the subsequent effects on the 
outcome of pregnacy. However, there are still important areas 
that require further investigation. In particular, the
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mechanisms responsible for the substantial and progressive 
decrease in the elimination of caffeine during the second and 
third trimesters of pregnancy (Aldridge et al., 1901; Knutti 
et al., 1982) are unknown, although they are generally 
considered to be hormonal in origin.
The following studies were performed to provide further 
information on the metabolism of caffeine during pregnancy and 
to investigate the relationship between exposure to caffeine 
and the onset of certain metabolic disorders in the newborn 
infant. All measurements of caffeine and its metabolites were 
performed using the HPLC procedures described in Sections 2 
and 3. Prior to commencing these studies, protocols were 
submitted to and approved by the Bromley Health District 
Ethics Committee.
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7.2. ASPECTS OF CAFFEINE METABOLISM DURING PREGNANCY
7.2.1. METHYLXANTHINE LEVELS IN MATERNAL SERUM AND SALIVA
A previous study by Tebbutt et a l . (1984) concluded that
dietary surveys of caffeine consumption during pregnancy were 
only moderately well correlated with plasma levels of 
caffeine. In view of the prolonged half-life of caffeine 
during pregnancy, the authors suggested that whilst interviews 
on diet provides a basis for advising the patient, the 
monitoring of plasma levels probably provides the best 
reflection of the patient's caffeine intake.
This study compares estimates of serum levels of caffeine 
and its dimethylxanthine metabolites in a group of pregnant 
females with values obtained for a non-pregnant population. In 
addition possible alterations in the extent of protein binding 
during pregnancy are investigated by comparing serum/sa1ivary 
caffeine ratios in the two populations.
Methods and materials
Levels of caffeine and its dimethylxanthine metabolites 
(theobromine, theophylline and paraxanthine) were measured in 
serum samples obtained from 63 randomly selected patients 
attending anti-natal clinics for routine assessment. In 17 of 
the subjects, methylxanthine levels were also determined in 
samples of saliva collected simultaneously at the time of 
venepuncture.
A statistical analysis of the random serum caffeine levels 
and the salivary versus serum concentration ratios were 
compared with results obtained previously for a non-preganant
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population (Section 5.).
Results
The levels of caffeine, theobromine, theophylline and 1,7- 
dimethylxanthine <paraxanthine>, estimated in serum samples 
collected at random from a population of pregnant females, are 
summarized in Table 7.1. The values for caffeine are compared 
in the form of a histogram, with those obtained from random 
sampling of non-pregnant volunteers (Fig 7.1) .
Theobromine paraxanthine Theophylline caffeine Total
1.05 0.89 0.40 3.45 5.74
0.84 0.64 0.24 2.16 3.03
0 - 3.89 0 - 4.40 0 - 1.12 0 - 12.1 0.65 - 15.7
Table 7.1 Summary of methylxanthine levels in maternal serum
The mean caffeine value for maternal serum samples <3.45 ±
2.43) was significantly higher (P <0.001) than that previously 
obtained for samples collected from a non-pregnant population 
<2.43 + 1.63). Regress ion analysis of the values for caffeine 
in samples of serum and saliva collected from the pregnancy 
group.showed a linear relationship. The coefficient of 
correlation was calculated to be 0.979 with a regression line 
of y = 0.806x - 0.217, where y = saliva and x = serum, (p.268)
Pi scuss i on
Previous studies on the elimination of caffeine during 
pregnancy h a v e .consistently shown a substantial and 
progressive decrease in its clearance during the second and 
third trimesters (Aldridge et al., 1981; Knutti et al., 1982).
A result of this is that peak concentrations following a
Mean
S.D.
Range 
(n = 63)
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caffeine load and the fluctuation in caffeine levels that are 
characteristic of usual consumption habits become less 
pronounced. The regular consumption of caffeinated beverages 
during pregnancy may therefore produce steady state maternal 
serum caffeine levels which may be used as an index of dietary 
caffeine intake. Since caffeine equlibrates rapidly across the 
placenta, the monitoring of caffeine levels in maternal serum 
may also provide an indication of foetal exposure.
The finding in this study of increased caffeine levels in 
maternal serum samples is not unexpected in view of known 
impairments in the elimination of caffeine during pregnancy 
However, completion of questionnaires by a 1imited number of 
the volunteers suggested that the consumption of caffeinated 
beverages decreased during pregnancy, the mean intake being 
approximately 260 mg/day. Since it has been reported that the 
apparent volume of distribution for caffeine is unaltered in 
pregnancy (Aldridge et al., 1981; Knutti et al., 1982), the 
increased concentrations of caffeine in maternal serum must be 
attributed to a delay in the clearance of caffeine. As the 
slope of the regression line for the ratio of levels in 
maternal serum and saliva samples was similar to that for the 
non-pregnant population, changes in the extent of protein 
binding can be eliminated. Subsequently it is probable that 
the delayed clearance of caffeine is the result of altered or 
impaired metabolism by the maternal liver.
An analysis of the histogram distribution of caffeine 
concentrations in maternal serum indicates that up to 10% of a 
pregnant' population may have circulating levels in excess of 6
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mg/1. Since the low molecular weight of caffeine freely 
facilitates transport across the placenta foetal exposure to 
caffeine may be significant. In addition many of the 
metabolites of caffeine have similar pharmacological 
properties (Williams et a l ., 1978) indicating a requirement to
assess exposure in terms of total methylxanthine levels.
7.2.2. URINARY METABOLITES OF CAFFEINE IN PREGNANT WOMEN
The metabolism of caffeine has received little attention, 
due mainly to the natural reluctance of pregnant women to 
ingest large single doses of caffeine and the ethical problems 
of using radio1abe11ed compounds. The following study 
investigates the biotransformation of caffeine in pregnancy by 
comparing urine metabolite profiles of a group of pregnant 
women, receiving a controlled dietary intake of caffeine, with 
those of a group of non-pregnant healthy volunteers under 
similar conditions.
M ethods and materials
A group of 15 pregnant women of between 34-36 weeks 
gestation and a control group consisting of 9 female 
volunteers not receiving oral contraceptives were enrolled 
after careful explanation of the study. A questionnaire was 
completed for each subject giving details of their normal 
dietary caffeine consumption, smoking habits and any current 
drug therapy. Each subject was given a series of pre-weighed 
amounts of coffee, of known caffeine content, equivalent to 
their normal consumption of caffeinated beverages, and 
requested to refrain from consuming any other form of 
caffeinated beverage, chocolate and caffeine containing 
analgesics. Using this protocol the 24 hour caffeine intake 
for the pregnancy group and the non-pregnant control group 
ranged from between 123-369 mg and 300-750 mg, respectively. 
Following a 24 hour period of controlled caffeine intake, 
participants were requested to collect urine samples for a 24
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Fig 7.2. Urinary methylxanthine metabolite excretion
(% administered dose/24 h in pregnant (— ) and 
non-pregnant (r— ) healthy subjects receiving a 
controlled 24 h dietary caffeine intake.
For key to abbreviations refer to page 3.
— 160 -
METABOLITE
RECOVERY 
Non-pregnant 
Mean SD
(% administered dose)
Pregnant Student's t-Test 
Mean SD (P)
7-methyluric acid 1.4 ± 0.5 2.0 £0.6 < 0.05
7-methylxanthine 4.0 £  0.3 5.0 £ 2.6 < 0.25
1-methyluric acid 19.5 £ 5.3 9.4 £ 3.7 < 0.001
3-methylxanth ine 2.6 £ 0.7 5.6 £_ 3.2 < 0.05
1-methylxanthine 11.4 £  2.1 7.3 ±  3.4 < 0.02
1,3-dimethyluric acid 1.6 ±0.5 2.6 £ 0.9 < 0.02
3,7-dimethylxanthine 1.4 £ 0.6 4.3 £ 3.4 < 0.05
1,7-dimethyluric acid 7.2 £ 2.1 9.3 £ 2.9 < 0.1
1,7-dimethylxanthine 4.7 £ 0.9 5.8 £1.1 < 0.05
1,3-dimethylxanthine 0.8 £.0.4 1.6 £ 0.5 < 0.001
1,3,7-trimethyluric acid 0.7 £ 0.2 1.4 £0.6 < 0.01
1,3,7-trimethylxanthine 2.0 £ 1.1 3.3 £ 1.4 < 0.05
Table 7.2 jurinary metabolites of caffeine in healthy subjects receiving
a controlled 24 hour dietary caffeine intake.
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hour period whilst maintaining the same caffeine intake. The 
urine volumes were recorded and aliquots stored at -20 C until 
required for analysis. Following the quantitation of the 
urinary methylxanthine levels by HPLC, a statistical 
comparison was made of the metabolite profiles of the 2 groups 
studied.
R esults
The urinary recoveries of caffeine metabolites obtained in 
the the two groups of volunteers are summarized in Fig. 7.2 
and Table 7.2. Details of the individual results for each 
volunteer are enclosed in Appendix 4 . The total 24 hour urine 
volumes were similar for both groups. Despite a variation in 
the 24 hr caffeine intake, the % recovery of the administered 
dose in 48 hours for the pregnancy group and the non-pregnant 
control group was similar, the mean values being 56.8 (+ SD. 
8.9) and 56.8 <+ SD. 8 .6 ) respectively.
Compared with the non-pregnant subjects,the pregnancy group 
showed a marked decrease in the excretion of 1-methylxanthine 
<11.4% ± SD. 1.9 to 7. 3% £  SD. 3.4) and 1-methyluric acid 
(19.5% £  SD. 5.3 to 9.4% £  S D . 3.7) with a general increase in 
the recoveries of the remaining metabolites, in particular 
those of 3,7-dimethyl xanthine <1.4% £  SD. 0.6 to 4.3% £  SD. 
3.4) and 3-methylxanthine <2.6% £ SD. 0.7 to 5.6% £ SD. 3.2).
D_i s cus s i on
The metabolic fate of caffeine <1,3,7-trimethylxanthine) 
is primarily demethyl ation and oxidation in the liver with 
unchanged caffeine accounting for only 1-3% of the
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administered dose in the urine (Fig.7.3). In man, the 
metabolic stability of the methyl groups increases in the 
order 3,1 and 7 (Arnaud and Welsch, 1981). Although initial 
demethyl ation may occur at any of these three positions, 
yielding formaldehyde as a secondary product, the importance 
of the reactions, in terms of urinary metabolite recovery, are 
3-N demethylation, 72%; 1-N demethyl at ion, 20% and 7-N 
demethyl ation, 8%.
The metabolite recoveries for the non-pregnant control 
group in this study are similar to those found previously 
following a single oral dose of caffeine (Bonati et al., 1982; 
Callahan et al.,1983; Blanchard et al.,1985), indicating that 
the majority of administered caffeine undergoes 3-N-demethy1- 
ation to form 1 ,7-dimethylxanthine, the primary metabolite 
found in serum. The major metabolites excreted in urine are 
1-methyluric acid, 5-acetylamino-6-formylamino-3-methy1 
uracil, and 1-methylxanthine (Fig 7.3).
The significant decrease in the production of 1-methyl 
metabolites, in the pregnancy group, with relatively normal 
values of 1,7-dimethyl metabolites, suggests that during 
pregnancy the further metabolism of 1 ,7-dimethylxanthine may 
be impaired. This could be the result of an impairement in 7-N 
demethylation with respect to 1 ,7-dimethylxanthine as a 
substrate, although the absence of a concomitant increase in
1 ,7-dimethylxanthine excretion would tend to refute this 
possibilty. Alternatively the regulation may be located at the 
level of 3-N demethyl ation of caffeine. It is of significance 
that the clearance of theophylline (1 ,3-dimethylxanthine),
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which does not involve 7-N demethyl ation, is not altered 
during pregnancy (Sutton et al., 1978). The increased 
recoveries of metabolites possessing a 3-methyl group suggests 
that, during pregnancy, the route of caffeine metabolism is 
altered in favour of an initial 1-N demethyl ation of caffeine 
to theobromine followed by 7-N demethylat ion to 3-methyl- 
xanthine. To a lesser extent, the initial 7-N demethyl ation of 
caffeine to form theophylline may also be increased during 
pregnancy, since the recoveries of 1 ,3-dimethyluric acid and 
theophylline are both significantly increased.
A previous study in which caffeine metabolite recoveries 
from normal ovulating females were compared with those 
obtained from women receiving oral contraceptives (Callahan et 
al., 1983), showed for the latter group, decreases in 1-methyl 
uric acid excretion from 16.14% to 11.06%, 1-methylxanthine
excretion from 12.28% to 9.32%, and 5-acetylamino-6-amino- 
3-methyl uracil excretion from 11.69% to 8.61%. The excretion 
of 1,7-dimethyluric acid excretion was increased from 6.05% 
to 9.0% but no significant differences were observed for the 
excretion of 3,7-dimethylxanthine or 3-methylxanthine. The 
authors concluded that, whilst the reduced plasma clearance of 
caffeine and its extended half life in women on oral 
contraceptives was reflected in reduced amounts and a slower 
rate of metabolite formation; the pattern of excretion was 
similar to that of ovulating females and normal male 
volunteers. Although no attempt has been made to measure the 
acetylated uracil metabolites of caffeine in this study, it is 
probable that the unaccounted metabolites in both groups (ca.
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43%) represents the formation of such compounds, in 
particular, 5-acetylamino-6-formylamino-3-methyluraci1. The 
majority of reactions involved in the metabolism of caffeine 
require catalysis by the hepatic microsomal cytochrome P-450 
mono-oxygenase system. Although pregnancy in animals has been 
associated with a progressive decrease in hepatocellular 
cytochrome P-450 mediated oxidative drug metabolism, in man 
the effect appears to depend on the particular drug in 
question. For example, the oxidative biotransformation of 
promazine and meperidine decreases during pregnancy (Rudofsky 
et al., 1966), whilst phenobarbita1 and phenytoin metabolism 
is increased (Mygind et al., 1976). The steroid hormones of 
pregnancy, progesterone, oestrogens and their metabolites, 
have been shown to induce, repress, or directly inhibit 
selective mono-oxygenase reactions (Feuer et al., 1975; 
MacKinnon et a l ., 1977; Field et al., 1979). These modulations
in hepatic metabolism in pregnancy have been suggested to be a 
conseqence of changes in microsomal membrane phospholipids 
and/or the cytochrome P-450 spin state equilibrium (Symons et 
al., 1982). The apparent impairment of 7-N demethyl ation of
1 ,7-dimethylxanthine but not of 3,7-dimethylxanthine may 
reflect heterogeneity of the response of hepatic cytochrome 
P-450 haemoproteins to pregnancy hormones.
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7 .3. ADVERSE EFFECTS OF CAFFEINE IN THE NEWBORN INFANT
Reports from epidemiological studies (Linn et al., 1982; 
Rosenberg et al.. 1982; Leviton et al., 1984) on the effects 
of caffeine consumption during pregnancy, have found no 
association between caffeine intake and an increased risk of 
low birthweight, preterm birth or congenital abnormalities in 
newborn infants. However the presence of high caffeine levels 
in maternal serum indicates that in some cases foetal exposure 
to caffeine may be sufficient to produce overt pharmacological 
effects. The extent of this exposure has been investigated by 
monitoring caffeine levels in umbilical cord blood (Parsons et 
al., 1976; Soyka et al., 1981; V a n ’t Hoff, 1982; breast milk 
(Horning et al.. 1975; Berlin et al., 1984), and amniotic 
fluid (Horning et al., 1986).In particular, a report by Van't 
Hoff (1982) has indicated that umbilical cord blood caffeine 
levels in the United Kingdom may be higher than those reported 
elsewhere in the world.
The adverse reactions of caffeine in the newborn infant are 
mainly exaggerations of the known pharmacological effects. 
These include tachycardia, tachypnoea, seizures, opisthotonus, 
tremors, jitteriness, increased reflexes, hypertension and 
gastrointestinal disturbances (Howell et al., 1981). However, 
reports on the occurrence of adverse effects of caffeine in 
the neonate have been restricted to those resulting from its 
therapeutic application in the treatment of neonatal apnoea. 
Aranda et al.. (1981) found no obvious cardiovascular, 
neurological or gastrointestinal toxicity with plasma 
concentrations up to 50 mg/1 and only transient jitteriness
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was observed with concentrations from 50 to 84 mg/1. Kulkarni 
and Dorand (1979) reported a case where marked jitteriness and 
tremors with increased reflexes and tachypnoea developed in a 
full term infant with asphyxia treated with 125 mg of caffeine 
sodium benzoate intramuscularly, producing caffeine plasma 
concentrations of 55 mg/1. Toxic reactions occurring in 4 
other cases of asphyxia with doses of 36-136 mg/kg were 
described by Banner and Czajka <1980). The adverse effects 
included seizures, tremors, tachypnoea, hypertension, 
tachycardia (hypotension and bradycardia in one) and fever.
The objective of this study was to further assess foetal 
exposure to caffeine in the UK and to test a hypothesis that 
high caffeine levels in the newborn infant may be a causative 
factor in the aetiology of certain metabolic disorders eg. 
neonatal apnoea and jitteriness. Information is provided on 
the levels of caffeine and its dimethylxanthine metabolites in 
maternal serum, cord blood and breast milk and the values are 
compared with the results of previous studies performed in the 
USA and W. Germany. In addition an assessment is made of the 
relationship between caffeine levels in the newborn infant and 
the onset of attacks of neonatal apnoea and jitteriness. A 
clinical assessment of the infants studied was achieved by 
completion of a questionnaire using a score rating system of 
bodily symptoms.
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Population study of caffeine leve ls in cord blood and 
breast m ilk.
Determinations were made of the concentrations of caffeine 
and its dimethylxanthine metabolites (theophylline, theobro­
mine and 1 ,7-dimethylxanthine) in samples of umbilical cord 
blood and breast milk, obtained at random from newborn infants 
and nursing mothers, using the HPLC procedure previously 
descr ibed.
Results
The values obtained for caffeine in cord blood are compared 
in Table 7.3. with results obtained from other studies. In 
agreement with previous reports from the United Kingdom, the 
cord blood caffeine levels found in this study (mean = 3.8 ± 
SD. 3.15) were significantly higher than reported values for 
both the USA and West Germany; 5 % of the values being in 
excess of 10 mg/1. Significant levels of theobromine,
1 ,7-dimethylxanthine and theophylline were detectable in 
samples of cord blood, breast milk and maternal serum (Table 
7.4), producing, in some cases, cumulative values of 
pharmacological significance.
7.3.2. Relationship between cord blood caffeine levels and 
symptoms related to caffeine toxicity.
Reported toxic effects of caffeine include tachycardia, 
agitation, tremors, jitteriness, convulsions and gastric 
disturbances. Whilst these sypmtoms have been described in 
neonates receiving caffeine therapeutically for neonatal 
apnoea, the possiblity of caffeine toxicity'occurring as a
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Vermont
USA
Marburg 
W. Germany
London
U.K.
Leeds
U.K.
Present
study
Mean value (mg/1) * 1.6 * 2.85 3.8
Range (mg/1) 0.01 - 5 0.2 - 8.9 up to 12.6 0-11 0.4 - 22.'
Number samples 327 69 55 113 101
% conc. > 3 mg/1 13 8 31 * 51
% conc. > 10 mg/1 0 0 1.8 0.9 5
Reference Soyka et al. Van't Hoff Hartley et al.
(1981) (1982) (1984)
Table 7.3 Summary of reported surveys on caffeine concentrations in 
umbilical cord plasma.
Theobromine Paraxanthine Theophylline Caffeine
mg/1 mg/1 mg/1 mg/1
Total
mg/1
a) Cord blood 
Mean 
S.D.
Range 
(n = 101)
0.85 
0.52 
0 - 2.83
0.77 
0.46 
0 -  2.88
0.40 
0.25 
0 -  1.12
3.80 
3.15 
0.43 - 22.7
5.75 
3.72 
1.13 - 25.7
b) Breast milk 
Mean 
S.D.
Range 
(n = 31)
0.78 
0.46 
0 - 2.39
0.77 
0.47 
0 - 1.75
0.19 
0.35 
0 -1.60
2.80 
2.18 
0 - 8.69
3.92 
2 99 
0.52 - 11.4
Table 7.4. Methylxanthine levels in cord blood and breast milk
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result of excessive foetal exposure has recieved little 
attention. Since these symptoms are frequently present in 
newborn infants, often with unknown aetiology, the following 
study was performed to investigate their relationship to 
circulating levels of caffeine.
Methods
Infants were selected for this study by Paediatric medical 
staff and were divided into those with symptoms of caffeine 
toxicity <ie. jittery infants, n = 12) and a control group of 
healthy newborn infants <n=10). Timed blood samples were 
collected and assayed for caffeine by the previously described 
techniques. An estimate of the infants caffeine level at birth 
was obtained by assuming a half-life of 80 hours <Aranda et 
al., 1981) and extrapolating the results. These values were 
then compared, for each infant, with information obtained from 
the completion of a questionnaire giving details of Apgar 
scores (Appendix 5. ) and a rating score (1-5) for the degree 
of jitteriness, tachycardia, tachypnoea, and gastrointestinal 
disturbances. Any additional information considered relevant 
to the study was also recorded.
R esults
A summary of the relationship between estimates of neonatal 
caffeine levels at birth and the presence of symptoms of 
caffeine toxicity is shown in Table 7.5. The mean caffeine 
level for the group of jittery infants was 4.83 mg/1 (SD = 
4.68) compared to 3.05 mg/1 (SD = 2.98) for the control group. 
However this difference was not statistically significant 
using a Student’s T-test (P <0.5). No significant degree of
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CODE CAFFEINE
mg/1
APGAR 
1 min
SCORE 
5 min Jit
BODILY SYMPTOMS RATING 
Tcard Tpnoea GI Total Comments
1 0 9 9 0 0 0 0 0 Prem
2 0.25 - - 0 0 4 0 4 RDS
3 0.65 2 7 0 0 3 0 3 Prem
4 0.70 6 8 3 0 2 0 5 Irritable
5 0.95 3 10 0 0 3 0 3 Prem
6 1.03 r 8 10 0 0 0 0 0 Prem SFD
7 1.12 3 8 3 0 0 0 3
8 1.3 9 10 3 0 2 0 5 Prem
9 1.84 5 9 4 0 0 0 4 Prem
10 2.21 - - 3 0 0 0 3
11 2.6 8 9 3 0 1 0 4 Prem SFD
12 3.2 8 10 4 0 4 0 8
13 3.38 7 9 0 0 5 0 5 Prem RDS
14 3.52 9 10 3 0 0 1 4 -
15 3.68 9 10 0 0 4 0 4
16 5.3 - - 0 0 4 0 4
17 6.92 9 10 2 0 4 0 6
18 7.2 9 10 0 0 0 0 0
19 8.1 9 10 0 0 0 0 0
20 8.2 3 8 3 1 0 0 4
21 10.24 7 9 Fits 0 1 0 ? Fits x 4
22 16.1 8 9 3 4 0 0 7
Table 7.5 Relationship between serum caffeine levels at birth 
and symptoms of caffeine toxicity
Abbreviations: Jit = Jitteriness; Tcard = Tachycardia; Tpnoea = Tachypnoea 
GI = Gastrointestinal; Prem = Premature delivery;
RDS =Respiratory distress syndrome; SFD = Small for dates.
For Apgar scoring system refer to Appendix 5.
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correlation was found between caffeine levels and the ratings 
for jitteriness, tachypnoea or gastrointestinal disturbances. 
However, symptoms of tachycardia were present only in infants 
with caffeine levels in excess of 8 mg/1. There is some 
evidence to suggest from the results that low caffeine levels 
are associated with low 1 minute apgar scores. The mean scores 
for caffeine levels of less than 3 and greater than 3 were 
6.18 (SD = 2.6) and 7.5 (SD = 2.0) respectively. However the 
majority of infants with caffeine levels of less than 3 mg/1 
were premature births.
DISCUSSION
The cord blood caffeine levels found in this study were 
significantly higher than those previously reported by Soyka 
et al.(1981); 5% being in excess of 10 mg/1. This confirms 
earlier reports from Britain (Van't Hoff, 1982; Hartley et 
al., 1984) suggesting that foetal exposure to caffeine may be 
higher than previously supposed and may lead to the 
manifestation of adverse effects in the newborn infant. These 
include tachycardia, tachypnoea, seizures, tremors, jitter­
iness, increased reflexes, hypertension and gastrointestinal 
disturbances. However, the limited report in this study, on 
the relationship between caffeine levels at birth and a score 
rating assessment of bodily symptoms, showed no evidence to 
implicate circulating levels of caffeine with attacks of 
either jitteriness or neonatal apnoea. Since it has been 
suggested that overt CNS stimulation of caffeine is negligible 
when caffeine concentrations are below 15-20 mg/1 (Howell et
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al., 1981), it may be argued that the levels found in this 
study were below those required to produce significant 
effects. The apparent correlation between the incidence of 
caffeine levels of less than 3 and low 1 minute Apgar scores
is in agreement with a previous report by Soyka et al. (1981)
although it is probable that the low Apgar scores found in 
this study were mainly attributable to premature births.
Whilst adverse effects from caffeine may be regarded as 
negligible when caffeine concentrations are below 15-20 mg/1, 
the delayed clearance of caffeine in the newborn infant (T 1/2 
= approx. 100 hours) may result in these levels being achieved 
by an accumulation of caffeine as a result of breast feeding. 
The caffeine concentrations for breast milk are similar to 
those described in 1984 by Berlin et al. (0-7.2 mg/1)
indicating that in some infants, dietary intake of caffeine
from breast feeding may be 4 mg/day or more. This value 
approaches the therapeutic maintenance dose (2.5 mg/kg) used 
for the treatment of neonatal apnoea and suggests that 
caffeine withdrawal from intrauterine habituated infants, 
especially where breast feeding is delayed or artificial 
feeding instituted, could play a part in the aetiology of 
neonatal apnoea. This concept is supported by a recent report 
by Khanna and Somani (1984) of a premature infant (31 weeks 
gestation) who developed respiratory distress ascribed to 
transient tachypnoea of >the newborn. The apnoea was first 
noted 4 days after birth and a blood sample collected on the 
fifth day, prior to caffeine therapy, showed a caffeine level 
of 40.3 mg/1. On the assumption that the average half life of
caffeine in the newborn infant is 100 hours, the authors 
calculated that caffeine levels in this infant at birth would 
have approximated 80 mg/1. Following a loading dose of 10 
mg/kg caffeine, and with maintenance doses of 5 mg/kg every 12 
hours, there were no further episodes of apnoea after the 6th 
postnatal day. A detailed history revealed that the mother had 
consumed up to 24 cups of coffee per day for several weeks 
prior to delivery.
Since the dimethylxanthine metabolites of caffeine are all 
pharmacologically active (Williams et al., 1978), the presence 
of significant levels of these compounds in maternal serum, 
cord blood and breast milk, indicates a requirement to assess 
the effect of total methylxanthine levels in pregnancy and in 
the newborn infant. The results for cord blood are in close 
agreement with those recently reported by Hartley et al.
(1984) and indicate that total methylxanthines may reach 
clinically significant proportions. As this study shows some 
evidence to suggest that the ratio of caffeine and its 
metabolites in maternal serum or saliva are consistent with 
values found in cord blood and breast milk, the screening of 
maternal serum or saliva for caffeine content may therefore 
provide a useful index to increased foetal exposure, 
especially in cases where the dietary consumption by the 
mother is known to be high.
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8^ THE PHARMACOKINETICS AND METABOLISM OF CAFFEINE IN 
CHRONIC LIVER DISEASE
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8.1. CHRONIC PARENCHYMAL LIVER DISEASE.
Chronic parenchymal liver disease may be broadly classified 
into chronic hepatitis and cirrhosis. In chronic hepatitis, 
the zonal architecture of the liver is preserved and is 
essentially reversible, whilst in cirrhosis, nodular 
regeneration leads to an irreversible loss of the essential 
hepatic arcitecture.
8 .1.1. Chronic hepatitis.
By definition, this is a chronic inflammatory reaction in 
the liver continuing without improvement for at least 6 
months. Histologically, chronic hepatitis is divided into 
chronic persistent hepatitis, chronic lobular hepatitis and 
chronic active hepatitis. Since necrosis is minimal in 
persistent and lobular hepatitis, the prognosis of these 
conditions is good. However, chronic active hepatitis is 
marked by the presence of portal tract infiltration of 
mononuclear cells, extending irregularly into the surrounding 
parenchyma so that swollen liver cells become isolated in the 
inflammatory cell infiltrate. This process of hepatocyte 
destruction is termed "piecemeal necrosis" and leads to septum 
formation linking portal tracts and central veins. The ensuing 
disruption of lobular architecture is accompanied by the 
development of regenerative nodules and thereby cirrhosis.
The characteristic histological changes of chronic active 
hepatitis may be seen following viral infection of the liver, 
in Wilson's disease, alcoholic liver disease, in association 
with the administration of certain drugs eg. methotrexate and 
methyldopa and in "lupoid hepatitis", an autoimmune disorder
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associated with other auotimmune diseases. Diagnosis of 
chronic active hepatitis can only be made with confidence 
following biopsy of the liver. Standard liver function tests 
are of little value as plasma levels of bilirubin, aspartate 
transaminase and alkaline phosphatase show considerable 
variation. Gamma globulin levels may be significantly 
increased, particularly in lupoid hepatitis, but similar 
increases are also seen in a number of other chronic 
parenchymal diseases. In autoimmune chronic active hepatitis, 
the diagnosis is questionable unless there is a high titre 
<1:80 or more) of antinuclear factor or smooth muscle 
antibodies. Antinuclear antibodies to double stranded DNA and 
smooth muscle antibodies to actin are also of diagnostic 
value. Chronic active hepatitis due to viral infections eg. 
hepatitis B, can also usually be diagnosed on immunological 
grounds.
8 .1.2 . Cirrhos i s
Cirhosis is defined as a diffuse process with widespread 
fibrosis and nodule formation following hepatocellular 
necrosis. Distortion of the liver architecture occurs 
resulting in portal-systemic vascular shunts. Predominant 
clinical features include portal hypertension, splenomegaly, 
ascites, jaundice, endocrine abnormalities, haemorrhagic 
tendancies and hepatic encephalopathy. Classification may be 
made into three types, namely micronodular, macronodular and 
mixed cirrhosis. Micronodular cirrhosis is characterised by 
the presence of thick, regular connective tissue septa; the
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small regenerative nodules varying little in size to the 
original lobules, but involving every lobule. The micro- 
nodular liver may represent impaired capacity for regrowth as 
in alcoholism, malnutrition, old age or anaemia. In macro- 
nodular cirrhosis the connective tissue septa vary in 
thickness and the nodules show marked differences in size, the 
larger ones containing histologically normal lobules. Mixed 
cirrhosis shows features of both micronodular and macronodular 
cirrosis. The aetiology of cirrhosis may be summarised as 
foilows:-
1. Viral hepatitis - types B; non-A, non-B.
2. Alcohol
3. Metabolic eg. haemachromatosis, W i 1 son *s .disease, 
alpha 1 anti-trypsin deficiency, diabetes 
mellitus, ga1actosaemia, congenital tyrosinosis, 
type IV glycogenosis.
4. Prolonged cholestasis - intra and extra-hepatic.
5. Hepatic-venous outflow obstruction eg. veno- 
occlusive disease, Budd-Chiari syndrome, 
constrictive pericarditis.
6 . Disturbed immunity - lupoid hepatitis.
7. Toxins and therapeutic agents eg. methotrexate, 
amiodarone.
8 . Intestinal bypass.
9. Indian childhood fcirrhosis.
10. Cryptogenic cirrhosis.
The diagnosis of cirrhosis can often be made confidently on
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purely clinical grounds. Biochemical investigations are of 
little diagnostic value and, in the absence of classical 
clinical features, a liver biopsy is required to establish a 
firm diagnosis. Liver biopsy also allows identification of the 
cause of cirrhosis in haemochromatosis, Wilson's disease, 
alpha-1-antitrypsin deficiency etc. In decompensated cirrhosis 
serum bilirubin levels are increased, albumin is depressed and 
gamma-g1obulin raised. Alkaline phosphatase activity is 
usually raised to about twice normal although occasionally 
very high readings may be found. Serum transaminase levels may 
also be increased; prothrombin times are prolonged and do not 
return to normal with vitamin K therapy. There is usually a 
mild normocytic (occasionally macrocytic), normochromic 
anaemia; gastrointestinal bleeding may produce a hypochromic 
anaemia. Leucocyte and platelet counts are reduced and the 
bone marrow is macronormoblastic. Excess urobilinogen is 
present in the urine and bilirubin may also be detecetd if the 
patient is jaundiced. In the presence of ascites, urinary 
sodium excretion is diminished and in severe cases, less than 
4 mmol/I are excreted daily.
8.1.3. P r imary Biliary Cirrhosis.
This condition is associated with progressive granulomatous 
destruction of intra-hepatic bile ducts, leading eventually to 
the development of cirrhosis. Pruritis is the most common 
initial complaint and may precede jaundice by months or even 
years. The disease predominantly affects women, usually in 
middle age. Whlist the aetiology remains unknown, the disease
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is associated with a profound immunological disturbance which 
has been related to the bile duct destruction. The final event 
appears to be an attack by cytotoxic lymphocytes on biliary 
epithelium. Hepatomegaly is virtually constant and spleno­
megaly occurs as portal hypertension develops. The disease 
usually lasts for 5 to 10 years terminating in liver failure 
or alimentary bleeding.
In its early stages, before the onset of jaundice, patients 
may have an isolated elevation of alkaline phosphatase and 
liver biopsy reveals the characteristic granulomata and bile 
duct damage. Eventually there may be deep jaundice, a moderate 
elevation of aminotransferases, raised alkaline phosphatase 
activity and a severe hypercho1estero1aemia. Whilst the 
diagnosis is frequently made on clinical grounds, the 
condition riiay mimic extrahepatic biliary obstruction. The 
finding of a mitochondrial antibody is of significant value in 
establishing a diagnosis since it is found in almost all 
cases. Serum IgM levels are usually elevated in patients with 
primary biliary cirrhosis. IgM levels tend to be higher than 
IgG levels, which is reversal of the findings in patients with 
autoimmune chronic active hepatitis. However, this finding is 
of limited diagnostic value as IgM increases may show 
considerable variation.
8 .1.4. The pathology of alcoholic liver disease.
The major factor in the pathogenesis of a 1coho1-re 1ated 
liver injury is the direct toxic effect of ethanol and its 
metabolites on the liver cell. Alcohol cannot be stored and
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obligitaory oxidation must take place, predominantly in the 
liver where it is coverted to aceta1dehyde, catalysed by the 
enzyme alcohol dehydrogenage. Acetaldehyde is then converted 
to acetyl CoA with acetaldehyde dehydrogenase acting as a 
coenzyme. This may then be further metabolized to acetate and 
oxidised to carbon dioxide and water in the citric acid cycle. 
The oxidation of ethanol is associated with a number of 
metabolic changes within the liver resulting in the generation 
of an excess of reducing equivalents, particularly the reduced 
form of nicotinamide adenine dinucleotide (NADH). The 
increased NADHiNAD ratio results in alterations in lipogenesis 
and lipid oxidation which favour hepatic triglyceride 
accumulation. Indirectly, the activity of the citric acid 
cycle is depressed resulting in decreased adenosine 
triphosphate (ATP) levels. In addition, acute ethanol 
intoxication causes abnormal fragility of cell lysosomes 
resulting in the release of lysosomal enzymes into the serum.
In Western countries the incidence of cirrhosis can be 
directly related to the amount and duration of alcohol 
ingested. There also appears to be an increased susceptibility 
of alcohol-induced damage in females (Morgan and Sherlock, 
1977). Using the criteria that a bottle of spirits contains 
240g of alcohol, the safe limit for daily consumption is now 
considered to be 60g in men and as little as 20g in women. 
Alcoholics with cirrhosis usually show a history of consuming 
about 190 g of alcohol daily for at least 10 years. The type 
of alcohol is not an important factor in determining the type 
and extent of damage. Although the total alcohol intake may be
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similar, the steady daily imbiber is much more at risk than 
the spree drinker, who probably allows some liver repair to 
take place between bouts of drinking.
Hepatic injury resulting from long term excessive ingestion 
of alcohol may range from trivial accumulation of fat to 
irreversible cirrhosis. The classification of alcohol-induced 
lesions is based primarily on histological features (Sherlock, 
1982; Maddrey, 1984) and includes fatty liver, alcoholic 
hepatitis, and alcoholic cirrhosis. Although a combination of 
these elements is present in most individuals, the necrosing 
and inflammatory lesions of alcoholic hepatitis are accepted 
as being the most importnat precursors to the development of 
cirrhosis.
Alcohol-induced fatty liver
The consumption of alcohol leads to a rapid accumulation of 
fat in liver cells but it is considered to be a reversible 
lesion and not a precursor for a more severe disease. Although 
many patients with a 1coho 1-induced fatty liver show no 
symptoms, hepatomegaly is usually present and some patients 
may develop jaundice. Nausea, vomiting, ascites, oedema, and a 
tendancy to bleeding may also be present.
A lcoh o lic hepatitis
This is an inflammatory lesion characterized by alterations 
in cell size, infiltration of the liver with polymorphonuclear 
leucocytes, cell necrosis, and in many patients the presence 
of alcoholic hyalin. It frequently appears as severe hepatic 
decompensation after particularly heavy drinking, perhaps 
precipitated by vomiting, diarrhoea, an acute infection, or
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prolonged anorexia. In its most florid form, alcoholic 
hepatitis presents as an overwhelming illness with fever, 
leucocytosis, abdominal pain, nausea, vomiting, bleeding, 
ascites and hepatic encephalopathy. Portal hypertension may 
occur even in patients in whom there is little or no evidence 
of cirrhosis. This may be reversible if and when the acute 
injury resolves. Nutritional changes of alcoholism, including 
peripheral neuritis, folic acid deficiency and scurvy may also 
be found.
Biochemically, serum transaminase and alkaline phosphatase 
levels are elevated. The concentration of serum albumin is 
usually low whilst gamma globulins levels are raised; these 
return to normal on improvement of the patients condition. 
Serum cholesterol levels may be very high and the liver serum 
lipaemic, often coinciding with pancreatitis. Hypokalaemia may 
also be prominant, epecially if there is diarrhoea.
Alcoholic cirrhosis
Cirrhosis in alcoholics results mainly from a progression 
of alcoholic hepatitis although the possiblity that it might 
follow alcohol induced fibrosis has also been investigated 
(Van Waes and Lieber, 1977). Furthermore, Goldberg (1977) has 
suggested that liver biopsy in alcoholics may reveal types of 
hepatitis other than alcoholic hepatitis. These include 
chronic active hepatitis and viral hepatitis which may provide 
additional routes to cirrhosis. Primary hepatocellular 
carcinoma (PHC) is predominantly associated with hepatitis B 
virus related cirrhosis but it is reported to occur in 3-15% 
cases of alcoholic cirrhosis (MacSween, 1982).
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Laboratory investigation o f alcoholic liver disease
The usual biochemical investigations are of little value in 
the detection and assessment of severity of alcoholic liver 
disease. Subsequently early diagnosis often depends on the 
patient's history which is notoriously unreliable, frequently 
resulting in a denial of excessive alcohol intake or 
considerable underestimation of the amount consumed. Elevated 
blood alcohol levels will only indicate recent excessive 
ingestion and are subsequently only of value as a follow up 
investigation for non-compliance with abstinence. Serum 
aspartate transaminase (AST) or alanine transaminase (ALT) are 
useful screening tests in assessing liver disease but they 
show poor correlation with the extent of injury. The.AST:ALT 
ratio is useful in differentiating alcoholic from viral 
hepatitis, where 70% of patients with alcoholic liver disease 
show ratios greater than 2. This may be related to alcoholic 
damage to mitochondria or smooth muscle, with predominant 
release of AST.
Gamma glutamy1transpeptidase(YGT) levels are frequently 
used in the screening for alcohol abuse (Rosalki and Rau,
1972). However, there are conflicting reports on their degree 
of correlation with the extent of alcohol-related liver 
damage. Serum glutamate dehydrogenase is also a reliable 
marker for liver-cell necrosis but it is not specific for 
alcoholism. Similarly, the serum ratio of alpha-aminobutyric 
acid to leucine is elevated in chronic alcoholics, but it is a 
relatively insensitve index of hepatocellular damage rather 
than alcoholism. Serum IgA and alkaline phosphatase values may
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also be markedly increased. Prolongation of the prothrombin 
time is perhaps the most useful index of the severity of 
alcoholic liver injury. A prothrombin value greater than 5 
seconds over the control value after vitamin K therapy is an 
important indicator of severe damage.
8.1.5 Quantitative assessment of hepatocellular function
In spite of the existence of a number of quantitative tests 
of liver function, they have failed to gain wide acceptance 
and are restricted mainly to research applications. This is 
mainly because they tend to be cumbersome, expensive, time 
consuming and frequently employ toxic test substances.
Quantitative assessment of hepatocellular function may be 
achieved by measuring the galactose elimination capacity 
(Tygstrup, 1964). This is impaired in hepatocellular disease, 
and unlike glucose tolerance tests, the results are 
independent of insulin secretion. Galactose removal by the 
liver has also been used to measure hepatic blood flow. An 
index of the functional microsomal mass and viable hepatic 
tissue can be assessed by orally administering carbon-14 
labelled aminopyrine and monitoring, for intervals over a two 
hour period, the amount of expired labelled carbon dioxide 
(aminopyrine breath test). Aminopyrine undergoes oxidative 
demethyl ation by the liver microsomal cytochrome p450 system. 
The test is mainly used to assess therapy and the effects of 
drugs on the hepatic microsomal enzyme system rather than for 
screening or diagnosis (Bircher et al., 1976). Labelled 
caffeine, galactose and phenacetin have also been used as
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breath test substances, but the complexity and cost of these 
tests has limited their application.
Hepatocellular damage in viral hepatitis or chronic liver 
disease is associated with an increase in the concentration of 
serum bile acids (Ferraris et al., 1983). The measurement of 
these compounds eliminates the requirement for ingestion of 
potentially toxic substances. In addition, they may be easily 
determined by the use of radioimmunoassay procedures and 
require only a single fasting blood sample. However, bile 
acids are endogenous compounds and their fate depends on many 
variables, including hepatic uptake, conjugation, biliary 
excretion, gallbladder emptying and the influence of gut 
flora. The importance of these factors on serum bile.acid 
levels is unclear and the lack of simple pharmacokinetic 
modelling prevents a rational interpretation of their results.
8>1.6tEffects of liver disease on drug disposition
It is well established that the clearance of a number of 
drugs in cirrhosis may be significantly impaired (Shand, 1975; 
Wilkinson and Schenker, 1976; Pessayre et al., 1978). Although
the mechanisms responsible are not well established, the major 
biological determinants of hepatic drug clearance are hepatic 
blood flow, the activity of the overall hepatic elimination 
process (intrinsic clearance), the extent of protein binding 
of the drug in plasma, and the anatomical arrangement of the 
hepatic circulation (Wilkinson and Shand, 1975). The relative 
significance of these factors on the elimination of a 
particular drug depends largely on the hepatic extraction
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ratio which may be estimated using the equation: E =
<Cp-Ch)/Cp, where Cp and Ch are the concentrations in the 
peripheral and hepatic venous blood. Hepatic clearance is 
defined as the product of the extraction ratio <E) and the 
liver blood flow (Q). By combination of these two values, the 
intrinsic hepatic clearance (IHC) may be calculated which is a 
mathematical concept expressing the maximal ability of the 
liver to remove a drug.
IHC = E.Q/<1-E>
Calculation of the liver blood flow, hepatic extraction 
ratio and hepatic clearance may be achieved by catheterization 
of the hepatic vein followed by infusion of indocyanine green 
(ICG). In order to compensate for a reduction in hepatic 
extraction ratio of ICG in cirrhotics, constant infusion 
methods are generally employed.
The elimination of highly extracted drugs, such as propanolol 
and chlormethiazole (Pessayre, 1978), is influenced mainly by 
liver blood flow rather than intrinsic clearance. These drugs 
exhibit significant presystemic (or first-pass) hepatic 
elimination, during their passage from the gut to the systemic 
circulation in portal venous blood, and a reduction in 
intrinsic clearance, or extrahepatic shunting of blood in the 
mesenteric vein, will greatly increase their bioavailability 
after oral administration. For poorly extracted drugs, such as 
theophylline, antipyrine, tolbutamide and phenytoin, hepatic 
clearance is independant to liver blood flow but highly 
sensitive to changes in intrinsic clearance rate. First pass 
elimination effects of these drugs are minimal after oral
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administration and most of the administered dose will reach 
the systemic circulation intact. Variations in the intrinsic 
clearance will not significantly affect this bioavai1abi1t y .
The effect of the extent of protein binding of a drug also 
depends on the extraction ratio and the fraction of drug 
present in the blood in the unbound form. If the extraction 
ratio of total drug exceeds the free-fraction in the blood, 
elimination will be non-restrictive. The systemic clearance of
total drug will be unaffected by alterations in binding whilst
!
that of the free drug will be increased as binding increases, 
resulting in a tendancy for the half-life to decrease. On the 
other hand, if elimination is restrictive, total systemic 
clearance will be dependent on the extent of binding,whereas 
free drug levels will not. Subsequently half life will be 
prolonged as binding is increased.
It is frequently assumed that altered elimination of drugs 
in liver disease is associated with an impaired activity of 
the cytochrome P-450 drug metabolizing system. However, a 
study by Farrell et a l . (1979), using hepatic tissue obtained
at biopsy from 69 patients, clearly established that the 
concentration of cytochrome P-450 and the activity of 
hydrocarbon hydroxylase are normal in mild liver disease and 
only decreased in the presence of extensive hepatocellular 
necrosis or active cirrhosis. In addition, the activity of 
another microsomal oxidase enzyme, ethylmorphine demethylase, 
remained unaltered even with severe liver disease.
In chronic liver disease there is a roughly parallel 
reduction in the clearance of both poorly and effecieptly
- 189 -
extracted drugs.
8 . 1«.7 . The me tabo l ism o f caffeine in liver disease
Caffeine disposition in man occurs almost exclusively by 
hepatic demethylation and oxidation with unchanged caffeine 
forming less than 2% of the urine metabolites. Studies have 
shown (Arnaud and Welsch, 1981; Callahan et a l ., 1982) that
during the first two hours after caffeine administration 
approximately 72 % undergoes initial demethyl ation to form
1,7- dimethylxanthine (paraxanthine). Demethylation also 
occurs at positions 1-N and 7-N and these reactions, catalysed 
by one or more of the cytochromes P-450 yield formaldehyde as 
secondary product. The effects of liver disease on caffeine 
elimination have been studied by monitoring plasma clearance 
following oral ingestion of caffeine (Statland et al., 1980; 
Desmond et al., 1980), and by measurement of H C O 2 in breath 
following I.V. injection of [3-methyl-^ C ] labelled caffeine 
(Wietholtz et al., 1981; Renner et a l . , 1984). Studies have
shown that in patients with cirrhosis, there is a highly 
significant reduction in the clearance of caffeine with a 
prolongation of half life. Statland et a l . (1979) described
serum caffeine half-lives of 60 and 168 hours in two patients 
with alcoholic liver disease, compared to a mean value of 5.7 
hours in 3 healthy subjects. In addition they investigated the 
effects of diazepam on caffeine metabolism which is also 
metabolized by the liver via demethyl ation and may compete 
with caffeine for metabolism. However, no difference was 
observed in the half life values of the normal subjects
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measured with and without diazepam ingestion. Desmond et al. 
(1980) compared plasma elimination half-lives of caffeine in 
15 normal subjects and in 10 patients with cirrhosis. In the 
normal subjects, peak caffeine levels appeared 30-60 minutes 
ater oral ingestion of caffeine <250 mg), after which, the 
concentration declined momo-exponentia1ly with a mean half 
life of 5.2 hours. There were no age related differences in 
the half life, volume of distribution or clearance values. In 
the cirrhotic group, the half life of elimination was longer, 
although not statistically significant. This could not be 
accounted for in terms of altered pharmacokinetic parameters 
as the peak levels and time taken to reach peak levels were 
similar in both groups. Two of the cirrhotic patients had 
caffeine present in their zero sample, collected 3 days 
following caffeine withdrawl, and although their levels rose 
after administration of caffeine, they did not decline 
significantly over 48 hours. The total clearance of caffeine 
was reduced by 35% in the cirrhotic group, compared to the 
controls.
An assessment of the cytochrome P-448 dependent liver 
enzyme system was shown by Wietholtz et al. (1981) using a 
caffeine breath test, involving the combined administration of 
C7-methyl- ] and [3 - m e t h y l - 3 caffeine. exhalation
curves in cirrhotics were clearly different from those in 
normal volunteers, being characterized by a slower rise and 
lower specific activity. The highest yield of ^ C 02 was 
obtained following administration of [3-methyl- ^ C 3  caffeine 
and the average rate was doubled in smokers. In a more
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recent study, Renner et a l . (1984) investigated the effects of
liver disease on caffeine clearance and the exhalation of ^  CO2 
following I.V. ingestion of 2 pCi of [ 3-methyl-14 c ] caffeine 
together with 125 mg of unalbelled caffeine in 15 patients 
with cirrhosis, 11 subjects with miscellaneous liver disease 
and 10 normal volunteers. Their results confirmed the 
contention that caffeine breath tests closely reflect the 
plasma clearance of the compound, the cummualtive 
production and specific activity decreasing in parallel with 
clearance. The cirrhotic group were characterized by a highly 
significant reduction in clearance and prolongation of half 
life although the volume of distribution was virtually 
unchanged.
NormaJ_group C irrhotic group 
Half life (hours) 3.8 + 0.9 13.7 + 13.0
Clearance (ml/min/kg) 2.02 + 0.68 0.76 + 0.4
V o l .distribution (1/kg) 0.64 + 0.13 0.57 + 0.16
Patients with miscellaneous liver disease eg. non-cirrhotic 
alcoholic liver disease, chronic persistent hepatitis, non­
cirrhotic chronic active hepatitis, haemaochromatosis and 
Gilbert's syndrome, exhibited only small changes in clearance 
and half life. This study also demonstrated a surprisingly 
close hyperbolic relationship between clearance and fasting 
plasma concentrations, suggesting that the latter may serve as 
a guide to the severity of liver disease.
There have been no reported studies on the urinary 
excretion of caffeine metabolites in liver disease. However, a
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study on metabolite excretion following theophylline 
administration (Staib et a l . f 1980) demonstrated altered 
patterns in acute hepatitis, cholestasis, compensated and 
decompensated cirrhosis. Compared to a control group, there 
was an increase in the excretion of 1-methyluric acid and a 
concomitant decrease of 1,3-dimethyluric acid and 3-methyl 
xanthine. This suggests that in liver disease the 1-N 
demethylation of theophylline is inhibited and is compensated 
by a shift towards 1-methyluric acid formation. A recent 
report by Jost et al. (1985) described the use of measuring 
overnight salivary caffeine clearance <SCC) for assessing the 
severity of liver diseases in children. Following a dose of 4 
mg/kg b.w., the SCC was significantly reduced in 33 patients 
with documented cirrhosis of alcoholic or post hepatic origin 
(0.58 ±. 0.4 ml/min/kg) compared with values obtained from a 
group of 20 non-smoking adult volunteers (1.65 + 0.4).
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 Out line of study
The aims of this study were as follows
1. To investigate the elimination of caffeine in 
compensated and decompensated chronic liver disease by 
comparing pharmacokinetic data, obtained from the 
measurement of caffeine levels in serum and saliva 
following oral ingestion of anhydrous caffeine (400 mg), 
with values previously obtained for a group of normal 
healthy volunteers (Section 5.).
2. To provide information on the rate of appearance and 
elimination of the dimethylxanthine metabolites of caffeine 
in serum and saliva
3. To investigate the biotransformation of caffeine in 
chronic liver disease by comparing urinary metabolite 
excretion patterns in patients with compensated and 
decompensated liver disease, with those found in normal 
subjects.
4. To assess the suitability and sensitivity of caffeine 
pharmacokinetic studies and/or the measurement of urine 
metabolites for assessing the severity of hepatocellular 
dysfunct ion.
5. To determine the value of monitoring overnight salivary 
caffeine clearance as a sensitive index of hepatic 
function.
Prior to commencing this study, a protocol was submitted to 
and approved by the Royal Free Hospital Medical Ethics 
Commi ttee.
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8.2. METHODS AND MATERIALS
Subjects selected for this study were divided into two 
categories based on a clinical assessment of their condition. 
Group 1 consisted of patients with well compensated cirrhosis 
<n=10) and Group 2 consisted of patients with clinically 
decompensated cirrhosis <n=8 ). Classification was made using a 
score rating of liver dysfunction based on a system previously 
described by Pugh et al.y (1973). The parameters considered 
were the extent of encephalopathy and ascites and the values 
obtained for serum bilirubin, albumin and prothrombin time. A 
weighting system was used whereby 1,2, or 3 points were scored 
for increasing abnormality of each of the five parameters 
(Appendix 6.>. Thus for patients with good hepatic function the 
total score was 5 points whilst those with poorer hepatic 
reserve had scores of up to 15 points. An allowance was made 
for patients with primary biliary cirrhosis where the level of 
bilirubin is normally out of proportion with other evidence of 
hepatic failure. An additional statistical analysis of the 
results was performed by dividing the subjects into 3 Pugh 
score groups: Group A, 5-6 points; Group B, 7-9 points; and 
Group C, 10-15 points.
Patients with alcoholic liver disease had all previously 
abstained from alcohol consumption, the minimum periods being 
1 year in the compensated group and 3 weeks in the decompens­
ated group. Patients with non-alcoholic liver disease and the 
control subjects consumed less than 5g alcohol per day. On 
enrollment into the study, a questionnaire was completed 
giving details of the subject's age, sex, nationality, weight,
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clinical history, normal dietary caffeine intake, present drug 
therapy, smoking habits and any other information considered 
relevant to the study (Appendix 6 ). A summary of the subject 
characteristics and Pugh score ratings is shown in Table 
8.1. Subjects were requested to refrain from consuming all 
forms of caffeinated beverage, chocolate, caffeine containing 
foods and all but essential medications for a period of 72 
hours before the study and for its duration.
On day 1 of the investigation, basal samples of serum,
saliva and urine were collected prior to the administration of
an oral dose of anhydrous caffeine <400 mg contained in a
gelatine capsule), taken together with approximately 150 ml of
water. Additional samples of blood and saliva were then
collected concurrently at 20 m i n s , 40 m i n s , lhr, 2hr, 3hr,
4 h r , 6h r , 8h r , 12hr, 24hr and 48hr post caffeine ingestion.
Total urine outputs were collected for the time intervals 0-24
hours and 24-48 hours. In anticipation of a delayed clearance
of caffeine in patients with decompenstaed liver disease,
further samples of blood and saliva were taken from these
subjects at 72hr and 96hr and where possible, additional
collections of urine were obtained for the periods 48-72 hr
and 72-96 hr. Following centrifugation of the blood samples,
the serum was separated and stored along with the saliva 
o
samples at - 20 C. Total urine volumes were recorded and 
aliquots (30 ml) were stored in a similar manner.
Using the analytical procedures previously described, the 
levels of caffeine and its dimethylxanthine metabolites were 
determined in the samples of serum and saliva and the urine
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samples were assayed to quantitate the excretion of methyl- 
xanthine metabolites. The serum/sa1ivary pharmacokinetic data, 
derived using a computer based non-linear kinetics programme, 
and metabolite excretion profiles, for both groups of liver 
disease patients were compared with results obtained for a 
group of normal volunteers previously studied using a similar 
protocol. Statistical analysis was made using a Student’s 
t-test for unpaired data; P <0.05 was regarded as being 
statistically significant.
RESULTS
a ) Serum/saliva kinetic data for caffeine
The caffeine levels in serum and saliva showed a linear 
relationship for both groups of liver disease patients. The 
mean coefficient of correlation for the compensated group was 
0.953 <S D . 0.0056) compared to 0.928 <SD. 0.037) for the 
decompensated group. The mean saliva/serum concentration 
ratios of caffeine for the compensated and decompensated 
cirrhotic groups were 0.84 and 1.07 respectively. In 
comparison with values obtained for a group of normal 
volunteers (mean ratio = 0.71), the ratios for the compensated 
cirrhotic subjects were not statistically different (P <0.1), 
whilst those for the decompensated subjects were significantly 
higher (P <0.01). Elimination curves of the mean salivary 
caffeine levels for both groups of patients are compared in 
Fig 8.2 with mean values previously obtained from normal 
volunteers receiving a similar oral dose of caffeine.
The pharmacokinetic data, derived from elimination curves
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TIME (hours)
Fig 8.1 Mean caffeine levels in saliva following an oral dose of caffeine (400mg)
in normal volunteers ( v ) ,  compensated ( o )  and decompensated ( • )  alcoholic 
■•v cirrhosis patients.
Su
bj
ec
t 
Pu
gh
 
Cm
ax
 
Cm
ax
 
Tl
/2
 
k.
el
 
Vd 
AU
C 
Cl
Sc
or
e 
mg
/1
 
Ti
me
(h
) 
(h
) 
(h
."
1
) 
(m
l.
kg
.-
1 
) 
(m
g.
I.
-1 
h.
“
1 
Mm
l.
kg
."
 
’m
in
 
) 
(5 
- 
15
) 
Se
r 
Sa
l 
Se
r 
Sa
l 
Se
r 
Sa
l 
Se
r 
Sa
l 
Se
r 
Sa
l 
Se
r 
Sa
l 
Se
r 
Sa
l
- 199 -
O  O  O  r H
to
o
•rl4JO
JG
V-iiH
•rlU
V
«atoc
§
voa\CTvr~inr~iMVDvDr-~
m c o f f i o i n c o ' o v o n H
*— l r H O r H a 4 O O O O r — I
v o o o o j ^ r n  ov a< rH
r ' O v o n i J i  i in h  in
id vo i co cm ro cri o  r--
r—i CM
N n ^ T H C M l O V O O M D O
oo^rcricrir^vocricotDvor'f^ oicorgoMnNinoo
r o  r »  o o  o v  c m  
c m  n 4 r o  h  r o
o o o o o  o o o o
Oi ^  CO VO lO f' H CM VO '^j,ncNjro^ ,'i,nTj'
o o o o o o o o o
r'O'HCOH CO I o lo CM CM CM I—I VO O H H H
O O O O O  O O O O
^ co ro in ovin cm r-'j N N H H i n H O H O H
O O O O O O O O O O
VOOMOOlH n o n
. . . . • I  . . . .cm cm co ro i-h co a4 r- a*
OlOniONOOOOMOO
cMroina4rH-a4CTiincriin
IMOHfOO | ro O O <-H
CMOl—ICMOOrOOO*—(
r'HmCMN 
Ok CM O  00 O  I
H H CO O O1 H O' f—I lD O
roo'HCOcoromo'ioo
i n  i n  i n  i n  m  i n  i n  i n  i n  r >
13 d 
s to
CM  00
C M  r H  CT> v o t— 1 ID H 4
C M  V O  •M' r— 1 O CM CM
O  O  O
1 •
o
1 •
o d  d
o  o o
V D M O  O ■a1 C N  r H V O  00
r o  a 4 i n O O  O r o  C M
o o o o O O  O d  d
00 00 a 4 vo t". . . . • o o
o  o ro 1 CM 1 vo o  vo o
<t > in ro VO CM O  CM o
ro CM CM CM VO CM
/\ A
in ov rH in rH in /v
. . . . . o O o .
OV rH a vo ro ■a4 i o o o to
O  VO O O  rH ■a- o o o ■rH
r—I CM CM CM CM CM CM CM to
/\ A A o/H
VO o 00 in 00 t-~- rH
JU
IH
ro rH 'a* in ro in a* rH la
1 • 1 • 1 1 * •H
o  o o o o o o  o O
•om
a\ co cm ci ro r» co r-~ o 4J
ro o a 4 a 4 vo •a4 rH a* rH CO
• * * too o oooo o o o
■a* r-~ vo in rH 00
cm in ro vo rH o 00 CM
CM rH o o o O o o  o y
1 . I • I I CL)
O  O o o o o o o o 'O
•oCTl CM in vo r-~ Coo in inin r-VO rH rH O ro cm COrH rH oooo o o o o o• TJo o oooo o O O o o 0)
HJ
(0
OO H 4 c
rH CM oo o oo inin o
1 i • > 1a4 CM in rH OV Ovf o
CM rH in■a* o o
rH r—1 oA
VO OO crH VO •H rH r- OO O CM O •rl
• 1in cm •'a*r o o v o  o O  O 0)rH rH rH O vo O Gr—1 rH •H
A 0)r- a* vo UHro O m in cm r" MHco
i—1 rH CM CM rH 1 O  1 o 1 * rH O V
MH
o  in oo ro o
CM OO cn vo to
VrH O CM CM CM a4 I a4 VO * CO rH •rl
4J
d)oo ro vo ro cro co CM CM M 1 rH ■a* oo ro •rl
rH CM OlCOVO 1 00 1 CM 1 * cm -a4 o>—1 rH rH rH rH t j
oocooi a\ vo 0\ OV a* CM I a* | a* ■*
COCOCTlCTlOi—(CMCMCM
§ Q 0) . s w
- 200 -
of caffeine in serum and saliva, for both groups of patients 
is summarized in Table 8.2 and in Fig 8.2 and Fig 8.3. 
Statistical analysis of the results for serum vs saliva using 
Student's t test showed no significant differences between the 
values obtained for the elimination constants (P <0.9), 
apparent volumes of distribution <P <0.9) and total body 
clearance <P <0.8). Corresponding coefficient of correlation 
values were 0.985, 0.935 and 0.985 respectively.
Basal salivary caffeine levels for the compensated cirrhotic 
group <0.49 + SD. 0.78) were similar to those found for normal 
controls (Less than 0.3 mg/1). Whilst the mean value for 
patients with decompensated liver disease was higher (1.46 + 
SD. 2.12), the values were not significantly different <P 
<0.1). However, three of the decompensated group (J.B, V.D, and 
A.S) had levels in excess of 2 mg/1. Compared to the normal 
control group, the peak levels of caffeine in saliva for both 
groups of liver disease subjects were significantly higher <P 
<0.01). Although the time required to reach peak levels was 
lower in the liver disease patients, the differences between 
the three groups were not statistically significant. For one 
subject <A.S), salivary caffeine levels remained in excess of 
12 mg/1 from 2 hr post dose, reaching a maximum value of 16.5 
mg/1 after 72 hours; data on this subject was excluded from 
the calculation of peak caffeine values.
Compared to the group of normal volunteers, patients from 
the compensated cirrhotic group showed a significant decrease 
in the apparent volume of distribution <P <0.002) assessed 
from the salivary data. However, the salivary pharmacokinetic
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Group Tl/2 k.el Clearance
(hr) (hr.~1) ( (ml.kg“1min“1)
a) Mean values
Mean SD Mean SD Mean SD
A 4.24 2.25 0.22 0.16 1.55 1'. 2 6
B 12.99 7.89 0.073 0.051 0.63 0.43
C 48.76 25.70 0.024 0.026 0.14 0.20
t's t-test (P)
A vs B 
B vs C 
A vs C
< 0.02
<0.05
< 0.001
c) Mann Whitney U-test (P)
A vs B 
B vs C 
A vs C
0.011
0.095
0.003
d) Linear Regression analysis
Coefficient of 0.844
correlation (r)
Significance (P) <0.01
< 0.1
< 0.1
<0.05
0.011
0.095
0.003
0.640
< 0.01
< 0.2
<0.05
<0.05
0.083
0.037
0.005
0.592
< 0.01
Table 8.3 Statistical analysis of the relationship between 
caffeine clearance and Pugh score ratings of 
liver disease.
For details of Pugh score system refer to Appendix 6. 
Abbreviations: Tl/2 - half life, k.el - elimination constant 
P = Level of significance
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values for this group were similar to those previously 
obtained for normal healthy volunteers. Respective probability 
values for the elimination constant and salivary clearance 
were <0.9, and <0.5. In contrast, the decompensated group 
showed a significant decrease in the elimination constant (P 
<0.001) and the total salivary clearance <P <0.001) although 
the apparent volumes of distribution were similar <P <0.9).
A statistical analysis of the relationships between 
salivary pharmacokinetic data for caffeine and the assigned 
Pugh scores/group classification was made by linear regression 
analysis (Table 8.3). In subjects where saliva samples were 
not obtained, substitutions were made using data calculated 
from serum. Linear correlations existed between the Pugh score 
ratings and values for elimination half-life, elimination 
constant and total salivary clearance. The significance <P> of 
these correlations, determined by variance ratio (F-test) 
distribution, was in all cases <0.01. The ability of caffeine 
clearance studies to differentiate between subjects in the 
Pugh score groups was demonstrated by Student t-test analysis. 
The values for elimination half-life were significantly 
different for all possible group combinations. Significant 
differences were present between groups A and C (P <0.05) for 
the elimination constant values and between groups B versus C 
<P <0.05) and A versus C <P <0.05) for levels of the total 
salivary caffeine clearance.
Additional statistical analysis of the Pugh score/caffeine 
clearance relationships, using a Mann Whitney U-test showed 
similar levels of significance.
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b) D imethvlxanthine m etabolites in serum/sa1iva
The concentrations of both theobromine and theophylline in 
samples of serum and saliva showed, for the majority of 
subjects investigated, only minimal increases over basal 
levels. However three of the decompensated subjects (J.B, V.D, 
and D.H) showed significant levels of theobromine (More than
1.5 mg/1) in both basal and post caffeine samples.
The levels of 1,7-dimethylxanthine in serum and saliva 
showed a linear relationship for both groups of liver disease 
patients. The overall mean coefficient of correlation was 0.09 
(SD. 0.084) with values ranging from 0.763 to 0.992. The ratio 
of concentrations in saliva versus serum were similar for both 
groups (P <0.5); respective mean values for the compensated 
group and decompensated group were 0.74 (SD. 0.14) and 0.83 
(SD. 0.19). The mean peak values for 1,7-dimethylxanthine 
(paraxanthine) are summarised in Table 8.4. Compared to the 
normal control group, the peak values of paraxanthine in 
saliva for the compensated cirrhotic group were significantly 
higher (P <0.05) whilst those for the decompensated group were 
significantly decreased <P <0.05). In addition, the mean time 
for peak paraxanthine levels to be reached for subjects in the 
decompensated group (26.6 hr + SD. 21.2) was significantly 
longer (P <0.01) than that for the normal volunteers (5.9 hr ± 
SD. 4.1) or the compensated cirrhotic subjects (6.9 hr ± SD. 
3.3). Only minimal levels of paraxanthine were present in 
samples obtained from the decompensated subjects D.H. and V.D. 
In one subject (H.O), significant levels of an eluted
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SUBJECT
Cmax
mg/1
SERUM
Time
hr
AUC Cmax
mg/1
SALIVA
Time
hr
AUC
Normal volunteers
N14 * * * 1.2 6 39.2
Nl 5 * * * 3.6 4 34.3
N16 * * * 2.2 6 31.3
N17 * * * 1.8 4 40.2
N18 * * * 2.0 6 39.0
N19 * * * 1.2 12 34.8
N20 * * * 1.8 6 28.8
N21 * * * 1.7 3 13.8
N22 * * * 1.6 2 24.2
Mean 1.9 5.44 31.7
SD 0.7 2.87 8.5
Compensated cirrhotic group
JC 4.4 6 64.9 3.1 6 42.9
AC 2.8 8 68.9 2.6 6 57.5
IC 4.2 8 56.6 4.0 6 55.1
PI 2.8 8 54.7 1.5 12 25.0
EM 3.0 12 50.0 2.5 8 35.5
EP 4.2 3 25.4 2.8 2 21.8
AS 3.7 6 88.3 3.1 4 53.2
BW 2.6 24 74.5 2.4 12 64.8
NW 3.0 12 70.6 2.5 6 39.4
Mean 3.41 9.4 61.5 2.72 6.9 43.9
SD 0.71 6.2 17.8 0.67 3.3 14.9
Decompensted cirrhotic: group
CB 2.0 24 41.4 * * *T?nJ. V n c. T O X X r n /- JO . D Insufficient samples
DH * * * 1.2 48 30.4
GG 1.8 12 47.3 1.1 12 30.4
MS 1.8 24 66.5 1.5 24 58.3
AS ** ** ** ** * * * *
VD 0.1 72 0.1 0.5 1 0.2
FF * * * 1.2 48 45.8
Mean
SD
Table 8.4
1.66 28.8 
0.93 24.9
Paraxanthine ki
41.8
25.1
netics for
1.10
0.37
serum and
26.6 33.0 
21.2 21.8
saliva samples
collected from normal volunteers and chronic liver
disease patient s following an oral dose of 400 mg
caffeine.
* Samples not collected. ** High magnitude peaks found during 
chromatography, possibly resulting from drug interference.
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compound with a similar retention time to paraxanthine were 
present in both basal and post caffeine samples of serum and 
saliva. However by using the more specific chromatographic 
conditions previously described for urine metabolite analysis, 
it was possible to resolve this compound from paraxanthine and 
identify it as a non-specific compound. The chromatographs 
obtained from the subject A.S. also contained high magnitude 
peaks with retention times similar to those of theobromine and 
paraxanthine. These were probably representative of non­
specific interference from concurrently administered drugs or 
their metabolites, although the possibility of caffeine 
metabolite accumulation in this subject cannot be completely 
ignored.
The bioavailablity of paraxanthine, assessed by AUC (area 
under curve of concentration vs time) values for the period of
0-24 hr post caffeine ingestion is summarized in Table 8.4.
The correlation between values for serum and saliva was 
favourable (r = 0.965, y = 0.978x + 1.44, where y and x 
represent values for saliva and serum respectively). Whilst 
the AUC values for the compensated group were statistically 
higher (P <0.05) than those found for the normal control 
group, this was mainly a result of their higher peak values, 
the overall rate of formation and clearance being similar. For 
the decompensated group, with the exception of H.O and A.S the 
AUC values generally reflected an impaired rate of formation 
of paraxanthine with significant values still detectable after 
48 hours.
Additional statistical analysis using a non-parametric
- 208 -
Mann-Whitney rank test showed similar levels of probability to 
those reported.
c) Urinary methvlxanthine metabolite profiles
The caffeine metabolite profiles of the two groups of liver 
disease subjects are compared in Table 8.5 and in Fig 8.4, Fig
8.5 and Fig 8.6 with data obtained from a group of normal 
volunteers treated in a similar manner. Basal urine samples, 
where collected, contained no appreciable amounts of xanthine 
metabolites. Compared to the normal control group, the 
decompensated patients showed a significant reduction <P 
<0.01> in total metabolite excretion during the first 24 hour 
period. This was largely reflected by a decreased recovery of 
1-methyluric acid (15.61 ± S D . 7.37 to 6.69 ±  SD. 6.03; P 
<0.05) and 1-methylxanthine (9.23 + SD. 4.40 to 3.37 ±. SD. 
2.83; P <0.01). Whilst the recovery of unchanged caffeine was 
increased (1.90 ±.SD. 1.48 to 3.03 ± S D .  1.65) in the decom­
pensated group for this time interval, the differences were 
not statistically significant (P <0 .2 ).
The recovery data for the period 24-48 hours showed a 
generalised increase in metabolite excretion for the 
decompensated group, in particular, the dimethylxanthine 
metabolites where significant increases were found for 1,7- 
dimethyluric acid (1.29 ±.SD. 1.12 to 3.65 ± SD. 2.67; P
<0.05) and 1,3-dimethylxanthine (0.19 ±  SD. 0.26 to 0.80 ± SD. 
0.69; P <0.05). The recovery of unchanged caffeine for this 
period remained significantly increased ( 0.10 ± SD. 0.16 to 
1.67 ±  SD. 1.61; P <0.02).
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volunteers and patients with compensated and decompensated 
liver disease.
N = Normal controls C = Compensated liver disease
DC = Decompensated liver disease.
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Fig 8.5 Methylxanthine excretion for the time interval 24 - 48 h 
following an oral dose of caffeine (400 mg) in normal 
volunteers and patients with compensated and decompensated 
liver disease.
N = Normal controls C = Compensated liver disease
DC = Decompensated liver disease.
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Fig 8.6 Methylxanthine excretion for the time interval 0 - 48 h
following an oral dose (400 mg) of caffeine in normal 
volunteers and patients with compensated and decompensated 
liver disease.
N = Normal controls C = Compensated liver disease
DC = Decompensated liver disease.
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Despite significant intra-group variations in the levels of 
metabolites, the mean total metabolite recoveries for the 48 
hour period following caffeine ingestion were similar for all 
three groups. However, in patients with decompensated liver 
disease, the recovery of 1-methylxanthine for this period was 
s igni f icant ly reduced ( 11 . 25 ±. S D . 4. 88 to 5. 65 ±. S D . 2.76; P 
<0.05), whilst that of unchanged caffeine was significantly 
increased (2.0 ± S D .  1.42 to 5.00 ± S D .  2.75; P <0.02). The 
mean metabolite recoveries for patients with compensated 
cirrhosis for both periods of urine collection were similar to 
those found for the group of normal controls.
For one compensated subject (BW) the low metabolite 
recovery and the significantly reduced excretion of 1-methyl- 
uric acid may be attributed to the concurrent administration 
of allopurinol, a known inhibitor of xanthine oxidase (Grygiel 
et al., 1979), the enzyme responsible for the conversion of
1-methylxanthine to 1-methyluric acid.
The relationship between metabolite recoveries and Pugh 
score assessments of the degree of hepatic insufficiency are 
summarised in Table 8 .6 . Whilst levels of serum creatinine 
were higher in the more decompensated subjects, there was no 
evidence to suggest overt impairment in renal function and 24 
hour urine outputs were normal. The increased levels of 
creatinine in these patients was probably attributable to 
muscle wasting. An analysis of the individual Pugh score 
ratings versus the metabolite recovery for the time interval 
0-24 hours showed a linear relationship. The coefficient of 
correlation (r), calculated by least squares linear regression
- 2135-
NORMAL COMPENSATED DECOMPENSATED
Mean SD Mean SD P Mean SD P
7MU 0.84 0.54 0.56 0.27 <0.2 0.96 0.60 <0.9
7MX 2.24 0.70 1.94 0.86 <0.5 1.39 0.73 <0.05
1MU 15.6 7.37 14.29 6.57 <0.7 6.69 6.03 <0.05
3MX 0.94 0.46 1.03 0.48 <0.7 0.54 0.53 <0.2
IMX 9.23 4.41 8.91 3.07 <0.9 2.83 2.13 <0.01
13U 0.94 0.41 0.81 0.36. <0.5 0.63 0.39 <0.2
37X 1.68 0.74 1.70 1.46 <0.9 1.01 0.68 <0.1
17U 6.08 1.25 5.60 2.14 <0.7 4.40 2.87 <0.2
17X 3.48 1.67 3.52 1.43 <0.9 1.69 1.55 <0.1
13X 0.44 0.40 0.55 0.15 <0.5 0.26 0.26 <0.5
137U 0.86 0.73 0.52 0.39 <0.25 0.49 0.47 <0.3
137X 1.90 1.48 1.70 0.67 <0.8 3.03 - 1.65 <0.2
TOTAL 44.14 12.41 41.26 11.42 <0.7 23.76 * 10.75 <0.01
Caffeine metabolite excretion (% dose) 0-24 hour
7MU 0.39 0.38 0.59 0.62 <0.5 0.60 0.53 <0.5
7MX 1.15 0.79 1.43 0.59 <0.5 1.27 0.53 <0.8
1MU 4.30 2.88 4.03 2.57 <0.9 6.48 4.22 <0.3
3MX 1.05 0.64 0.80 0.29 <0.3 0.60 0.34 <0.2
IMX 2.03 1.37 3.19 2.46 <0.25 2.55 1.73 <0.7
13U 0.65 0.45 0.61 0.72 <0.9 0.53 0.40 <0.7
37X 0.73 0.45 0.97 1.22 <0.7 1.13 0.42 <0.2
17U 1.29 1.12 1.86 1.51 <0.3 3.65 2.67 <0.05
17X 0.50 0.64 1.44 1.48 <0.1 1.93 2.24 <0.2
13X . 0.19 0.26 0.39 0.32 <0.2 0.80 0.69 <0.05
137U 0.09 0.15 0.36 0.55 <0.2 0.48 0.62 <0.2
137X 0.10 0.16 0.46 0.40 <0.05 1.67 1.61 <0.02
TOTAL 12.29 7.78 15.94 10.91 <0.5 20.93 10.46 <0.1
Caffeine metabolite excretion (% dose) 24 -48 hour
7MU 1.23 0.63 1.15 0.77 <0.9 1.53 0.48 <0.5
7MX 3.39 1.24 3.37 0.86 <0.9 2.63 1.01 <0.25
1MU 19.83 8.50 18.32 5.95 <0.7 12.73 9.08 <0.2
3MX 1.99 0.96 1.81 0.55 <0.7 1.18 0.50 <0.1
IMX 11.25 4.88 12-10 2,83 <0,7 5.65 2.76 nc;> v •
13U 1.59 0.63 1.42 0.90 <0.7 1.20 0.79 <0.5
37X 2.40 0.58 2.67 1.71 <0.7 2.21 0.88 <0.7
17U 7.36 2.04 7.46 2.96 <1.0 8.11 4.96 <0.7
17X 3.98 2.00 4.96 2.13 <0.5 3.80 3.81 <0.9
13X 0.63 0.45 0.94 0.38 <0.2 1.08 0.65 <0.2
137U 0.95 0.72 0.88 0.74 <0.9 1.05 1.04 <0.9
137X 2.00 1.42 2.16 0.93 <0.8 5.00 2.75 <0.02
TOTAL 56.43 16.47 57.2 11.45 <0.9 45.85 15.40 <0.25
Total caffeine metabolite excretion (% dose) 0-48 hour
Table 8.5 Caffeine metabolite excretion in normal volunteers and
chronic liver disease patients following an oral dose of
caffeine (400 mg).
Subject Pugh Rating 
Score Grade
Urine volume (1) Metabolite recovery Serum 
0-24h 24-48h 0-24h 24-48h creatinine
JC 5 A 1.22
IC 5 A 1.58
PI 5 A 1.70
EM 5 A 1.40
EP 5 A 1.05
AS 5 A 1.90
BW 5 A 1.45
NW 5 A 1.90
HO 5 A 1.30
AC 7 A 1.10
FC 8 B 0.25
MS 8 B 1.90
BJ 9 B 1.82
GG 9 B 0.70
FF 10 C 1.05
VD. 11 C 1.00
DH 12 C 1.70
96 58.8 6.3 70
00 49.8 6.8 64
00 46.3 12.4 85
75 31.8 9.1 71
75 45.6 4.5 50
55 51.0 18.4 65
00 20.0 19.9 82
38 41.7 19.6 69
05 34.0 41.3 70
20 33.6 21.1 57
90 43.3 10.2 98
60 22.4 28.7 62
00 30.7 36.9 90
80 25.6 22.2 151
16.0 157
90 11.6 16.4 104
50 16.7 11.2 105
0
2
2
0
1
1
1
1
2
1
0
1
3
0
0
1
Table 8.6 Urine metabolite recoveries in alcoholic cirrhosis subjects 
following an oral dose of caffeine (400 mg)
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analysis, was 0.738. Whilst there were no significant 
differences between the metabolite recoveries for this period 
between subjects in Pugh score groups A versus B (P <0.2), 
significant differences were found between groups A versus C 
<P <0.01) and B versus C <P <0.05).
Additional statistical analysis of the three groups of 
subjects using a non-parametric Mann-Whitney rank test showed 
similar levels of significance to those reported.
8.3 Salivary caffeine clearance in chronic liver disease.
Although the previous report has clearly demonstrated the 
value of caffeine elimination studies in differentiating 
comensated and decompensated forms of chronic liver disease, 
the requirement for multiple sampling of blood or saliva 
imposes limitations on their application to the routine 
assessment of hepatocellular function. In attempt to simplify 
the procedure, the following study investigates the value of 
measuring the 24 hour salivary clearance of caffeine, using a 
4 point salivary caffeine analysis, following an oral dose of 
anhydrous caffeine (400 mg).
Methods
The groups of liver disease patients selected for this 
study and the conditions of enrollment and preparation were as 
described in Section 8.2. Following the collection of a basal 
sample of saliva, an oral dose of 400 mg anhydrous caffeine 
was administered to all participants and additional samples of 
saliva were collected after periods of 4 hr, 12 hr and 24 hr. 
Salivary caffeine concentrations were determined using HPLC
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Fig 8.7 Elimination of caffeine in saliva of normal controls 
(V), compensated (O) and decompensated (•) liver 
disease patients -following an oral dose of 400mg 
anhydrous caffeine.
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and the clearance of caffeine in the compensated and 
decompensated subjects was compared with values obtained for a 
group of normal volunters (Section 5).
Results
The salivary caffeine levels for the three groups studied 
are shown in Table 8.7. Compared to the normal control group, 
the salivary caffeine concentrations for the compensated 
cirrhotic group were similar in both basal samples <P <0.25) 
and samples collected 12 hr <P <0.5) and 24 hr post caffeine 
<P <0.25). In contrast, the decompensated group showed 
significant increases in caffeine concentrations (P <0.001) 
for samples collected at 4 hr, 12 hr and 24 hr post caffeine 
administration. Although the basal caffeine levels for the 
decompensated group were higher than those found in both the 
normal controls and compensated liver disease patients, the 
increases were not significant <P <0.1). Statistical analysis 
of the results for the compensated group versus the decompen­
sated group showed, for the latter, significant differences in 
caffeine concentrations at 4 hr (P <0.01), 12 hr (P <0.001)
and 24 hr (P <0.001 ) .
In agreement with the results obtained for the more detailed 
pharmacokinetic study, the salivary caffeine clearance values 
clearly differentiate decompensated liver disease patients 
from normal controls and patients with compensated liver 
disease. This suggests that measurement of overnight salivary 
caffeine clearance, following an oral dose of 400mg caffeine, 
may provide a simpler alternative means of assessing hepato­
cellular function. However, since the procedure was unable to
- 218 -
SUBJECT PUGH SALIVARY CAFFEINE (mg/1)
SCOPE Basal 4 h 12 h 24 h
Normal control group
N13 - 0 4.0 1.5 04
N14 - 0 2.7 1.2 1.5
N15 - 0 3.8 0.33 0
N16 - 0.2 7.1 1.99 0.2
N17 - 0.2 4.5 1.62 0.3
N18 - 0 3.8 1.95 0.4
N19 - 0.3 6.3 2.75 0.5
N20 - 0.3 4.0 2.88 0.5
N21 0.5 4.1 1.29 0.2
Mean - 0.17 4.48 1.72 0.43
S.D. — 0.18 1.36 0.78 0.43
Compensated liver disease patients
JC 5 0 6.9 1.2 0
IC 5 0.7 6.7 1.8 0
HO 5 0 9.7 5.6 3.0
PI 5 0.3 5.2 2.3 0.4
EM 5 0.2 7.1 3.4 0.6
EP 5 2.6 2.0 0.2 0
AS 5 0.3 5.8 0.9 2.9
BW 5 0.2 7.8 4.2 2.4
NW 5 0.6 6.7 2.3 0.6
AC 7 0 6.0 1.2 0
Mean - 0.49 6.39 2.31 0.99
S.D. — 0.78 1.98 1.67 1.26
Decompensated liver disease patients
MS 8 0.9 8.2 6.1 5.7
FC QV n oV • £+ ^ c1 . V it o n/
GG 9 0 12.0 7.4 6.4
FF 10 0.2 7.6 5.5 2.7
VD 11 5.8 - 14.5 14.9
CB 12 2.2 14.1 * 11.8
AS 12 2.6 12.6 12.0 12.2
Mean - 1.55 10.32 9.10 7.98
S.D. 1.98 2.92 3.95 4.45
Table 8.7* Salivary caffeine levels at times 0, 4, 12 and 24 h ir
normal control subjects and chronic liver disease patients
following an oral dose of caffeine (400 mg)
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differerentiate compensated liver disease patients from normal 
controls, further investigations are required in order to 
assess its sensitivity.
DISCUSSI ON
Since coventional liver fuction tests, with the possible 
exception of prothrombin times and serum albumin levels, are 
of limited value in the detection and assessment of severity 
of alcoholic liver diesease (Sherlock, 1981), attempts have 
been made in recent years to develop more precise means of 
quantitating hepatocellular function. These have included the 
use of galactose elimination tests (Tygstrup, 1964), carbon-14 
labelled aminopyrine (Bircher et al., 1976) or caffeine breath 
tests (Wietholtz et al., 1981) and the measurement of serum 
bile acid levels (Ferraris et al., 1983). However, the 
complexity and cost of these tests has resulted in their use 
being largely confined to clinical research. Whilst previous 
reports have suggested that the use of a simple oral caffeine 
loading test may provide an accurate means of measuring the 
degree of hepatic insufficiency, they fail to show conclusive 
evidence of its clinical significance. This study provides a 
detailed investigation of the clearance of caffeine in 
patients with chronic liver disease, of varying aetiology and 
severity, and correlates the serum and salivary clearance 
values with a clinical and biochemical assessment of the 
severity of their hepatic dysfunction.
The close correlation between caffeine levels in serum and
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saliva for the two groups of liver disease patients was 
similar to that found for normal healthy volunteers (Section 
5), confirming the suitability of salivary measurements for 
determining pharmacokinetic data. Peak caffeine levels for 
normal controls and both groups of liver disease patients were 
obtained within 3 hours after oral administration of caffeine 
(400 mg), after which the concentrations declined mono­
exponent i a 1 ly . Although peak drug concentrations in serum or 
saliva following oral administration may be affected by 
numerous physiological factors, such as its rate and extent of 
absorption, first pass elimination effects and rates of 
metabolism, the statistically significant increase in peak 
levels of caffeine in saliva of the compensated liver disease 
patients, compared to the normal controls, was probably due to 
the observed decrease in apparent volumes of distribution. A 
similar, but statistically insignificant decrease in apparent 
volume of distribution in liver disease patients has been 
previously reported by Renner et al. (1984). In contrast, the 
increased peak values in the decompensated patients are more 
likely to be explained by a decrease in the extent of protein 
binding in blood and the development of mesenteric porta-caval 
anastamoses which may significantly reduce first pass 
elimination effects. However, since the hepatic extraction of 
caffeine is less than 10% (Bircher, 1986), the resulting 
increase in bioavai1ab1ity would be minimal.
Analysis of the kinetic data on a group basis shows that, 
compared to normal volunteers, the clearance of caffeine is 
relatively unchanged in compensated cirrhosis. In contrast,
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the reduction in mean values for both the elimination 
constants and clearance values in patients with decompensated 
liver disease suggests that, in these subjects, the drug 
metabolizing capacity of the liver is severely impaired. 
Although the kinetic results are in close agreement with 
previously published studies (Desmond et al., 1980; Renner et 
al., 1984), a strict comparison is difficult owing to 
variations in experimental design.
The urine metabolite recoveries obtained from this study 
showed a similar configuration of results; significant 
impairements in metabolite excretion being apparent only in 
subjects with decompensated liver disease. However, with the 
exception of a decreased recovery of 1-methyl derivatives, the 
overall pattern of metabolite excretion for this group was not 
significantly different. This suggests that in decompensated 
liver disease there is a generalised impairement in the 
clearance of caffeine rather than specific alterations in its 
biotransformation. Although a study by Staib and his 
colleagues (1980) has indicated that the impaired metabolism 
of theophylline in liver disease may be associated with a 
decrease in 1-N demethylation, the failure to find an 
increased recovery of 1-methyl metabolites with concomitant 
decrease in 3-methyl and 7-methyl metabolites in this present 
study would tend to refute this possibility for caffeine.
The presence of significant amounts of paraxanthine (1,7- 
dimethylxanthine) in serum and saliva is in agreement with 
reports by Arnaud et al. (1981) and Callahan et al. (1981) 
which indicate that approximately 75% of administered caffeine
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undergoes an initial 3-N demethyl ation. Compared to the normal 
control group, the level of this metabolite in the serum/ 
saliva of the compensated cirrhotic subjects was significantly 
higher. However, since the total recovery of this metabolite 
in urine was similar for both groups, these differences are 
probably attributable to the corresponding decreases in 
apparent volume of distribution for this group. The reduction 
in peak levels of paraxanthine in the decompensated subjects 
in the absence of a corresponding decrease in bioavailability 
(AUC) is consistent with an impaired but normal disposition of 
caffeine in these subjects.
In agreement with previous reports (Desmond et al., 1980; 
Renner et al., 1984), the results of conventional liver 
function tests showed no apparent relationship to either the 
severity of liver disease or to the rate of elimination of 
caffeine. Although serum albumin levels in the decompensated 
group were significantly lower (P <0.001) than those found in 
compensated liver disease patients, the corellation between 
albumin levels and caffeine clearance was poor (r = 0.670). 
However, the close relationship between Pugh score ratings of 
liver dysfunction and caffeine clearance indicates that the 
monitoring of caffeine elimination in serum or saliva and/or 
the measurement of urine metabolite recoveries may be used as 
a sensitive means of assessing the severity of hepatocellular 
dysfunction. By relating the salivary pharmacokinetic data to 
the severity of liver disease, clear cut of points are 
apparent which may be used to differentiate compensated and 
decompensated conditions. More patient studies are required to
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clarify these points, but it is possible that an indication of 
decompensated liver disease could be based on the finding of a 
half-life of greater than 10 hours, an elimination constant of 
less than 0.6 and a salivary clearance of less than 0.4 
ml/kg/min. Although the inability to differentiate between 
caffeine elimination rates in compensated cirrhotics and 
normal volunteers suggests that caffeine clearance studies may 
lack sufficient sensitivity to detect mild impairments in 
hepatocellular function, it is possible that the patients 
selected for this study may have resumed normal liver function 
since they were regarded as being "well compensated".
The use of a simplified procedure, involving a 4 point 
determination of salivary caffeine clearance, showed a similar 
differentiation of the severity of liver disease to that 
obtained using the more detailed pharmacokinetic and urine 
metabolite studies. Further investigations are required to 
define the sensitivity of the procedure and to provide 
suitable reference ranges, but, the preliminary results 
suggest that 24 hour or overnight measurement of salivary 
caffeine clearance may provide a simple means of assessing 
hepato-ce1lular function. In addition, it has been reported by 
Renner et al. <1984) that a close hyperbolic relationship 
exists between caffeine clearance and caffeine concentrations 
determined in serum samples collected following an overnight 
fast. Although the increases in basal caffeine concentrations 
for the decompensated patients in this study failed to reach 
significance, they were measured after a 3 day abstinence from 
caffeinated beverages. Since commencing this study, a report
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by Wang et al. (1985) has suggested that the discrimination 
between patients with both cirrhotic and non-cirrhotic forms 
of liver disease and healthy volunteers, is best achieved by 
measuring caffeine concentrations in samples collected 12 
hours after oral administration of a caffeine dose. However, 
the significance of this is questionable since the present 
study was unable to differentiate between the clearance of 
caffeine in compensated liver disease patients and normal 
contro1s
Chronic liver diseases, such as alcoholic cirrhosis, 
generally pass through a long period of minimum, non-specific 
symptoms ("compensated") until reaching the final stages in 
which ascites, jaundice, encephalopathy and pre-coma <"de­
compensated" ) are common features. In addition to damage 
caused to the hepatic cells and architecture, the various 
pathophysiological disturbances may lead to a reduction in 
overall hepatic blood flow, the presence of intra- or extra- 
hepatic shunting and alterations in plasma protein synthesis. 
Although the total body clearance of a drug is a product of 
both metabolic and renal clearance, the previously described 
urine metabolite studies in normal volunteers have shown that 
renal excretion of unchanged caffeine, accounts for only 1-3% 
of an orally administered dose. The results of this present 
study indicate that even in patients patients with chronic 
liver disease, thd excretion of unchanged caffeine is minmal. 
Subsequently, since caffeine elimination occurs almost 
entirely by the liver, the rate of hepatic clearance may be 
regarded as being equvalent to the total clearance of caffeine
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calculated from pharmacokinetic data. A reduction in hepatic 
clearance, as observed in the decompensated group of patients 
is probably the result of combination of a) disordered hepato- 
cyte function, b> shunting of blood away from the liver due to 
the presence of portasystemic anastamoses and c) a decrease in 
hepatic blood flow. However, since the hepatic extraction of 
caffeine is estimated to be about 10 per cent in normal 
subjects (Bircher, 1986), the effects of liver blood flow are 
minimal. The delayed clearance of caffeine is therefore more 
likely to be due to a reduction in intrinsic clearance 
resulting from a reduced mass of viable hepatocytes.
In this particular study, the absence of significantly 
elevated levels of aspartate transaminase suggests that it is 
unlikely that the extent of hepatic necrosis in the 
decompensated group would be sufficient to cause a profound 
reduction in microsomal drug metabolizing activity. In 
addition, although the concurrent administration of additional 
drugs to some of the patients may have enhanced microsomal 
drug metabolism, induction effects were assumed to be minimal. 
This is supported by a report by Farrell et al (1979) which 
demonstrated that patients with severe liver disease fail to 
show the normal increase in levels of cytochrome P-450 and 
microsomal oxidase activities associated with the ingestion of 
strong inducing drugs such as phenobarbita1 , phenytoin and 
glutethimide.
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9.GENERAL DISCUSSION AND CONCLUSIONS
The ubiquitous consumption of caffeine, in the form of 
caffeinated beverages and various medications, has prevailed 
world-wide for many years. Whilst moderate doses of caffeine 
produce minimal pharmacological effects, consumption estimates 
in this study indicate that approximately 20% of the U.K. 
population have a dietary caffeine intake in excess of 500 mg 
per day. Despite this widespread usage, the scientific and 
medical literature has, until recently, contained only limited 
information on its pharmacokinetics, metabolism and pharmaco­
logical properties. This has been largely due to the absence 
of sensitive and specific methodologies for the measurement of 
caffeine and its metabolites in biological fluids. The present 
study describes the development and application of such 
procedures using high performance liquid chromatography.
Measurement of caffeine and its dimethvlxanthine metabolites
in serum and saliva.
Using a reverse phase chromatography system, incorporating 
a 100 x 4.5 mm i.d. Hypersil octadecysi1ane column with an 
elution system of acetonitri1e /tetrahydrofuran/ 50 mM acetate 
buffer, pH 4.0 (4:1:95, v/v), levels of caffeine and its 
dimethylxanthine metabolites have been measured in serum, 
saliva (p.35) and breast milk (p.168). Eluted peaks were 
detected by monitoring their UV absorption at a wavelength of 
280 nm. The incorporation of tetrahydrofuran into the mobile
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phase has produced significant improvements in specificity- 
over previously described methods by resolving theophylline 
from 1 ,7-dimethylxanthine (paraxanthine), the primary 
metabolite of caffeine found in these body fluids. Sample 
preparation using organic extraction with a chloroform/ 
isopropanol mixture has been adopted in order to eliminate the 
specificity problems associated with deproteinisation 
techniques. The recovery values and precision of the 
extraction procedure were very satisfactory and results 
suggest that aqueous standards may be suitably employed as an 
alternative to those prepared in drug-free serum. Caffeine 
levels determined by HPLC agreed well with those obtained 
using a radioimmunoassay (RIA) procedure (p.56). Whilst RIA 
procedures allow a large throughput of samples for analysis, 
the ability of the described HPLC procedure to simultaneously 
determine the concentrations of dimethylxanthine metabolites 
of caffeine in serum or saliva, and its high specificity, 
makes it ideal for precise pharmacokinetic studies. The method 
has also been satisfactorily applied to the determination of 
methylxanthine concentrations in beverages by injection of 
diluted samples directly into the system.
D etermination of the urinary metabolites of caffeine.
The development of a chromatographic procedure for the 
separation of methylxanthine metabolites using a Hypersil 
octadecy1si1ane column with a simple concave gradient elution 
programme of 0-12.75% acetonitrile in 1% tetrahydrofuran, pH 
4.6, produced significant improvements in specificity over
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previously described procedures (p.60). In particular, the 
ability to resolve 7-methylxanthine from 1-methyluric acid, 
theophylline from 1 ,7-dimethylxanthine or 3,7-dimethylxanthine 
from 1-methylxanthine has permitted more precise studies to be 
made on the biotransformation of caffeine. In order to 
optimise sample preparation in terms of selectivity, recovery, 
precision and preparation time, a critical assessment has been 
made of the use of direct injection of diluted urine samples 
and a procedure involving the formation and extraction of an 
ion-pair complex. The extraction procedure showed excellent 
selectivity and much improved recovery from previous 
techniques based on chloroform/isopropanol extraction (p.73). 
Whilst the direct injection technique (p.6 8 ) significantly 
reduces sample preparation time and eliminates variations in 
recovery, its susceptibi1ty to high blank values and the 
occasional presence of an interfering peak impose limitations 
on its use. However, providing suitable cut off values are 
applied to compensate for these factors, experience has shown 
that the convenience of this technique is of value where 
quantitation is only required for the major metabolites. Such 
applications include screening for toxicity or detecting 
alterations in the pattern of metabolite excretion resulting 
from diseased states such as chronic liver disease.
Population studies related to dietary caffe ine intake.
An assessment of dietary caffeine consumption, obtained 
using a retrospective questionnaire (p.91>, showed an overall 
mean daily intake of 359 mg (SD = 189). This value is
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significantly higher than previously reported intake levels 
for both American and Canadian populations. Whilst there was 
no significant variation between caffeine consumption and age, 
the consumption of caffeinated beverages in smokers was 
significantly higher than that found for non-smokers. For the 
total population studied, coffee drinking was found to be the 
major source of dietary caffeine, accounting for approximately 
55% of per capita intake. The consumption of tea accounted for 
44%, whilst caffeine intake from chocolate and cola flavoured 
drinks was minimal. In a separate survey, the mean caffeine 
concentration in serum samples collected from a non-pregnant 
population was 2.42 mg/1 (SD = 1.59) with values ranging from 
0 - 9.2 mg/1 (p.108). In agreement with a similar study 
reported previously by Smith et al. (1982), 6% of the 
population studied were shown to have circulating levels in 
excess of 5 mg/1; this is comparable to the mean peak caffeine 
found following 250 mg oral doses of caffeine. However, no 
association was found between symptoms of anxiety and levels 
of caffeine in serum (p.110).
Pharmacokinetics and metabolism of caffeine in healthy human 
subjects.
The non-invasive nature of saliva sampling and the ability 
to obtain multiple samples, prompted further investigation 
into the suitability of salivary caffeine determinations for 
establishing pharmacokinetic data. A satisfactory correlation 
was found between concentrations of caffeine in samples of 
serum and saliva, collected simultaneously and assayed using
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HPLC (p.53). Data derived from caffeine determinations in 
samples of serum and saliva, collected from normal volunteers 
following oral doses of caffeine, showed good correlation and 
enabled "reference ranges" to be established for use in future 
studies (p.101). The calculated mean values for elimination 
half-life <4.35 h ± S D . 1.95), elimination constant <0.185 h”^
±  SD. 0.07) and total salivary clearance < 1.605 ml . kg mirv^  ±. 
SD. 0.55) are similar to those previously reported by Parsons 
and Neims (1978) and Zylbei— Katz et al. (1984). Determination 
of the dimethylxanthine metabolites of caffeine showed that 
measurable concentrations of 1 ,7-dimethylxanthine were present 
in samples of serum and saliva 4-6 hours following an oral 
dose of caffeine (p.111). This is in agreement with a previous 
study by Arnaud and Welsch (1980) which, by monitoring the 
fate of radio1abe11ed caffeine, confirmed that 72% of an 
administered dose of caffeine undergoes an initial 3-N de- 
methylation. However, levels of theobromine and theophylline, 
dimethylxanthine metabolites, produced by respective 1-N and 
7-N demethylation of caffeine were minimal.
In normal volunteers, the urine methylxanthine metabolite 
recoveries for the 48 hour period following an oral dose of 
400 mg caffeine (p.130) accounted for 56% (SD = 16.4) of the 
administered dose. The principal urinary products of caffeine 
were 1-methyluric acid (19.9% ± SD. 8.5), 1-methylxanthine
<11.3% JL SD. 4.9) and 1,7~dimethyluric acid (7.4% ±. S D . 4.9); 
the recovery of unchanged caffeine accounted for only 2% (SD = 
1.4) of the administered dose. These findings are in agreement 
with earlier reports by Arnaud and Welsch (1981) and Callahan
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et al. <1982) which investigated the metabolic fate of 
radiolabelled caffeine. Since the completion of this study, 
further reports on the biotransformation of caffeine (Callahan 
et al.,1983; Tang et al., 1983; Blanchard et al., 1985; Grant 
et a l ., 1985) have conistently shown similar methylxanthine
recovery patterns for both oral and intravenous doses of 
caffeine. Measurement of the acetylated uracil metabolites of 
caffeine, such as 5-acetylamino-6-amino-3-metyluraci1 (AAMU) 
and 5-acetylamino-6-formylamino-3-methyluraci1 (AFMU), has not 
been possible in this study due to the inability to obtain 
pure standards and the requirement for additional methodology. 
However, it is probable that the unaccounted metabolites for 
the normal volunteers (ca. 44%) represents the formation of 
such compounds.
Psvchopharmaco1oaica1 and e 1ectrophysio1oqica1 effects of 
caf fe ine.
In collaboration with the Institute of Psychiatry, an 
assessment has been made of the psychophysiological and 
pharmacological effects of caffeine of caffeine in-healthy 
human subjects. Quantitative EEG measurements provided 
evidence for the stimulatory effects of caffeine by showing 
highly significant dose-related decreases in slow-wave (theta) 
activity and similar, but not dose related decreases in alpha 
wave activity (p.130). The results also suggested that a 
concomitant dose-related increase in beta activity may occur 
as a direct result of the stimulant action. Further evidence 
for the stimulatory action of caffeine was provided by dose-
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related increases in skin conductance and from self-rating 
mood scales which demonstrated increased measures of 
alertness, enery, quick wittedness and attentiveness (p.133). 
Self-rating bodily symptoms indicated less tiredness and 
increases in the degree of shaking and trembling following 
ingestion of caffeine. However, since changes in tremor, 
measured using an accelerometer, were not significant, the 
tremulousness was probably mainly subjective in nature. Whilst 
the design of the study permitted only a limited period for 
collection of serum and urine samples, the pharmacokinetic 
data and urine metabolite recoveries were similar to those 
found previously in more prolonged studies. It is anticipated 
that an understanding of the described physiological, 
psychological and subjective measures, combined with the 
ability to determine caffeine and its metabolites in body 
fluids, will enable the implications of caffeine in patients 
with chronic anxiety states to be assessed and also the 
effects of caffeine withdrawl.
Caffeine metabolism during pregnancy and its exposure effects 
on the newborn infant.
Compared to a normal non-pregnant population, the mean 
levels of caffeine in serum samples collected at random from a 
series of pregnant females (p.153) were significantly higher 
(3.45 mg/I ± S D . 2.43 versus 2.43 mg/I ± S D . 1.63). However
this finding is consistent with reports from previous studies 
on the elimination of caffeine which have shown a substantial 
and progressive decrease in its clearance during the second
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and third trimesters (Aldridge et al., 1981; Knutti et al., 
1982). The increased serum levels of caffeine were not related 
to changes in dietary consumption of caffeinated beverages or 
to alterations in the extent of protein binding (p.155). In 
fact the completion of a retrospective questionnaire by a 
limited number of volunteers suggested that the consumption of 
caffeinated beverages is considerably decreased during 
pregnancy^
Whilst the impaired clearance of caffeine during pregnancy 
may be the result of alterations in metabolism, studies into 
this possibilty have been restricted by the natural reluctance 
of pregnant women to ingest large single doses of caffeine and 
the ethical problems of using radio1abe11ed compounds. These 
problems have been overcome in the present stuby by comparing 
the excretion of caffeine and its metabolites in urine samples 
collected from pregnant and non-pregnant women receiving a 
controlled dietary intake of caffeine. This has provided 
valuable information on the biotransformation of caffeine 
during pregnancy (p.158). The mean percentage of the 
administered dose of caffeine recovered in the urine was 56.8% 
in both groups. However compared to the non-pregnant group, 
the pregnant subjects excreted smaller amounts of 1-methyl- 
xanthine and 1-methyluric acid, whereas the excretion of most 
of the other metabolites, particularly 3,7-dimethylxanthine 
and 3-methylxanthine tended to be greater. Since the values 
for the 1 ,7-dimethyl metabolites were similar in both groups, 
it is suggested that during pregnancy the further metabolism 
of 1 ,7-dimethylxanthine may be impaired. This could result
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from an impairment in 7-N demethyl ation with respect to
1 ,7-dimethylxanthine as a substrate or alternatively 
regulation may be located at the level of 3-N demethyl ation of 
caffeine. The increased recoveries of metabolites possessing a 
3-methyl group suggests that, during pregnancy, the route of 
caffeine elimination is altered in favour of an initial 1-N 
demethylation of caffeine to theobromine followed by 7-N 
demethyl ation to 3-methylxanthine. To a lesser extent, the 
initial 7-N demethyl ation of caffeine to form theophylline may 
also be increased during pregnancy, since the recoveries of 
1,3-dimethyluric acid and theophylline were shown to be 
significantly increased. In view of previous reports relating 
to the effects of steroid hormones on drug metabolism in 
pregnancy, it was concluded that the altered biotransformation 
of caffeine in pregnancy may be the result of hormonal 
influences on the hepatic drug metabolizing enzymes.
The estimates of cord blood caffeine levels in this study 
were significantly higher than those previously reported for 
the USA and W.Germany; 5% of the values being in excess of 10 
mg/1 (p.168). This suggests that foetal exposure to caffeine 
in the U.K. may be higher than previously supposed and may 
lead to the manifestation of adverse effects in the newborn 
infant. These include tachycardia, tachypnoea, seizures, 
tremors, jitteriness, increased reflexes and gastro-intestina1 
disturbances. Whilst it is unlikely that such effects occur at 
concentra t i o n s  be 1ow 15-20 mg/1 (Howell et al., 1981), these 
levels could be attained as a result of caffeine intake from 
breast feeding which may be 4 mg/day or more. Caffeine
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withdrawl from intrauterine habituated infants, especially 
where breast feeding is delayed or artificial feeding 
instituted, could play a part in the aetiology of neonatal 
apnoea. Although no correlation could be found between 
caffeine levels and score ratings for jitteriness, tachypnoea 
or gastrointestinal disturbances (p.169), the caffeine levels 
in the group of infants studied were all below those required 
to produce significant effects. Since the dimethylxanthine 
metabolites of caffeine are all pharmacologically active, the 
presence of significant levels of these compounds in maternal 
serum (p.158), cord blood and breast milk (p.168), indicates a 
requirement to assess the effects of total methylxanthine
levels in the newborn infant. As there is some evidence to 
suggest that the ratio of caffeine and its metabolites in 
maternal serum or saliva are consistent with values found in 
cord blood or breast milk, maternal screening may provide a 
useful index to increased foetal exposure, especially in cases 
where the dietary consumption of caffeine by the mother is 
known to be high.
The pharmacokinetics and metabolism o f caffeine in liver 
disease.
Although the total body clearance of a drug is a product of 
both metabolic and renal clearance, the described urine 
metabolite studies in normal volunteers have shown that renal 
excretion of caffeine is minimal. Consequently, since caffeine 
metabolism occurs almost entirely in the liver, the total 
clearance of caffeine calculated from pharmacokinetic data,
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may be regarded as being equivalent to the actual hepatic 
clearance. On the basis of these assumptions, this study has 
investigated the suitability of caffeine clearance studies as 
a means of assessing the extent of hepatocellular damage in 
patients with chronic liver disease. Following oral doses of 
caffeine, the salivary pharmacokinetic data (p.197) and urine 
metabolite recoveries (p.208) for patients with compensated 
liver disease were shown to be similar to values found for 
normal healthy volunteers. In contrast the salivary clearance 
of caffeine in patients with decompensated liver disease was 
significantly impaired. Whilst the excretion of urinary 
methylxanthine metabolites for this group was also reduced, 
the absence of significant variations in the pattern of 
metabolite excretion suggested that the biotransformation of 
caffeine in chronic liver disease is unaltered.
It is frequently assumed that the impaired clearance of 
drugs in liver disease is related to a reduction in the 
activity of the cytochrome P-450 drug metabolizing system. 
However, evidence for this is largely indirect and reports 
have shown that the microsomal enzymes show functional 
heterogeneity and are influenced to a different extent 
according to the form of liver disease ( Farrell et al.,
1979). In the absence of significantly elevated levels of 
aspartate transaminase in the decompensated subjects it is 
unlikely that the extent of hepatic necrosis in these patients 
was sufficient to cause a profound reduction in the degree of 
cytochrome P-450 related drug metabolism. Subsequently, since 
the low hepatic extraction of caffeine minimises the effects
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of altered hepatic blood flow on caffeine clearance, the 
observed impaired clearance of caffeine in chronic liver 
disease is probably associated with a reduction in its 
systemic clearance due to the presence of intra- or 
extra-hepatic shunts.
Although the severity of liver disease and the rate of 
caffeine elimination were poorly reflected by the results of 
conventional liver function tests (p.195), a close correlation 
was shown between Pugh score ratings of liver dysfunction 
(Appendix 6 ) and caffeine clearance in serum or saliva (p.203) 
and the recovery of urine metabolites (p.214). This confirms 
the suitability of caffeine elimination studies as a means of 
distinguishing between compensated and decompensated 
conditions of cirrhotic liver diease. Whilst the inablity to 
differentiate compensated cirrrhotic patients from a normal 
control group suggests that these studies lack sufficient 
sensitivity to detect mild impairements in hepatocellular 
function, it is possible that the patients selected for this 
study may have resumed normal liver function, since they were 
regarded as being "well compensated". A simplified protocol 
measuring the 24 hour or overnight salivary caffeine clearance 
enabled similar assessments to be made of the extent of hepato 
-cellular dysfunction (p.215), although further investigations 
are required to determine fully the sensitivity of this test as 
a means of assessing functional hepatic reserve. However, the 
indications are, that salivary caffeine clearance studies may 
provide a safe and non-invasive method for the initial 
assessment and monitoring of treatment in patients with
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chronic liver disease. In addition its use as an index of 
prognosis may be of assistance in the selection of patients 
for transplant surgery.
In conclusion, this study has provided sensitive and 
specific methodolgies for the simultaneous analysis of 
caffeine and its metabolites in body fluids. The establishment 
of "reference ranges" for pharamcokinetic data and urine 
metabolite recoveries, in normal healthy volunteers following 
oral doses of caffeine, have enabled comparisons to be made 
between the metabolism of caffeine in pregnancy and in 
alcoholic liver disease, both of which are associated with a 
delayed clearance of caffeine. Whilst there is direct evidence 
to implicate hormone induced alterations in the 
biotransformation of caffeine during the third trimester of 
pregnacy, the impaired clearance of caffeine in decompensated 
alcoholic liver disease is probably related to a reduction in 
hepatic uptake caused by altered architecture of the 
hepatocyte. However, further investigations are required to 
investigate the effects of different forms of liver disease on 
caffeine elimination. In particular, it would be of interest 
to examine the effects of conditions associated with 
hepatocellular damage, such as active hepatitis and hepatic 
necrosis, where alterations in the biotransformation may be 
apparent.
Since overt responses to caffeine withdrawl have been found 
both in this study and in previous reports by Dreisbach and 
Pfeiffer (1943) and Greden, (1980), a study is being prepared 
in which responses to the described physiological and
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psychological measurements during periods of withdrawl will be 
related to subjective reports and to bodily concentrations of 
caffeine and its metabolites. Additional studies are also 
required to clearly establish the effects of foetal exposure 
to caffeine and also to assess the implications of caffeine in 
chronic anxiety states.
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APPEND IX 1 Urine "clean-up" procedures for HPLC analys is.
a)C-18 Sep-Pak Cartridges (Waters Associates Ltd. Hartford.
Chesh i r e )
Columns were conditioned by attaching a 5 ml syringe on the 
column inlet and flushing through 2 ml methanol followed by 4 
ml 0.2mM acetate buffer, pH 4.2. A 1 ml aliquot of standard or 
urine (diluted 1:10 with 20mM acetate buffer, pH 4.2) was then 
applied to the column inlet and allowed to permeate through 
the column bed. The solutes were eluted from the column by 
flushing with 1 ml acetate followed by 1 ml 1% acetonitrile in 
acetate buffer, pH 4.2 and finally 2 x 1 ml of 30% aceto- 
nitrile/1% tetrahydrofuran, pH 4.2. The collected fractions 
were then analysed to determine the methylxanthine recovery 
and the efficiency of the columns in removing non-specific 
substances.
b )Merck Extrelut columns (BDH Ltd. Poole. Dorset).
Columns were prepared using glass Pasteur pipettes filled
with approximately 0.5g of Extrelut. A 0.6 ml aliquot of 
standard or urine (diluted 1:10 with 20mM acetate buffer, pH 
4.2) was then added to the surface of the column and allowed 
to permeate for 10 minutes before purging with 5 ml chloroform 
/isopropanol to elute the methylxanthines. Following evaporat­
ion to dryness, under air at 45 C, the residue was dissolved 
in 1 ml of the mobile phase prior to chromatography. The 
columns were assessed in terms of their methylxanthine 
recovery and efficiency in removing non-specific substances.
MATERIAL REDACTED AT REQUEST OF UNIVERSITY
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APPENDIX 3.
Test sequences for monitor ing the psvchopharmaco1ogica1 and 
electrophvsioloqical effects of single doses of caffeine.
Physiological measures.
a) Electroencephalogram and Evoked Response. These were 
monitored in parallel using the same EEG recording obtained 
from vertex and left temporal electrodes <Cz and T 3 ). After 
amplification the signal was passed through a 2-32 Hz bandpass 
filter before undergoing a Fourier Transform and power- 
spectral density analysis. Subjects were requested to press a 
key in response to each of a series of click stimuli. Thirty 
two samples each of 4.8s, were taken during the reaction time 
task (commencing at least 3s after each click), subject's eyes 
open and the spectral data pooled. The spectra were divided
forconvenience into the clinical wavebands: "theta" 4-7.5;
"alpha"7.5-13.5; and "beta" 13.5-32 Hz. The mean log power in 
each waveband was computed.
b) Skin Conductance level. Skin conductance was measured from 
a marked area on the left thumb. The mean level and number of 
fluctuations per minute were monitored during the reaction 
time task
c) Pulse rate and blood pressure. These were measured using a 
"Copal" Auto-inflation digital sphygmomanometer with counter.
d) Tremor was measured using an accelerometer attached to the 
middlefinger, extended horizontally with the arm supported 
from theelbow to the wrist. The output was amplified analysed
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in the computer using a Fourier power-spectral density 
programme.
e> Critical flicker fusion. Subjects held a monocular device 
with Maxwellian view optics to the dominant eye. The stimulus 
was a red light-emitting diode activated by the computer. 
Background illumination was excluded. Three runs from flicker 
to fusion alternated with three from fusion to flicker to 
allow computation of a mean of the six values.
Psychological measures
a) Tapping rate. The subject tapped a key with two fingers of 
his preferred hand as quickly as possible for 60s. The mean 
inter- tap-interval was calculated.
b) Reaction time. 32 auditory clicks were presented to which 
the subject was asked to respond as fast as possible.
c) Digit-symbol substitution (DSST). This was a coding task 
in which the subject had to code symbols for digits. The score 
was calculated from the number completed in 90s.
d) Symbol Copying (SCT). The same symbols were used as for 
the DSST but the subject had to copy and not code them. It 
was scored similarly to the DSST.
e) Number cancellation time (CT). As a means of a measuring 
the levels of attention subjects were instructed to cancel 4's 
in a series of numbers. The time to complete the task and the 
number of errors were noted.
Parallel versions of the DSST, SCT, and CT were used on each 
occas i o n .
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Self-ratings.
a) Mood rating scale. Feeling at the time of each testing was 
measured on a series of sixteen analogue scales (Bond and 
Lader, 1974). This mood rating scale has been previously 
subjected to a principal component analysis which yielded 
three factors. The first factor is one of alertness and 
consists of nine scales; alert-drowsy, strong-feeble, 
muzzy-cleai— headed, well coordinated -clumsy, lethargic- 
energetic, mentally slow-quick- witted, attentive-dreamy, 
incompetent-proficient and interested-bored. The second factor 
measures contentedness and the five scales which load on it 
are; contented-discontented, troub1ed-tranqui1, happy-sad, 
antagonistic-amicable and withdrawn-gregarious. The third 
factor, calmness, is composed of two scales; calm-excited and 
tense-relaxed. On each scale, the subject marked the point 
along a 100 mm line that represented how they felt.
b) Bodily symptom scale. A similar scale has been constructed 
to measure bodily symptoms. It has 13 items which have been 
used in the investigation of anxiety; anxiety, sweating, 
shaking or trembling, palpitations, nausea or sickness, 
dizziness, irritability, loss of appetite, muscular tension, 
indigestion or stomach trouble, physical tiredness, headache 
and concentration. The subject rated them along a 100 mm line 
between absent and severe.
c) State anxiety inventory (Spielberger , 1970) consists of a 
20-item self-report scale designed to measure the current 
level of tension and apprehension. Widely used in a variety of 
research settings, the STAI is easily administered and scored.
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BODILY SYMPTOMS SCALE 4
AME
ATE.
1. Please rate the way you feel in terms of the dimensions given below
2. Regard the line as representing the full range of each dimension
3. Rate your feelings as they are AT THE MOMENT
4. Mark clearly and perpendicularly across each line
a anxiety very severe anxiety
o sweating very severe sweating
o shaking or 
ambling
very severe shaking or 
trembling
o palpitations or 
jart beating fast
very severe palpitations 
or heart beating fast
o nausea or sickness very severe nausea or 
sickness
a dizziness Very severe dizziness
a irritability very severe irritability
a loss of appetite very severe loss of appetite
a muscular tension very severe muscular 
tension
a indigestion or 
amach trouble
very severe indigestion or 
stomach trouble
a physical tiredness very severe tiredness
) headache very severe headache
a loss of concentration very severe
loss of concentration
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SELF-EVALUATION QUESTIONNAIRE
Developed by C. D. Spielberger, R. L. Gorsuch and R. Lushene
STAI FORM X-1
NAME ................................................................................................................. DATE
DIRECTIONS: A number of statements which people have used 
to describe themselves are given below, Read each statement and 
then circle the appropriate number to the right of the statement to 
indicate how you feel right now, that is, at this moment. There are 
no right or wrong answers. Do not spend too much time on any 
one statement but give the answer which seems to describe your 
present feelings best.
1. I feel calm
2. I feel secure
3. I am tense
4. I am regretful
5. I feel at ease
6. I feel upset
7. I am presently worrying over possible misfortunes
8. I feel rested
9. I feel anxious
10. I feel comfortable
11. I feel self-confident
12. I feel nervous
13. I am jittery
14. I feel “high strung’
15. I am relaxed
16. I feel content
17. I am worried
18. I feel over-excited and rattled
19. I feel joyful
20. I feel pleasant
2 3 4
2 3 4
2 3 4
2 3
2 3
2 3 4
VERY 
MUCH 
SO
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MOOD RATING SCALE
JAME
)ATE..
1. Please rate the way you feel In terms of the dimensions given below
2. Regard the line as representing the full range of each dimension
3. Rate your feelings as they are AT THE MOMENT
4. Mark clearly and perpendicularly across each line
ALERT
CALM
STRONG
MUZZY
WELL-COORDINATED
LETHARGIC
CONTENTED
TROUBLED
MENTALLY SLOW
TENSE
ATTENTIVE
INCOMPETENT
HAPPY
ANTAGONISTIC
INTERESTED
WITHDRAWN
DROWSY
EXCITED
FEEBLE
CLEAR-HEADED
CLUMSY
ENERGETIC
DISCONTENTED
TRANQUIL
QUICK WITTED
RELAXED
DREAMY
PROFICIENT
SAD
AMICABLE
BORED
GREGARIOUS
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APPENDIX 4
Procedure for the investigation of caffeine metabolism during 
pregnancy
The collection of samples for this study may be linked to the 
collection of 24h urine samples for oestriol estimations, if 
applicable. Patients must adhere to a controlled dietary 
intake of coffee for 48 hours and other related compounds must 
be excluded from the diet. These include tea, cocoa, 
chocolate, coca-cola and the following drugs - theophylline 
and caffeine containing analgesics.
Day 1 Commence controlled intake of caffeine by selecting a 
daily consumption of either 4,6,8 or 10 cups of coffee. This 
will be supplied in pre-weighed aliquots and should ideally be 
consumed at approximately the same times on each day.
Day 2 Continue with controlled caffeine intake
0800 Empty bladder and discard urine. Collect total 
urine output for the following 24h period including 
sample voided at 0800 on day 3.
N.B. 0800 is merely a suggested starting time and may be 
altered for individual convenience providing a 24h cycle 
is maintained.
Name: ............................  Gestational dates: .......
Coffee intake throughout study:
4 cups 6 cups 8 cups 10 cups per day 
Normal daily consumption of tea/coffee
Do you smoke? (If yes, please give details)
Please give brief details of any drugs taken during this 
study.
CAFFEINE METABOLITE EXCRETION (% Dietary intake per 24 hours)
INTAKE
mg
7MU 7MX 1MU 3MX 1MX ” 13MU 37MX 17MU 17MX 13MX 137MU 137X
1 123 2.9 5.0 8.0 5.0 4.6 3.2 0 8.1 5.8 2.6 2.4 7.0
2 123 2.1 4.4 12.4 3.2 8.5 2.2 2.1 8.6 5.4 1.5 1.2 4.4
3 184 1.9 8.1 12.9 9.5 13.0 2.6 3.9 10.3 6.3 1.5 1.0 2.6
4 246 2.5 6.4 9.5 6.9 5.6 1.9 5.5 8.7 6.1 0.9 0.8 3.3
5 246 1.9 4.1 9.7 4.7 9.2 2.8 2.0 16.3 5.4 1.9 2.0 4.4
6 246 2.5 2.7 5.6 2.7 4.3 1.3 4.1 5.6 7.3 1.7 0.9 4.2
7 246 1.2 3.5 7.1 5.2 6.9 3.7 4.7 8.0 7.4 2.0 2.2 4.2
8 246 0.6 2.0 14.4 4.1 10.8 2.2 3.5 11.0 5.7 1*1 2.0 2.4
9 246 1.6 2.1 4.3 2.9 5.9 1.5 1.7 6.8 5.0 0.8 1.0 2.8
10 246 3.0 5.9 9.2 7.5 6.3 2.1 5.0 9.0 5.4 2.1 0.9 2.7
11 246 2.6 5.6 9.8 5.6 15.0 2.7 4.6 9.0 6.1 1.9 0.8 1.4
12 308 2.1 4.1 14.6 2.9 6.1 ,4-5 1.8 12.8 7.1 1.7 1.8 3.1
13 369 2.0 3.8 13.8 2.4 5.7 3.7 2.5 13.0 7.1 1.5 1-7 2.9
14 369 1.9 12.5 3.4 14.6 3.6 2.2 8.7 6.8 3.4 0.9 0.9 1.1
15 369 1.9 5.2 6.1 7.1 3.4 2.0 13.9 5.9 4.2 2.0 1.3 3.3
Mean values 2.0 4.9 8.9 5.6 7.3 2.4 4.8 8.9 6.0 1.6 1.3 3.5
S.D 0.6 2.7 3.4 3.3 3.4 0.8 3.2 2.8 1.3 0.5 0.6 1.5
Mean caffeine methylxanthine metabolite excretion in urine 
samples obtained from pregnant women receiving a controlled 
dietary intake of caffeine.
(Results are obtained from a single 24 hour urine collection.) 
For key to abbreviations refer to page 3.
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Caffeine 24 hour methylxanthine excretion. % Dietary intake
Intake
mg
7MU 7MX IMU 3MX 1MX 13MU 37MX 17MU 17MX 13MX 137MU 137MX
1 300 2.3 4.5 23.7 2.9 14.0 2.0 2.2 8.5 6.0 1.3 0.7 1.3
2 300 1.9 3.9 20.8 2.9 10.2 1.0 2.0 5.4 5.0 0 0.9 4.8
3 300 2.2 4.0 16.5 3.3 7.5 2.8 1.2 11.1 5.3 1.3 0.9 2.4
4 450 1.2 3.8 25.1 2.2 10.9 1.3 1.1 5.2 3.1 0.9 0.4 1.6
5 450 0.8 3.5 9.5 1.3 9.4 1.5 0 8.8 3.9 0.4 0.7 1.8
6 450 1.2 3.9 21.0 3.8 13.5 1.5 1.7 7.0 4.5 1.1 0.5 1.1
7 450 1.2 4.0 23.2 2.4 12.7 1.5 1.5 6.0 4.5 0.5 0.6 1.5
8 600 1.1 4.3 22.6 3.0 12.9 1.8 1.6 8.3 4.9 0.8 0.8 1.8
9 750 1.3 3.7 13.5 2.1 11.4 1.3 1.4 4.7 5.3 0.7 0.4 1.4
Mean value 1.4 4.0 19.5 2.6 11.4 1.6 1.4 7.2 4.7 0.8 0.7 2.0
S.D. 0.5 0.3 5.3 0.7 2.1 0.5 0.6 2.1 0.9 0.4 0.2 1.1
Methylxanthine excretion in non-pregnant normal volunteers 
receiving a controlled dietry intake of caffeine.
(Results are expressed as the mean values of two consecutive 24 hour 
urine collections).
APPENDIX 5 - Study of caffeine levels in jittery infants
SURNAME............ FIRST NAME.............. Unit No.
CONSULTANT..... .....Ward/Dept ..............Age---
Date and time of collection of blood sample ............
Clinical details
a) Apgar score at birth: 1 min...... .. 5 min......
b) Bodily symptom ratings (Please mark perpendicularly across each
line)
0 1 2 3 4 5 /
Not jittery •----*—
No palpitations 
or tachycardia
No sickness 
or diarrhoea
No sweating or 
fever
c) General comments
— 1 -... 1 . 1--------1 Severely jittery
Severe palpitations 
or tachycardia
Severe sickness 
or diarrhoea
Very severe sweating 
or fever
0
SCORE
1 2
Heart rate absent less than 
100 per min
more than 
100 per min
Respiratory
effort
absent gasping or 
irregular
crying or rhyth­
mic breathing
Muscle tone flaccid some flexor 
tone
good with 
movement
Resonse to none poor (with a good with a cry 
facial grimace)
Colour of 
abdominal skin 
or tongue
pallor
Apgar
cyanosis 
scoring system
pink
Re: Kelnar CJH, Harvey D. The sick newborn baby. Bailliere Tindall, 
1981, London.
\
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CAFFEINE CONCENTRATION mg/1 
Subject Dietary Maternal saliva Cord blood Breast
intake serum milk
yp 90 3.4 2.8
00•1—1 —
TB 120 2.7 1.9 5.3 7.2
YR 210 1.4 1.2 1.5 -
TW 240 2.4 1.8 - -
HC 240 2.2 1.6 1.6 1.2
TH 280 5.7 4.7 4.6 -
HP 280 5.9 4.5 - -
CB 280 12.1 10.0 12.7 8.7
GM 300 4.4 6.1 - -
JC 300 6.9 4.9 9.6 8.5
SW 360 1.1 0.6 7.5 -
MC 360 3.6 2.8 1.4 -
TB 7 6.6 3.9 - 1.9
TT 7 5.3 4.8 2.7 2.7
HJ 7 3.7 2.4 - 2.1
ME 7 2.1 1.2 - -
EA ? 3.0 2.6 4.4 _
Relationship between caffeine levels in maternal 
serum and saliva, at 34-36 weeks gestation, and 
corresponding samples of cord blood and breast milk
collected post-natally.
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Caffeine Metabolism in Alcoholic Liver Disease 
Protocol for sample collection
Name : .................................. Unit No. . .......
Date of study : ...... ................... Caffeine dose (mg)
Time of Collection 
Sample Time Plasma Saliva
0 min
30 min
60 min
2 hour
3 hour
4 hour
6 hour
8 hour
12 hour
24 hour
48 hour
72 hour
96 hour
Urine collections
Basal urine Time of collection : ...............
Sample 1. (0-24 hours)
Time started ..........  Time finished ...........Vol.
Sample 2. (24-48 hours)
Time started ..........  Time finished .........  Vol.
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APPENDIX 6
Caffeine Metabolism in Alcoholic Liver Disease
Name: .....................   Unit No.......
Age: ........  Sex: M/F Nationality: ................
Weight (kg): ........................
Clinical history
Liver Function Tests
Bilirubin(umol/l) AST(U/1)
Gamma GTP(U/1) Aik.phos(U/l)
Albumin(g/1) Prothrombin time(secs)
Daily caffeine intake
Coffee a) instant b) percolated
Tea Drinking chocolate
Coca-cola
Present drug therapy (including oral contraceptives)
Daily alcohol consumption
Smoking habits
Any other relevant information
Adverse effects noted during study
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Clinical and Biochemical 
Measurements
Points scored for increasing 
abnormality 
1 2  3
Encephalopathy grade* 
Ascites
Bilirubin (umol/1)
PBC patients **
Prothrombin time 
(sec prolonged)
Albumin (g/l)
None
Absent
<33
<68
1-3 sec 
>35
1 and 2
Slight
34-51
69-171
4-6 sec 
28-35
3 and 4
Moderate
>51
>171
>6 sec 
<28
Grading system for severity of liver disease (Pugh et al., 1973)
* According to grading of Trey, Burns and Saunders (1966)
** An allowance is made in the grading of patients with primary 
biliary cirrhosis in whom the level of serum bilirubin is usually 
out of proportion to other evidence of hepatic failure.
Category A = 5-6 points 
Category B = 7-9 points 
Category C = 10-15 points
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% administered dose 
7MU 7MX 1MU 3MX 1MX 13U 37X 17U 17X 13X 137U 137X Total
J.C.
0-24 hr 0.4 3.1 25.2 1.2 13.7 1.2 5.5 4.1 0.4 0.5 1.4 1.4 58.8
24-48 hr 0.1 0.8 2.3 0.5 0.9 0 0.5 0.4 0.7 0.1 0.1 0 6.3
A.C.
~0-24 hr 0.2 1.2 9.6 0.7 10.6 0.8 1.0 4.9 3.0 0.6 0.2 1.0 33.6
24-48 hr 0.4 1.9 5.0 0.8 5.8 0.7 0.8 2.8 2.0 0.2 0.3 0.5 21.1
I.C.
0-24 hr 0.8 
24-48 hr 0.1
P.I.
0-24 hr 0.5 
24-48 hr 0.2
E.M.
0-24 hr 0.1 
24-48 hr 0.6
2.3 15.5 2.0
1.2 1.5 1.0
2.5 13.4 1.3
1.6 3.3 0.9
1.5 11.5 0.7
1.1 2.1 0.8
10.3 1.2 2.4
0.9 0.4 0.5
10.2 1.0 1.4
2.6 0.5 0.4
5.5 0.6 0.5
1.1 0.3 0.6
7.7 4.7 0.7 
0.5 0.5 0.2
7.5 5.7 0.6
1.1 1.2 0
4.9 4.2 0.4 
0.9 0.9 0.3
0.4 1.8 49.8 
0 0 6.8
0.8 1.5 46.3
0.3 0.6 12.4
0.3 1.8 31.8 
0.2 0.3 9.1
E.P.
0-24 hr 0.8 2.8 20.0 1.5 10.5 0.3 1.5 4.3 2.9 0.3 0.2 0.5 45.6
24-48 hr 0.5 1.0 0.9 0.2 0.3 0.3 0.3 0.3 0.5 0.1 0.1 0 4.5
A.S.
0-24 hr 0.9 1.5 20.5 
24-48 hr 1.2 2.3 4.7
B.W.
0-24 hr 0.5 2.4 3.7
24-48 hr 0.3 0.8 4.3
N.W.
0-24 hr 0.6 0.2 16.3 
24-48 hr 0.4 1.2 7.3
H.O.
0-24 hr 0.8 1.9 7.2
24-48 hr 2.1 2.4 8.9
48-72 hr 0.6 3.3 3.1
1.1 11.5 0.5 1.5 6.4
1.3 3.6 0.4 0.6 2.5
0.5 5.3 0.3 0.4 1.4
0.8 7.1 0.5 0.8 2.4
0.8 6.6 1.0 1.7 6.1
0.9 3.5 0.4 0.8 2.6
0.5 4.9 1.2 1.1 8.7
0.8 6.1 2.6 4.4 5.1
0 0 0.7 0.7 1.1
3.5 0.8 0.2 2.7“ 51.0 
0.8 0.7 0.3 0.5 18.4
2.7 0.6 0.3 2.0 20.0
1.7 0.8 0.1 0.6 19.9
4.2 0.4 0.6 1.7 41.7 
0.7 0.8 0.3 1.0 19.6
3.9 0.6 0.8 2.6 34.0
5.4 0.7 1.9 1.1 41.3
1.8 2.1 1.0 0 14.3
Methylxanthine metabolite excretion in compensated cirrhotic 
patients following an oral dose of caffeine (400 mg)
% administered dose 
7MU 7MX 1MU 3MX 1MX 13U 37X 17U 17X 13X 1370 137X Total
F.C.
0-24 hr 1.1 2.8 18.3 0.9 7.3 0.4 2.1 8.2 1.1 0.1 0 1.1 43.3
24-48 hr 0.2 1.2 4.0 0.7 1.4 0.2 0.6 1.4 0.3 0.1 0.1 0.2 10.2
G.G.
0-24 hr 0.6 1.0 9.4 0.5 1.5 0.3 1.5 6.8 1.3 0.5 0.5 1.8 25.6
24-48 hr 0.5 0.7 7.8 0.8 0.9 0.3 1.7 6.0 2.1 0.8 0.3 0.5 22.2
48-72 hr 0.4 0.5 3.3 0.6 0.2 0.2 0.8 0.8 0 0.5 0.1 0.1 7.4
72-96 hr 0.6 0.3 1.8 0.2 0.5 0.6 0.2 0.6 0.4 0.2 0 0.1 5.5
D.H.
0-24 hr 1.9 0.6 1.8 1.5 1.4 0.3 1.3 2.1 1.0 0 0.2 4.7 16.7
24-48 hr 0 1.0 1.9 0 0.7 0.3 1.4 2.3 0.7 0.7 0.1 2.2 11.2
B.J.
0-24 hr 1.4 1.6 8.0 0.6 3.2 0.7 0.8 6.6 2.6 0.6 1.3 3.5 30.7
24-48 hr 0.8 2.1 13.6 1.0 4.4 0.6 1.3 7.2 2 0.7 1.7 1.5 36.9
48-72 hr 2.9 1.7 4.8 1.0 2.9 0.6 0.6 1.3 0 0.8 0 0 16.4
V.D.
0-24 hr 0.2 1.4 0.6 0 2.9 1 0 0.4 0.4 0.1 0.7 3.9 11.6
24-48 hr 1.5 0.9 0.5 0.5 4.2 0.5 0.7 0.5 0.3 2.1 0.2 4.6 16.4
48-72 hr 1.2 1.0 0.5 0.3 1.9 0.3 0.3 0.4 0.3 0 0.5 3.0 9.6
72-96 hr 1.2 0.6 0.9 0.2 0.4 0.5 0.2 0.4 0.3 0 0.6 3.4 8.6
F.F.
0-24 hr 1.1 1.5 5.4 0.3 .1.1 0.4 0.6 4.0 0.6 0 0 1.2 16.0
72-96 hr 1.1 1.1 5.0 0.3 0.4 0.2 0.4 2.0 0.2 0 0 0.2 10.6
M.S.
0-24 hr 0.4 0.8 3.3 0 2.4 1.3 0.8 2.7 4.8 0.5 0.7 5.0 22.4
24-48 hr 0.6 1.7 7.2 0.6 3.7 1.3 1.1 4.5 6.2 0.4 0.5 1.0 28.7
Methylxanthine metabolite excretion in decompensated cirrhotic 
patients following an oral dose of caffeine (400 mg)
